CA2312940A1 - Antipicornaviral compounds and methods for their use and preparation - Google Patents

Abstract

Picornaviral 3C protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of picornaviral 3C proteases. These compounds, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses. Several novel methods and intermediates can be used to prepare the novel picornaviral 3C protease inhibitors of the present invention.

Description

ANTIPICORNAVIRAL COMPOUNDS AND METHODS FOR
THEIR USE AND PREPARATION
RELATED APPLICATION DATA
This application relates to U.S. Patent Application Nos. 08/825,331, filed March 28, 1997, and 08/850,398, filed May 2, 1997. Additionally, this application relates to U.S.
Provisional Patent Application No. 60/046,204, filed May 12, 1997. Each of these U.S.
patent applications relates to antipicornaviral compounds, compositions containing them, and methods for their production and use. Each of these applications also is entirely incorporated herein by reference. Additionally, this application relates to a concurrently filed U.S. patent application entitled "Antipicornaviral Compounds, Compositions Containing Them, and Methods for Their Use," U.S. Patent Appln. No. 08/991,282, filed in the names of inventors Peter S. Dragovich, Thomas J. Prins, and Ru Zhou. This concurrently filed application also is entirely incorporated herein by reference.
BACKGROUND OF THE INVE\TTION
The invention pertains to the discovery and use of new compounds that inhibit the en-zymatic activity of picornaviral 3C proteases, specifically rhinovirus proteases ("RVPs"), as well as retard viral growth in cell culture.
The picornaviruses are a family of tiny non--enveloped positive stranded RhIA
containing viruses that infect humans and other animals. These viruses include the human rhinoviruses, human polioviruses, human coxsackieviruses, human echoviruses, human and bovine enteroviruses, encephalomyocarditis viruses, menigovirus, foot and mouth viruses, hepatitis A virus, and others. The human rhinoviruses are a major cause of the common cold.
To date, there are no effective therapies to cure the common cold, only treatments that relieve the symptoms.

Picornaviral infections may be treated by inhibiting the proteolytic 3C
enzymes.
These enzymes are required for the natural maturation of the picornaviruses.
They are responsible for the autocatalytic cleavage of the genomic, large polyprotein into the essential viral proteins. Members of the 3C protease family are cysteine proteases, where the sulfhydryl group most often cleaves the glutamine-glycine amide bond.
Inhibition of 3C proteases is believed to block proteolytic cleavage of the polyprotein, which in turn can retard the maturation and replication of the viruses by interfering with viral particle production. Therefore, inhibiting the processing of this cysteine protease with selective, small molecules that are specifically recognized, should represent an important and useful approach to treat or cure viral infections of this nature and, in particular, the common cold.
SLTMMARY OF THE INVENTION
The present invention is directed to compounds that function as picornaviral protease inhibitors, particularly those that have antiviral activity. It is further directed to the preparation and use of such 3C protease inhibitors. The Inventors demonstrate that the compounds of the present invention bind to rhinovirus 3C proteases and preferably have antiviral cell culture activity. The enzymatic inhibition assays used reveal that these compounds can bind irreversibly, and the cell culture assays demonstrate that these compounds can possess antiviral activity.
The present invention is directed to compounds of the formula (I): --R4 ~ M R2 Z
R N N / Z (1)~
s ~ RS i R3 R~ R~
wherein:
MisOorS;
R, is H, F, an alkyl group, OH, SH, or an O-alkyl group;
Rz and RS are independently selected from H, ~' ~Y~ ~B~ ~ ~Y~ ,B2 X A~ , X A2 , D~ Dz or an alkyl group, wherein the alkyl group is different from - ~X~Y~Ai B~ and ' X~Y~Az B2 , D~ D2 with the proviso that at least one of RZ or RS must be X~Y~A~ B~ or X'Y~Ai B2 , I I
D~ D2 and wherein, when Rz or RS is X~Y~A~ B~
I
D~
X is =CH or =CF and Y, is =CH or =CF, _ or X and Y, together with Q' form a three-membered ring in which Q' is ---C(R,o)(R")- or -O-, X is -CH- or -CF-, and Y, is -CH-, -CF-, or -C(alkyl)-, where R,o and R" independently are H, a halogen, or an alkyl group, or, together with the carbon atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group, or X is -CHZ-, -CFZ-, -CHF-, or -S-, and Y, is -O-, -S-, -NR,2-, C~13)(R14) s -C(O s -C S) ~ ~r -C(CR,3R~a) wherein R,2 is H or alkyl, and R,3 and R,4 independently are H, F, or an alkyl group, or, together with the atoms to which they are bonded, form a cycloalkyl group or a heterocycloalkyl group;
A, is C, CH, CF, S, P, Se, N, NR,S, S(O), Se(O), P-OR,S, or P-NR,SR,6, wherein R,5 and R,6 independently are an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, or, together with the atom to which they are bonded, form a heterocycloallcyl group;
D, is a moiety with a lone pair of electrons capable of forming a hydrogen bond; and B, is H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -OR", -SR", -NR,~R,g, -NR,9NR"R,B, or -NR"OR,B, wherein R,~, R,B, and R,9 independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;
and with the provisos that when D, is the moiety ---N with a lone pair of electrons capable of forming a hydrogen bond, B, does not exist; and when A, is an spa carbon, B, is not -NR,~R,B
when D, is the moiety -NRZSRzs with a lone pair of electrons capable of forming a hydrogen bond, wherein R25 and R26 are independently H, an alkyl group, a cycloalkyl group, a --heterocycloalkyl group, an aryl group, or a heteroaryl group;
and wherein D,-A,-B, optionally forms a vitro group where A, is N;

and further wherein, when RZ or RS is X'Y~A2 B2 X is =CH or =CF and YZ is =C, =CH or =CF, or X and YZ together with Q' form a three-membered ring in which Q' is -C(R,a)(R")- or -O-, X is -CH- or -CF-, and Yz is -CH-, -CF-, or -C(alkyl)-, where R,o and R" independently are H, a halogen, or an alkyl group, or, together with the carbon atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group, or X is -CHZ-, -CFz-, -CHF-, or -S-, and YZ is -O-, -S-, -N(R',Z)-, -C~~n)(Raa)-~ -C(O)-~ -C(S)-~ or -C(CR'nRn4)-wherein R',2 is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -OR',3, -~usRaa~ -C(O)-Rua> -SOZR'is~ or -C(S)R~n~ ~d R'is ~d R'~a independently are H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group or, together with the atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group;
AZ is C, CH, CF, S, P, Se, N, NR,S, S(O), Se(O), P-OR,S, or P-NR,SR,6, wherein R,5 and R,6 independently are an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group or, together with --the atom to which they are bonded, form a heterocycloalkyl group;
DZ is a moiety with a lone pair of electrons capable of forming a hydrogen bond; and -S-BZ is H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -OR,~, -SR,~, -NR"R,B, -NR,9NR"R,B, or -NR,~OR,B, wherein R,~, R,B, and R,9 independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;
and further wherein any combination of Y2, Az, B2, and Dz forms a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;
R3 and Rs are independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -C(O)R,~, -OR", -SR", -NR"R,B, -NR,9NRoR,B, or -NR1~OR,~, wherein R", R,g, and R,9 independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;
or, R3 and R6, together with the carbon atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group;
R4 is any suitable organic moiety, or R, and R3 or R6, together with the atoms to which they are attached, form a heterocycloalkyl group;
R~ is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -OR,7, -SR", -NR"R,B, -NR,9NR"R,B, or -NR"OR,B, wherein R", R,B, and R,9 independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;
or R, together with R3 of Rb and the atoms to which they are attached form a heterocycloalkyl group;

R8 is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -NRZ9R3o, -ORz9, or -C(O)RZ9, wherein R29 and R3o each independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;
or R8 together with R4 and the nitrogen atom to which they are attached form a heterocycloalkyl group or a heteroaryl group, or R$ and R3 or R6, together with the atoms to which they are attached, form a heterocycloalkyl group;
Z and Z, are independently H, F, an alkyl group, a cycloalkyl group, a heterocycloallcyl group, an aryl group, a heteroaryl group, -C(O)RZ,, -COZRZ,, -CN, -C(O)NRZ, RZZ, -C(0)NRZiORzz, -C(S)R21, -C(S)NRZiRz2, -NO2, -SORZ,, -SOZR2,, -SOZNRZ~R22~
-SO~R2~)(ORzz)~ -SONR2,, -S03Rz,, -PO(ORzO2~ -PO(RxO(Rzz)~ -PO~z~Rz~)(ORz~)~
-PO(NRz,R22)(NR~Rza), -C(O)NRZiNRz2R23, or -C(S)NRZ,NRZZRz3, wherein Rz,, R22, Rzs, and R24 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or wherein any two of RZ,, R2z, Rz3, and RZa, together with the atoms) to which they are bonded, form a heterocycloalkyl group;
or Z,, as defined above, together with R,, as defined above, and the atoms to which Z, and R, are bonded, form a cycloalkyl or heterocycloalkyl group, or Z and Z,, both as defined above, together with the atoms to which they are bonded, form a cycloalkyl.or heterocycloalkyl group;
with the proviso that when R~ is H, R8 is a moiety other than H; ~-and pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates thereof;

and wherein these compounds, pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates preferably have antipicornaviral activity with an ECso less than or equal to 100 ~cM in the HI-HeLa cell culture assay, and more preferably antirhinoviral activity with an ECso less than or equal to 100 ~.M in the HI-HeLa cell culture assay and/or anticoxsachieviral activity with an ECM less than or equal to 100 ~.M
in the HI-HeLa cell cultuie assay.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to compounds of the formula I

R~N N ~ Z (I)~
s i RS t R3 R~ Rt wherein R,, RZ, R3, R4, RS, R6, R.,, R8, M, Z, and Z, are as defined above, and to the pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates thereof, where these compounds, pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates preferably have antipicornaviral activity with an ECso less than or equal to 100 ~cM in the HI-HeLa cell culture assay, and more preferably antirhinoviral activity with an ECso less than or equal to 100 p,M in the HI-HeLa cell culture assay and/or anticoxsachieviral activity with an ECM less than or equal to 100 pM in the HI-HeLa cell culture assay.
The present invention preferably relates to compounds of the formula II:
R~ O R~ Z
R~~C~N N~Z~ (II)~
II
0 R53 R5t R5~
_g_ wherein:
R5, is H, F, or an alkyl group;
R5z is selected from one of the following moieties:
R3s ~C'O R3' ~ N-R36 , C~S'R3~ ~ ~C~S R3~
H ~ C H2 II H2 z O H (O~, O
O
N35 R N36 ~C OR
~/ 36 36 ~ Ci R41 , H
H2 11 H2 ~ 2 O
O O
OR36 ' C~~S~R3~ ' ~~~CN , and C~CN , H I I IH CH; H2 _ O (O)n wherein:
R35 is H, an alkyl group, an aryl group, -OR38, or -NR38R39, wherein R38 and R39 independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;
and R36 is H or an alkyl group, or R35 and R36, together with the nitrogen atom to which they are attached, form a - heterocycloalkyl group or a heteroaryl group;
R3~ is an alkyl group, an aryl group, or -NR3gR3g, wherein R38 and R39 are as defined above;
R4, is H, an alkyl group, an aryl group, -OR38, -SR39, -NR38R39, -NR.4oNR38R39, or -NR3gOR3g, or R4, and R36, together with the atoms) to which they are attached, form a heterocycloalkyl group;
wherein R3g and R39 are as defined above, and R4o is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group; and n is 0, 1 or 2;
R53 is H or an alkyl group;
R54 is an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an O-alkyl group, an O-cycloalkyl group, an O-heterocycloalkyl group, an O-aryl group, an O-heteroaryl group, an S-alkyl group, an NH-alkyl group, an NH-aryl group, an N,N-dialkyl group, or an N,N-diaryl group;
or R54 together with R58 and the nitrogen atom to which they are attached form a heterocycloalkyl group or a heteroaryl group;
R5~ is H or an alkyl group;
R58 is H, an alkyl group, a cycloalkyl group, -OR~o, or NR,oR~,, wherein R,o and R7, are independently H or an alkyl group; and Z and Z, are independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -C(O)Rz,, -COZRz,, -CN, -C(O)NRz,Ru, -C(O)NRz~ORzz~ -C(s)Rzn -C(S)NRnRzz~ -NOz~ -SORz,, -SOZRz,, -SOZNRziRn~
-SO~Rz~)(ORzz)~ -SONRzn -S03Rz,, -PO(ORz~)z~-P0~2ORzz)~ -PO(NRz,Rzz)(ORz3)~
-PO~z~Rzz)~RzaRza)~ -C(O)NRzWzzRz3~ or -C(S)NRz,NRzzRz3, __ wherein Rz,, Rzz, Rz3, and Rz4 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or wherein any two of Rz,, Rzz, Rz3, and Rz4, together with the atoms) to which they are bonded, form a heterocycloalkyl group, or wherein Z and Z,, together with the atoms to which they are bonded, form a heterocycloalkyl group;
with the proviso that when Rs~ is H, RSB is a moiety other than H;
and pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates thereof.
As used in the present application, the following definitions apply:
An "alkyl group" is intended to mean a straight or branched chain monovalent radical of saturated and/or unsaturated carbon atoms and hydrogen atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, ethenyl, pentenyl, butenyl, propenyl, ethynyl, butynyl, propynyl, pentynl, hexynyl, and the like, which may be unsubstituted (i.e., containing only carbon and hydrogen) or substituted by one or more suitable substituents as defined below.
A "cycloalkyl group" is intended to mean a non-aromatic, monovalent monocyclic, bicyclic, or tricyclic radical containing 3, 4, S, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbon ring atoms, each of which may be saturated or unsaturated, and which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more heterocycloalkyl groups, aryl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties: -a. o. U. 0 0 ~.
_11_ and A "heterocycloalkyl group" is intended to mean a non-aromatic, monovalent monocyclic, bicyclic, or tricyclic radical, which is saturated or unsaturated, containing 3, 4, S, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 ring atoms, and which includes 1, 2, 3, 4, or 5 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the radical is unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, aryl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable _ substituents. Illustrative examples of heterocycloalkyl groups include, but are not limited to the following moieties:
O N O
O ~ ~> > > > > >
N RN NR
O N N
R R R
O N N O
S
> > -N ~ \ > > NR
S ~N J O N
R
O O
, , , ~ , and R O N~ R R ~ _ An "aryl group" is intended to mean an aromatic, monovalent monocyclic, bicyclic, or tricyclic radical containing 6, 10, 14, or 18 carbon ring atoms, which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, heterocycloallcyl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Illustrative examples of aryl groups include, but are not limited to, the following moieties:
/ / \ / \ \
and / \
\ \ / \ / /
\ /
A "heteroaryl group" is intended to mean an aromatic monovalent monocyclic, bicyclic, or tricyclic radical containing 4, S, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 ring atoms, including 1, 2, 3, 4, or 5 heteroatoms selected from nitrogen, oxygen, and sulfur, which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or aryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Illustrative examples of heteroaryl groups include, but are not limited to, the following moieties:
N
N
N
N ~ ~
R R s R __ / / N iN / NON NON NON
N ' N N ~N N' N

N
/ I \ / \ / I \~ / \. /
v \ N>> I S ~ ~ N ~ I ~ \ N /N~
R R '' O
/ \ / \ / ~N / ~N / N~
I N~ I ~\ I N~\ I
N ~ N ~ N
Ni \ ~N
\ / \ / ~ / I / , and \ I / / .
N S N
R
An "acyl group" is intended to mean a -C(O)-R radical, wherein R is any suitable substituent as defined below.
A "thioacyl group" is intended to mean a -C(S)-R radical, wherein R is any suitable substituent as defined below.
A "sulfonyl group" is intended to mean a -S02R radical, wherein R is any suitable substituent as defined below.
The term "suitable substituent" is intended to mean any of the substituents recognizable, such as by routine testing, to those skilled in the art as not adversely affecting the inhibitory activity of the inventive compounds. Illustrative examples of suitable substituents include, but are not limited to, hydroxy groups, oxo groups, alkyl groups, acyl groups, sulfonyl groups, mercapto groups, allcylthio groups, alkoxy groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, carboxy groups, amino groups, alkylamino groups, dialkylamino groups, carbamoyl groups, aryloxy groups, heteroarlyoxy groups, arylthio groups, heteroarylthio groups, and the like.
The term "suitable organic moiety" is intended to mean any organic moiety recognizable, such as by routine testing, to those skilled in the art as not adversely affecting the inhibitory activity of the inventive compounds. Illustrative examples of suitable organic moieties include, but are not limited to, hydroxy groups, alkyl groups, oxo groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, acyl groups, sulfonyl groups, mercapto groups, alkylthio groups, alkoxy groups, carboxy groups, amino groups, alkylamino groups, dialkylamino groups, carbamoyl groups, arylthio groups, heteroarylthio groups, and the like.
A "hydroxy group" is intended to mean the radical -OH.
An "amino group" is intended to mean the radical -NH2.
An "alkylamino group" is intended to mean the radical -NHR where R is an alkyl group as defined above.
A "dialkylamino group" is intended to mean the radical -NRaR~ where Ra and Rb are each independently an alkyl group as defined above.
An "alkoxy group" is intended to mean the radical -OR where R is an alkyl group as defined above, for example, methoxy, ethoxy, propoxy, and the like.
An "alkoxycarbonyl group" is intended to mean the radical -C(O)OR where R is an alkyl group as defined above.
An "alkylsulfonyl group" is intended to mean the radical -SOZR where R is an --alkyl group as defined above.

An "alkylaminocarbonyl group" is intended to mean the radical -C(O)NHR
where R is an alkyl group as defined above.
A "dialkylaminocarbonyl group" is intended to mean the radical -C(O)NRaRe where Ra and Rti are each independently an alkyl group as defined above.
A "mercapto group" is intended to mean the radical -SH.
An "alkylthio group" is intended to mean the radical -SR where R is an alkyl group as defined above.
A "carboxy group" is intended to mean the radical -C(O)OH.
A "carbamoyl group" is intended to mean the radical -C(O)NH2.
An "aryloxy group" is intended to mean the radical -OR~ where R~ is an aryl group as defined above.
A "heteroarlyoxy group" is intended to mean the radical -ORS where Rd is a heteroaryl group as defined above.
An "arylthio group" is intended to mean the radical -SR~ where R~ is an aryl group as defined above.
A "heteroarylthio group" is intended to mean the radical -SRd where Rd is a heteroaryl group as defined above.
A "pharmaceutically acceptable prodrug" is intended to mean a compound that may be converted under physiological conditions or by solvolysis to a compound of formula I.
A "pharmaceutically acceptable active metabolite" is intended to mean a --pharmacologically active product produced through metabolism in the body of a compound of formula I.

A "pharmaceutically acceptable solvate" is intended to mean a solvate that retains the biological effectiveness and properties of the biologically active components of compounds of formula I.
Examples of pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
A "pharmaceutically acceptable salt" is intended to a mean a salt that retains the biological effectiveness and properties of the free acids and bases of compounds of formula I and that is not biologically or otherwise undesirable.
Examples of pharmaceutically acceptable salts include, but are not limited to, sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, y-hydroxybutyrates, glycolates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.
If the inventive compound is a base, the desired salt may be prepared by any --suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, malefic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acids such as glucuronic acid and.galacturonic acid, alpha-hydroxy acids such as citric acid and tartaric acid, amino acids such as aspartic acid and glutamic acid, aromatic acids such as benzoic acid and cinnamic acid, sulfonic acids such a p-toluenesulfonic acid or ethanesulfonic acid, or the like.
If the inventive compound is an acid, the desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the' like. Illustrative examples of suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary and tertiary. amines, and cyclic amines such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
In the case of compounds, salts, or solvates that are solids, it is understood by those skilled in the art that the inventive compounds, salts, and solvates may exist in different crystal forms, all of which are intended to be within the scope of the present invention.
The inventive compounds may exist as single stereoisomers, racemates and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the present invention. --Preferably, the inventive compounds are used in optically pure form.

As generally understood by those skilled in the art, an optically pure compound is one that is enantiomerically pure. As used herein, the term "optically pure"
is intended to mean a compound which comprises at least a sufficient amount of a single enantiomer to yield a compound having the desired pharmacological activity. Preferably, "optically pure" is intended to mean a compound that comprises at least 90% of a single isomer (80% enantiomeric excess), preferably at least 95% (90% e.e.), more preferably at least 97.5% (95% e.e.), and most preferably at least 99% (98% e.e.).
Preferably in the above formulas I and II, R, and R51 are H or F. Preferably in the compounds of formula I, at least one of R4 and R$ is an acyl group or a sulfonyl group. Preferably in the above formulas I and II, D1 and Dz are -ORu, =O, =S, ---N, =NRu, or -NRuRz6, wherein Ru and Rz6 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, or, together with the nitrogen atom to which they are bonded, form a heterocycloalkyl group, and more preferably D, and Dz are =O. Preferably A, and Az are C, CH, S, or S(O), and more preferably A1 and Az are C.
Preferably B, and Bz are NR"R,B, wherein R" and Rl8 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group, or wherein R,~ and R18, together with the atoms) to which they are bonded, form a heterocycloalkyl group.
Preferably Z and Zl are independently H, an aryl group, or a heteroaryl group, _ -C(O)Rzu -COzRzt, -CN, -C(O)NRzi,Rzz, -C(O)NRzIOR~, -C(S)Rzl, -C(S)NRzIRu, _ _ -NOz, -SORzI, -SOZRz,, -SOZNRzIRzz, -SO(NRz,)(ORzz), -SONRzI, -SO3Rzt, -C(O)NRz,NR~Rz3, or -C(S)NRZINRzzR~; wherein Rz,, Rte, and R~ are independently H, an alkyl group, a cycloalkyl group, a heterocycloallcyl group, an aryl group, a heteroaryl group, or an acyl group, or wherein any two of R21, Rte, and R23, together with the atoms) to which they are bonded, form a heterocycloalkyl group, or Z
and Z,, together with the atoms to which they are attached, form a heterocycloalkyl group.
Preferably M is O.
Preferably R52 is one of the following moieties:

C~ N-R36 ~ CAN R4t , or C~S'R3~
H~ H ~ H2 O
O z O
wherein R35, R36, Rs>> Rm, and n are as defined above.
Compounds according to formula I include those described below, where indicates the point of attachment. For example, the invention includes compounds 1-17 having the formula Ia:

N ~ ~ ~a)~
Rs ~ N Zi Rs' R6 R7 R1 wherein Rl, R5, R6, and R~ are H, RZ is CHZCHzC(O)NH2, R4 is CH3, and R3, Z, Zl, and R8 are selected from one of the following groups:

1. R3 is CHZPh, Z is _H, Z, is COZCHZCH3, and R8 is 2. R3 is CHzPh, Z is H, Z, is COzCH2CH3, and R8 is ° ~ .
w I ~H O
3. Z is H, Z, is COZCHZCH3, R3 is HZo ~ ~ ~~ and R8 is °
w ~ ~H O
4. R3 is HZo ~ ~ ~3 , Z is H, Z, is COZCHzCH3, and R8 is H O
R3 is CHZPh, Z is H, Z, is COZCHzCH3, and R8 is s~ N
H O
6. R3 is CHZPh, Z and Z, together form ~~ (where the C=O group is preferably cis to the RI group), and R8 is~~ ~ -~lN
H O

a0~ N O
7. R3 is CHZPh, Z is H, Z1 is / ~ , and R$ is ~ ;
CH;CHZS
O
8. R3 is CH2Ph, Z and Z, together form ~~ (where the C=O group is preferably cis to the R, group), and R8 is ;
~~~ZS~ H
O
Ph 9. R3 is CHZPh, Z is H, Z, is COZCHZCH3, and R$ is o w I s H o 10. R3 is CHZPh, Z and Zl together form ~~ (where the C = O group Ph preferably is cis to the R, group), and R8 is oII
w I S~ H 0 11. R3 is CHZPh, Z is H, ZI is COZCHZCH3, and R$ is ~°
- CH~CHZS~ N
H O

12. R3 is CHZPh, Z and Z, together form ~~ (where the C=O group preferably is cis to the R rou t g p), and R$ is , CH~CHzS~ H
O
13. R3 is H2~ ~~3 , Z is H, Zl is COZCHZCH3, and Rg is Ph O
w ~ S H O
14. R3 is HZ~ ~~3 , Z is CH3, Z, is COZCHZCH3, and h R8 is 0 ;
O
15. R3 is CH?Ph, Z is H, Z, is COZCHZCH3, and R8 is °
s~ H o 16. R is CH Ph Z is CH Z is CO CH CH and R is 3 2 s 3~ 1 2 2 3~ 8 ; and s H O

O
17. R3 is CHZPh, Z is H, Z, is ~ o and R8 is ° , C(0~1~ CH3CHZS' -N
H O
Additional compounds according to the invention include compounds 18-24 having the formula Ib:
W ~ O RZ Z
N ~ Z1 N ~~~''R3 ~ RS
R~ R~
R$
wherein R1, R3, R5, R~, and Z are H, RZ is CHZCHZC(O)NHZ, and Z1, W, W1, and R8 are selected from one of the following groups:
18. Z, is C02CHZCH3, W is H, W, is Ph, and R8 is ~O~N
~l i~ H O
19. Z1 is COZCHZCH3, W is H, W, is H, and R8 is ~O~N i , O
20. Zl is COZCHZCH3, W is OCHZPh, Wl is H, and R8 is ~O~N
~ i H O

21. Zt is COZCHZCH3, W is H, W, is CH3, and R8 is ~ ~ ;
~O~ N
I' i~ H O
22. Z is C O N CH OCH W is H W is Ph and R is t ( ) ~ 3) s> > t > s , ~O~N
I' i~ H O
23. Z, is COZCH2CH3, W is OC(CH3)3, W t is H, and R8 is ~ ~ ; ~d ~O N
I i H O
24. Z, is COZCHZCH3, W is H, W 1 is H, and R8 is ~ , CHgCH2,S~N
H O
'The invention further includes compounds 25-29 having the formula Ic:

~N R N R / Zt R 3 R~ 5 Rt s wherein R R R R and Z are H R is CH CH C O NH R is 1~ 3~ 5~ 7> > 2 2 2 ( ) 2~ 8 ~ , N
H O
and Wz and Z1 are selected from one of the following groups:

2~. WZ is CH2 and Z, is COZCH2CH3;
26. W2 is CHZ and Z, is c(ol-N~;
b 27. WZ is NH and Z, is C02CHZCH3;
28. W2 is NCHZPh and Z, is COZCHZCH3; and 29. W2 is NS02Ph and Zl is COZCHZCH3.
Additionally, the invention includes compounds 30 and 31 according to formula Id:
~P O R2 Z
~d) I-I O R3 R~RsRi Z~
wherein Rl, R3, R5, R6, R,, and Z are H, RZ is CHZCH2C(O)NHZ, Z1 is COZCHZCH3, and W3 is ~oJ in Compound 30, and W3 is H in Compound 31.
~I
The invention also includes compounds 32 and 33 according to formula Ie:

i Z
i O R3 R~ R' Ri wherein Rl, R5, Itb, R~, and Z are each H, RZ is CHZCHZC(O)NHZ, R3 is CHZPh, O
Z, is COZCH2CH3, and W4 is H in Compound 32, and W4 is ~o~NH m Compound 33.
The invention further includes compounds 34-36, 38-49, and 56-58 also according to formula Ia above, wherein Rl, R5, R6, and R, are each H, RZ is CHZCH2C(O)NH2, R4 is CH3, and R3, Z, Z,, and R8 are selected from one of the following groups:
OII
34. R~ is CHZPh, Z is H, Z1 is COZCHZCH3, and R$ is ;
CH3CHZS~NH
O
O
35. R3 is CHZPh, Z is H, Z, is COzCH2CH3, and R$ is ~ S~NH ' O
36. R3 is CHZPh, Z is H, Z1 is C(O)N(CH3)OCH3, and R8 is ~ ~ ;

O
38. R3 is CHZPh, Z is H, Zt is COZCHZCH3, and R8 is - S NH
O

39. R is CH Ph, Z is CH Z is CO CH CH and R is 3 2 3~ 1 2 2 3~ 8 , S I
O
40. R3 is CH2Ph, Z is H, Z, is COZCHZCH3, and Rg is O ~;
s~N I
O
41. R is CH Ph Z is CH Z is CO CH CH and R is O
3 2 a 3~ 1 2 2 3~ 8 , S~NH I
O
42. R is CH Ph Z is H Z is CO CH CH and R is O
3 2 a r 1 2 2 3i 8 ~ , O
43. R3 is CHZPh, Z is CH3, Z, is COzCH2CH3, and R8 is ~ ~ ;
S
O

44. R is CH Ph Z is H Z is CO CH CH and R is O
3 2 s ~ l 2 2 3s 8 , S t~H I
45. R3 is CHZPh, Z is CH3, Z, is COzCH2CH3, and R8 is ~ ;
I
O
O SPh 46. R3 is CHzPh, Z is H, Z, is COzCHZCH3, and R8 is ~ ~ ;

O SPh 47. R3 is CHZPh, Z is CH3, Z, is COZCHzCH3, and R8 is ~ ~ ;

48. R3 is ~2 ~ / ~3 , Z is H, Z, is COzCHZCH3, and R$ is S
I
o --49. R3 is ~Z ~ ~ ~3 , Z is CH3, Z, is COZCHZCH3, and R8 is O
S~NH
I

56. R3 is CHZPh, Z is H, Z, is COZCHZPh, and R8 is ~ o ~N
H O
57. R3 is CHzPh, Z is H, Z, is COZCH2CHZCH3, and R8 is~ ~ ; and S N
H O
58. R3 is CHZPh, Z is H, Z, is COzCH2CHzOCH3, and R8 is S N

The invention also includes compounds 37 and 50-52 having the formula Ig:
Ws.... W60 Rz Z
r~ZI __ R3 R~ Rs Ri ~g)~
O

wherein R1, R3, R5, R,, W5, W6, and Z are H, RZ is CHZCHZC(O)NH2, Z, is COZCHZCH3, and W~ is ~ I O~NH in Compound 37, W, is Qs~N~s~ m O
Compound 50, W~ is Q ~ in Compound 51, and W, is ~ in Compound 52.
Compound 53 also corresponds to this invention. This compound has the formula Ih:

W8 ~ ~ Z~ ~).
i RS
O R3 R~ Rt wherein R1, R5, R6, and R~ are H, RZ is CHZCHzC(O)NHz, R3 is CHZPh, Z is H, Z, is i COZCHZCH3, and W8 is ~ ~ O NH .
O
The invention also relates to compounds 54 and 55 having the formula (Ij):

Wg N~ ~ Z~
I RS
O R3 R~ R~
wherein R1, R5, R6, and R~ are H, RZ is CHZCHZC(O)NH2, R3 is CHZPh, Z is H, Z1 is --O
COZCHZCH3, and Wg is ~ ~ in Compound 54, and W8 is S NH
NH in Compound 55.
o Other compounds according to the invention include the following compounds of formula X:
H3 C ~ O R2 Z
~ Z (X) H ~

wherein R,, R6, and Z are H, RZ is CH2CHZC(O)NHz, R3 is CHzPh, Z1 is COZCHZCH3, and Rd is selected from one of the following:
O
59. R4 is H
O-N O
O
60. RQ is ~
VAR-S' _N
H O
SH
O --61. R4 is ~ ;
VAR-S N
H O

H
SAN-Ac O
62. R4 is ~ ;
VAR-S N
H O

S
63. R4 is O ;
VAR- S' _ N
H O
O 'Ph 64. R4 is V~-S' _N ' H O
O
65. R4 is V~-S' _N ' H O
,,T H
66. R.4 is O ;
VAR- S' _ N
H
S
67. is ~ .
N
~ S I __ O O

O
68. R4 is ~ ,, H ;
VAR-S N
H
O

O
69. R4 is ~ ;
VAR-S' 'N
H
O
N
r~
70. R4 is O 'N .
~ H ' VAR-S' 'N
H
O
O
71. R4 is ~ ;
VAR-S' 'N
H I
O
CI
72. R.4 is O
VAR-S' O
73. R4 is O ; _ _ VAR-S' 'N
H

i 4. R, is O ;
VAR-S' _ " O

O
75. Rd is ~ ;
VAR-S N
H
O
OH
O
76. R4 is ~ ;
VAR-S N
H
O
_ O 'SCH3 77. ~
R4 is V~-S' 'N ' H O
OCHZPh O
78. R4 is ~ ;
VAR-S' _N
H
O

79. R4 is O
' VAR-S' 'N
H

8~. ~q 1S
O
VAR- S O
H
SAN-Ac O
81. R.~ is ;
VAR-S' 'N
H O
F
82. R4 is O -_ VAR-S' 'N
H
Ph Ph O
83. R~ is ~ ;
VAR- S' _ N
H
O
Ph O
84. R4 is ~ ;
VAR-S' _N
H
O
O 'C02H _ 85. R4 is V~-S' 'N ; _ _ H
O

SCH2Ph O
86. R4 is ~ ;
VAR-S N
H O
-S
87. R4 is O ;
VAR-S' _N
H O
88. Rd is O ;
VAR- S' O
~ ~N
O
89. R4 is VA.R- S N
H
O
Ph 9Q. ~ is O -VAR- S' _ N
H O

91. R,~ is O
VAR-S' _N
H
O
OH
92. R4 is O
VAR- S' O
S ( \
O
93. R4 is ~ / .

VAR-S
O
CHZPh N
94. t~ is O N ;
VAR-S' 'N
H O
OCH2Ph 95. R4 is O
VAR- S' N
H
O _-N
96. RQ is O
VAR-S' 'N
H O
O S~CH3 O~ ~O
97. R4 is VAR-S N
H O
O
98. R4 is ~ ~ / ; and VAR-S N ~I OH
H
O
SPh O
99. R.4 is ~
VAR-S' _N
H O
wherein VAR is selected from the group consisting of -CHZCH3, -CH(CH3)2.
- CHZCH(CH3)2, - CHZPh, , and The present invention is further directed to methods of inhibiting picornaviral 3C
protease activity that comprises contacting the protease for the purpose of such inhibition with an effective amount of a compound of formula I or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof. For example, one can inhibit picornaviral 3C protease activity in mammalian tissue by administering a compound of formula I or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof. More particularly, the present invention is directed to methods of inhibiting rhinoviral protease activity.
The activity of the inventive compounds as inhibitors of picornaviral 3C
protease activity may be measured by any of the methods available to those skilled in the art, including in vivo and in vitro assays. Examples of suitable assays for activity measurements include the Antiviral HI-HeLa Cell Culture Assay and the Normal Human Bronchial Epithelial Cell Assay, both described herein.
Administration of the compounds of formula I, or their pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates, may be performed according to any of the accepted modes of administration available to those skilled in the art.
Illustrative examples of suitable modes of administration include, but are not limited to, oral, nasal, parenteral, topical, transdermal, and rectal.
The inventive compounds of formula I and their pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates, may be administered as a pharmaceutical composition in any suitable pharmaceutical form recognizable to the skilled artisan. Suitable pharmaceutical forms include, but are not limited to, solid, semisolid, liquid, or lyopholized formulations, such as tablets, powders, capsules, suppositories, suspensions, and aerosols. The pharmaceutical composition may also include suitable excipients, diluents, vehicles, and carriers, as well as other pharmaceutically active agents, depending upon the intended use. _ Acceptable methods of preparing suitable pharmaceutical forms of the w pharmaceutical compositions are known to those skilled in the art. For example, pharmaceutical preparations may be prepared following conventional techniques of the pharmaceutical chemist involving steps such as mixing, granulating, and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraural, and/or rectal administration.
Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles, or excipients may be employed in the pharmaceutical compositions. lllustrative solid carriers include starch, lactose, calcium sulphate dihydrate, terra alba, sucrose, talc, gelatin, pectin, acacia, magnesium stearate, and stearic acid. Illustrative liquid carriers may include syrup, peanut oil, olive oil, saline solution, and water. The carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g. solution), or a nonaqueous or aqueous liquid suspension.
A dose of the pharmaceutical composition contains at least a therapeutically effective amount of the active compound (i.e., a compound of formula I or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof) and preferably is made up of one or more pharmaceutical dosage units. The selected dose may be administered to a mammal, for example, a human patient, in need of treatment mediated by inhibition of 3C protease activity, by any known method of administering the dose including topical, for example, as an ointment or cream; orally;
rectally, for _ example, as a suppository; parenterally by injection; or continuously by intravaginal, --intranasal, intrabronchial, intraaural, or intraocular infusion.

A "therapeutically effective amount" is intended to mean that amount of a compound of formula I that, when administered to a mammal in need thereof, is sufficient to effect treatment for disease conditions alleviated by the inhibition of the activity of one or more picornaviral 3C proteases, such as human rhinoviruses, human poliovirus, human coxsackieviruses, encephalomyocarditis viruses, menigovirus, and hepatitis A virus. The amount of a given compound of formula I that will correspond to a "therapeutically effective amount" will vary depending upon factors such as the particular compound, the disease condition and the severity thereof, and the identity of the mammal in need thereof, but can nevertheless be readily determined by one of skill in the art.
"Treating" or "treatment" is intended to mean at least the mitigation of a disease condition in a mammal, such as a human, that is alleviated by the inhibition of the activity of one or more picornaviral 3C proteases, such as human rhinoviruses, human poliovirus, human coxsackieviruses, encephalomyocarditis viruses, menigovirus, and hepatitis A virus, and includes:
(a) prophylactic treatment in a mammal, particularly when the mammal is found to be predisposed to having the disease condition but not yet diagnosed as having it;
(b) inhibiting the disease condition; and/or (c) alleviating, in whole or in part, the disease condition.
The inventive compounds, and their salts, solvates, crystal forms, active ---metabolites, and prodrugs, may be prepared by employing the techniques available in the art using starting materials that are readily available. Certain novel and exemplary methods of preparing the inventive compounds are described below.
Preferably, the inventive compounds of formula I are prepared by the novel methods of the present invention, including the four general methods shown below. In each of these general methods, Rl, RZ, R3, Ra, R5, R6, R~, R8, Z, and Z, are as defined above (for formula n.

General Method I:
Rg O

P1~N OH ~ OH
+ Rs R3 R~
A
Rg O R2 P i N ~ N OH -----s I Rs I
R3 R~ RI
C

HN ~ N OH + R4- Lv -I Rs R3 R~ R~
D E

~~N N OH ~ G
I Rs R3 R~ RI
F ~ Modified F
R8 ~ O R2 _ ~N O -R ~ ~ __ s R3 R~ Ri G

R4~N N / Z1 _ _ _ ~ Deprotected or I Rs Modified H
R3 R~ R~
H
In General Method I, protected amino acid A, where P, is an appropriate protecting group for nitrogen, is subjected to an amide forming reaction with amino alcohol (or salt thereof) B to produce amide C. Amide C is then deprotected to give free amine (or salt thereof) D. Amine D and compound E, where "Lv" is an appropriate leaving group, are subjected to a bond forming reaction generating compound F.
Compound F is oxidized to intermediate G, or modified at R4 and/or R8, to give one or more modified F compounds. Modified F compounds are oxidized to intermediate G.
Intermediate G is then transformed into unsaturated product H. If protecting groups are used on any R groups (R,-RB) and/or on Z and/or Z,, product H is deprotected and/or further modified to yield "deprotected or modified H. "
An alternative method to prepare intermediate F is described as follows:
HN Rs O Rg ~S O
E + ~OP2 -~ R4~ ~OPZ --->

I J
__ N
R4~ OH + B --~ F

K

Compound E and amino acid (or salt thereof) I, where PZ is an appropriate protecting group for oxygen, are subjected to a bond forming reaction to produce intermediate J. Intermediate J is deprotected to yield free carboxylic acid K, which is subsequently subjected to an amide forming reaction with amino alcohol (or salt thereof) B to generate intermediate F.
Amino alcohol B can be prepared as follows:
H R O H O H Rs R~
P~ N 5 OH ~ p iN RS ~ ~ P1 N~OH

Q
H RS R~
R~~N~OH
Rz B
Amino acid L, where P, is an appropriate protecting group for nitrogen, is converted to carbonyl derivative M, where "Lv" is a leaving group. Compound M
is subjected to a reaction where "Lv" is reduced to protected amino alcohol Q.
Amino alcohol Q is deprotected to give amino alcohol B.

General Method II:
R~ Rs O ~ ~ O R~ R O
N ~ N 5 P ~ OOH ~ P~~ ~ ~LV ~ P~~ ~R~
R2 Rz R2 L M N
R7 R~ ~ R~ R~
Rs ~ ~ Rs P / N ~ Z~ HN ~ Z + K ~ H - - - ~ deprotected or modified R2 Z~ R2 Z~ H
O P
modified O
In General Method II, amino acid L, where P, is an appropriate protecting group for nitrogen, is converted to a carbonyl derivative M, where "Lv" is a leaving group.
Compound M is subjected to a reaction where "Lv" is replaced by R, to give derivative N. Derivative N is then transformed into unsaturated product O. Unsaturated compound O is deprotected to give free amine (or salt thereof) P, or modified one or more times at RZ, R5, R~, Z, and/or Z, to give one or more modified O compounds.
Modified O is then deprotected to give amine (or salt thereof) P. Amine P is subsequently subjected to an amide forming reaction with carboxylic acid K, prepared as described in General Method I, to give final product H. If protecting groups were used on any R group (R,-R8) and/or on Z and/or Z,, product H is deprotected and/or further modified to yield "deprotected or modified H. " _ An alternative method to prepare intermediate N is described as follows:
R
I~ R5 M ----~ N --P~~ ~OH
Rz Q
Compound M is subjected to a reaction where "Lv" is reduced to protected amino alcohol Q. Amino alcohol Q is subsequently oxidized to derivative N.
General Method III:
R~ R O
L ----~ M ---s R
R~
R R3 ~ R5 O
----> G --a H _ _ _ .~ deproteded or modified R ~ O R2 ~ H
S F ---~ modified F
In General Method III, amino acid L, where P, is an appropriate protecting group for nitrogen, is converted to a carbonyl derivative M, where "Lv" is a leaving group.
Derivative M is deprotected to give free amine (or salt thereof) R, which subsequently is subjected to an amide forming reaction with carboxylic acid K to give intermediate S.
Intermediate S is then either converted directly to carbonyl intermediate G, or successively reduced to alcohol F, which is then oxidized to G. Intermediate G
is ~ w subjected to a reaction to yield the unsaturated final product H. If protecting groups were used on any R groups (R,-Rg) and/or on Z and/or Z,, product H is deprotected and/or further modified to yield "deprotected or modified H. "
General Method IV:
s N7 Rs R' Z ~ R~ R R~ N8 O
HN Z +
Pi ~ ~ Pi OH
Rz Zi RZ Zi R3 O ~P A
Modified /O
R~ R ,Rt PIwN N s ~ Z --Rg R3 O R2 Zl T
R6 R~ R~
N ~ ~ Z + R4-Lv U E
H - - - ~ Deprotected or Modified H
In General Method IV, free amine (or salt thereof) P, prepared from intermediate O as described in General Method II, is converted to amide T by reaction with amino --acid A, where P, is an appropriate protecting group for nitrogen. Compound T
is further deprotected to free amine (or salt thereof) U, which is subsequently converted to H with reactive intermediate E. If protecting groups were used on any R groups (R,-R8) and/or on Z and/or Z,, product H is deprotected and/or further modified to yield "deprotected or modified H. "
Suitable protecting groups for nitrogen are recognizable to those skilled in the art and include, but are not limited to benzyloxycarbonyl, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, p-methoxybenxyloxycarbonyl, trifluoroacetamide, and p-toluenesulfonyl. Suitable protecting groups for oxygen are recognizable to those skilled in the art and include, but are not limited to -CH3, -CHZCH3, tBu, -CHZPh, -CHZCH=CHz, -CHZOCHZCHZSi(CH3)3, and -CHZCCl3. Other examples of suitable protecting groups for nitrogen or oxygen can be found in T. Green & P. Wuts, Protective Groups in Organic Synthesis (2nd ed. 1991), which is incorporated herein by reference.
Suitable leaving groups are recognizable to those skilled in the art and include, but are not limited to, Cl, Br, I, sulfonates, O-alkyl groups, O
O O
O R, O O O-N ~ O- ~ N~OCH3 R, N
~,or N=N CH3 wherein "R" is any suitable substituent, such as an alkyl group or an aryl group. Other examples of suitable leaving groups are described in J. March, Advanced Organic Chemistry. Reactions Mechanisms and Structure (4th ed. 1992) at pages 205, 351-56, _ _ 642-43, 647, 652-53, 666, 501, 520-21, 569, 579-80, 992-94, 999-1000, 1005, and 1008, which are incorporated herein by reference.

EXAMPLES
Proton magnetic resonance spectra (NMR) were determined using a Tech-Mag spectrometer operating at a field strength of 300 megahertz (MHZ) or Varian IJNITYpIus 300. Chemical shifts are reported in parts per million (8) and setting the references such that in CDCl3 the CHC13 is at 7.26 ppm, in CD30D the CH30H is at 4.9 ppm, in C6D6 the C6I-I~ is at 7.16 ppm, in acetone-db the acetone is at 2.02 ppm, and in DMSO-d6 the DMSO
is at 2.49 ppm. Standard and peak multiplicities are designated as follows: s, singlet; d, .
doublet; dd, doublet of doublets; ddd, doublet of doublet of doublets; t, triplet; q, quartet;
bs, broad singlet; bt, broad triplet; m, multiplet. Mass spectra (FAB; fast atom bombardment) were determined at the Scripps Research Institute Mass Spectometry Facility, San Diego, CA. Infrared absorption (IR) spectra were taken on a MIDAC
Corporation FTIR or a Perkin-Elmer 1600 series FTIR spectrometer. Elemental microanalyses were performed by Atlantic Microlab Inc. Norcross, Georgia and gave results for the elements stated with ~ 0.4% of the theoretical values. Flash chromatography was performed using Silica gel 60 (Merck Art 9385). Thin layer chromatographs ("TLC") were performed on precoated sheets of silica 60 Fu4 (Merck Art 5719). Melting points were determined on a Mel-Temp apparatus and are uncorrected. Anhydrous N,N dimethylformamide (DMF), N,N dimethylacetamide (DMA), dimethysulfoxide (DMSO), were used as is. Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl under nitrogen. "Et20" refers to diethyl ether. "Pet.
ether" refers to petroleum ether with a boiling range of 36-53 'C. "TFA" refers to trifluoroacetic acid. --"Et,N" refers to triethylamine. Other abbreviations include: methanol (MeOH), ethanol (EtOH), ethyl acetate (EtOAc), acetyl (Ac), methyl (Me), triphenylmethyl (Tr), benzyloxycarbonyl {CBZ), tert-butoxycarbonyl (BOC), m-chloroperoxybenzoic acid (m-CPBA), alanine (Ala), glutamine (Gln), proline (Pro), leucine (Leu), methionine (Met), phenylalanine (Phe), and homophenylalanine (hPhe), where "L" represents natural amino acids and "D" unnatural amino acids. "D1." represents racemic mixtures. A
simplified naming system was used to identify intermediates and final products: Amino acid and peptide alcohols are given the suffix'ol' (for example "methionol"). Amino acid and peptide aldehydes are given the suffix'af (for example "methional"). When naming final products, italicized amino acid abbreviations represent modifications at the C-terminus of that residue where the following apply:
1. acrylic acid esters are reported as either "E" (traps) or "Z" (cis) propenoates.
2. lactones 6, 8, 10, and 12 are reported as E-a-vinyl-y-butyrolactones.
3. acrylamides are reported as either E or Z propenamides except in the case of compound 7, which is reported as 1-(2',3'-Dihydroindolin-1-yl)-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenone and compound 26, which is reported as 1-[1',2'-oxazin-2'-yl]-3-(CBZ-L-Leu-L-Pip-L-Gln)-E-propenone.
4. acryloxazolidone 17 is reported as 1-[2'-oxazolidon-3'-yl]-3-(ethylthiocarbonyl-L-Leu-L-N-Me-Phe-Gln)-E-propenone.

Ezample 1 Preparation of Compound 1: Eth~CBZ-L-N-Me-Phe-L-Gln E-Propenoate.
Preparation of Intermediate BOC-L-(Tr-Gln)-N(OMe)Me.
Isobutyl chloroformate (4.77 mL, 36.8 mmol, 1.0 equiv) was added to a solution of BOC-L-(Tr-Gln) (18.7 g, 36.7 mmol, 1 equiv) and 4-methylmorpholine (8.08 mL, 73.5 mmol, 2.0 equiv) in CHZC12 (250 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 20 min, then N, O-dimethylhydroxylamine hydrochloride (3.60 g, 36.7 mmol, 1.0 equiv) was added. The resulting solution was stirred at 0 'C for 20 min and at 23 °C for 2 h, and then it was partitioned between water (150 mL) and CHZCIz (2 x 150 mL). The combined organic layers were dried over NazS04 and concentrated. Purification of the residue by flash column chromatography (gradient elution, 20-40% hexanes in EtOAc) provided BOC-L-(Tr-Gln)-N(OMe)Me (16.1 g, 82%) as a white foam: IR (KBr) 3411, 3329, 3062, 1701, 1659 cm'; 'H NMR (CDCI,) 8 1.42 (s, 9 H), 1.63-1.77 (m, 1 H), 2.06-2.17 (m, 1 H), 2.29-2.43 (m, 2 H), 3.17 (s, 3 H), 3.64 (s, 3 H), 4.73 (s, bs, 1 H), 5.38-5.41 (m, 1 H), 7.20-7.31 (m, 15 H); Anal. (C3,H3,N305) C, H, N.
Preparation of Intermediate BOC-L-(Tr-Glutaminal) Diisobutylaluminum hydride (50.5 mL of a 1.5 M solution in toluene, 75.8 mmol, 2.5 equiv) was added to a solution of [BOC-~-(Tr-Gln)]-N(OMe)Me (16.1 g, 30.3 mmol, 1 equiv) in THF at -78 °C, and the reaction mixture was stirred at -78 °C for 4 h. Methanol (4 mL) and 1.0 M HCl (10 mL) were added sequentially, and the mixture was warmed to 23 °C. The resulting suspension was diluted with EtzO (150 mL) and was washed with 1.0 M HCl (3 x 100 mL), half saturated NaHC03 (100 mL), and water (100 mL). The organic layer was dried over MgS04, filtered, and was concentrated to give crude BOC-L-(Tr-Glutaminal) (13.8 g, 97%) as a white solid: mp = 114-116 °C;
IR (KBr) 3313, 1697, 1494 crri';'H NMR (CDCl3) 8 1.44 (s, 9 H), 1.65-1.75 (m, 1 H), 2.17-2.23 (m, 1 H), 2.31-2.54 (m, 2 H), 4.11 (bs, 1 H), 5.38-5.40 (m, 1 H), 7.11 (s, 1 H), 7.16-7.36 (m, 15 H), 9.45 (s, 1 H).
Preparation of Intermediate Ethyl-3-[BOC-Ir(Tr-Gln)]-E-Propenoate.
Sodium bis(trimethylsilyl)amide (22.9 mL of a 1.0 M solution in THF, 22.9 mmol, 1.0 equiv) was added to a solution of triethyl phosphonoacetate (5.59 g, 22.9 mmol, 1.0 equiv) in THF (200 mL) at -78 °C, and the resulting solution was stirred for 20 min at that temperature. Crude [BOC-L-(Tr-Glutaminal)]-H (10.8 g, 22.9 mmol, 1 equiv) in THF (50 mL) was added via cannula, and the reaction mixture was stirred for 2 h at -78 °C, warmed to 0 °C for 10 min, and partitioned between 0.5 M HCI (150 mL) and a 1:1 mixture of EtOAc and hexanes (2 x 150 mL). The organic layers were dried over NazS04 and were concentrated. Purification of the residue by flash column chromatography (40%
EtOAc in hexanes) provided ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (10.9 g, 88%) as a white foam:
IR (thin film) 3321, 1710 cm''; 'H NMR (CDCl3) 8 1.27 (t, 3 H, J= 7.2), 1.42 (s, 9 H), 1.70-1.78 (m, 1 H), 1.80-1.96 (m, 1 H), 2.35 (t, 2 H, J= 7.0), 4.18 (q, 2 H, J= 7.2), 4.29 (bs, 1 H), 4.82-4.84 (m, 1 H), 5.88 (dd, 1 H, J= 15.7, 1.6), 6.79 (dd, 1 H, J=
15.7, 5.3), 6.92 (s, 1 H), 7.19-7.34 (m, 15 H); Anal. (C33H38NzOs) C, H, N.

Preparation of Intermediate Ethyl-3-[BOC-IrN-Me-Phe-L~-(Tr-Gln)]-E-Propenaate.
Ethyl-3-[BOC-L-(Tr-Gln)]-E-Propenoate (0.751 g, 1.38 mmol) was dissolved in 1,4; dioxane (5 mL). A solution of HCl in 1,4-dioxane (4.0 M, 5 mL) was added dropwise.
The reaction solution was stirred for 2 h and then the solvent was evaporated to provide the amine salt as a foam which was used without purification. The crude amine salt was dissolved in dry CHZC12 (12 mL) under argon. 4-Methylmorpholine (1.05 mL, 9.55 mmol), hydroxybenzotriazole hydrate (0.280 g, 2.07 mmol), BOC-L-N-Me-Phe (0.386 g, 1.38 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.397 g, 2.07 mmol) were added successively. The reaction mixture was stirred overnight and poured into water (25 mL). The resulting mixture was extracted with CHZCl2 (3 x 75 mL). The combined organic phases were dried over NaZS04 and evaporated. The residue was purified by chromatography (25% acetone in hexanes, then 3% MeOH in CHZC12) to provide ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)J- E-propenoate (0.40 g, 46%) as a foam:
IR (thin film) 3318, 1708, 1667 cm''; 'H NMR (CDC13) (major rotamer) b 1.28 (t, 3H, J=
7.2 Hz), 1.37 (s, 9H), 1.63-1.87 (m, IH), 1.94-2.06 (m, IH), 2.26-2.37 (m, 2H), 2.66 (s, 3 H), 3.00 (dd, 1 H, J = 13.5, 9.2 Hz), 3.29 (dd, 1 H, J = I 3. S, 6.4 Hz), 4.18 (q, 2H, J = 7.2 Hz), 4.51-4.70 (m, 2H), 5.71 (d, 1H, J=15.6 Hz), 6.40 (d, 1H, J= 8.1 Hz), 6.73 (dd, 1H, J
= 15.6, 4.8 Hz), 6.97 (s, 1H), 7.12-7.36 (m, 20H); Anal. (C43I-I49Ns06) C~ H, N.
Preparation of Intermediate Ethyl-3-[CBZ-L-N-Me-Phe-L-(Tr-Gln)]-E-Propenoate Ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.433 g, 0.615 mmol) was --dissolved in 1,4-dioxane (2.5 mL) and treated dropwise with a solution of hydrogen chloride in 1,4-dioxane (4.0 M, 2.5 mL). After stirring for 2 hours, the solvent was -SS-evaporated to provide ethyl-3-[L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate hydrochloride which was used without purification. One half of the crude amine salt formed was dissolved in dry CHZCIz (3 mL). 4-Methylmorpholine (0.169 mL, 1.54 mmol) and benzyl chloroformate (0.088 mL, 0.62 mmol) were added sequentially. After stirring overnight, the solvent was evaporated. The residue was purified by chromatography (20% to 25%
acetone in hexanes) to provide ethyl-3-[CBZ-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.112 g, 49%) as a foam: IR (thin film) 3316, 1708, 1684, 1664 cm'; 'H NMR (CDCI,) (major rotamer) 8 1.29 (t, 3H, J = 7.2 Hz), 1.59-1.72 (m, 1 H), 1.82-2.01 (m, 1 H), 2.19-2.26 (m, 2H), 2.73 (s, 3H), 2.99 (dd, 1H, J= 14.2, 9.2 Hz), 3.29 (dd, 1H, J= 14.2, 6.8 Hz), 4.18 (q, 2H, J= 7.2 Hz), 4.48-4.60 (m, 1H), 4.66 (dd, 1H, J= 9.2, 6.8 Hz), 4.93 (d, 1H, J= 12.3 Hz), 5.02 (d, 1 H, J = 12.3 Hz), 5.71 (dd, 1 H, J = 15.6, 1.6 Hz), 6.48 (d, 1 H, J = 8.1 Hz), 6.70 (dd, 1H, J= 15.6,5.4 Hz), 6.87 (s, 1H), 7.05-7.37 (m, 25H); Anal.
(C46H4,N3O6~O.S
Hz0) C, H, N.
Preparation of Product - Ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-Propenoate.
Ethyl-3-[CBZ-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.096 g, 0.13 mmol) was dissolved in dry CH,CI, (4 mL). Triisopropylsilane (0.077 mL, 0.376 mmol) and trifluoroacetic acid (2 mL) were added sequentially to give a bright yellow solution. After stirring for 30 min, no yellow color remained. The solvents were evaporated to give a semi-solid residue which was purified by chromatography (S% methanol in CHZCl2) to provide ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)- E-propenoate (0.061 g, 95%) as a colorless '-glass: IR (thin film) 3412, 3336, 3213, 1696, 1684, 1655 cm''; 'H NMR (CDCl3) (major isomer) b 1.28 (t, 3H, J= 7.2 Hz); 1.63-2.03 (m, 2H), 2.11-2.18 (m, 2H), 2.88 (s, 3H), 3.05 (dd, 1 H, J-- 14.0, 9.3 Hz), 3 .31 (dd, 1 H, J = 14.0, 6.8 Hz), 4.18 (q, 2H, J
= 7.2 Hz), 4.51-4.63 (m, 1 H), 4.71-4.80 (m. 1 H), 4.95-5.16 (m, 2H), 5.73 (d, 1 H, J =
15.9 Hz), 5.77-5.92 (m, 1 H), 6.10 (s, 1 H), 6.65-6.78 (m, 2H), 7.09-7.38 (m, l OH);
Anal.
(C27H33N306~O.7S HzO) C, H, N.
Example 2 - Preparation of Compound 2: Ethyl-3-(CBZ-1,-Leu-L-N-Me-Phe-IrGlny-E-Propenoate.
Preparation of Intermediate Ethyl-3-[CB~L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.216 g, 0.308 mmol) was deprotected and coupled with CBZ-L-Leu (0.082 g, 0.309 mmol) using the procedure described for the formation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate to provide ethyl-3-[CBZ-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate after two chromatographies (30% acetone/hexanes, then 2% methanol/CHZC12) as a glass (0.095 g, 36%): IR (thin film) 3304, 1708, 1659 cm'; 'H NMR (CDC13) (mixture of rotamers) b 0.63 (d, 3H, J= 6.7 Hz), 0.66 (d, 3H, J= 6.8 Hz), 0.83-0.89 (m, 6H), 1.12-1.48 (m, 4H), 1.26 (t, 3H, J= 7.2 Hz), 1.28 (t, 3H, J= 7.2 Hz), 1.51-1.66 (m, 2H), 1.69-1.80 (m, 1H), 1.88-2.04 (m, 2H), 2.16-2.32 (m, 4H), 2.90 (s, 6H), 2.95-3.17 (m, 2H), 3.25 (dd, 1H, J=
14.6, 3.4 Hz), 3.37 (dd, 1H, J= 13.7, 6.5 Hz), 4.11-4.25 (m, 2H), 4.17 (q, 4H, J= 7.2 Hz), 4.38-4.51 (m, 2H), 4.53-4.67 (m, 3H), 4.85-5.16 (m, 7H), 5.72 (d, 1H,J= 15.9 Hz), 5.95 (dd, 1H, J -= 15.9, 1.2 Hz), 6.43 (d, 1 H, J = 8.4 Hz), 6.74 (dd, 1 H, J = 1 S .9, 5.3 Hz), 6.80 (s, 1 H), -6. 84 (dd, 1 H, J = 15.9, 6.5 Hz), 7.09-7.3 8 (m, S OH), 8.00 (d, 1 H, J = 7.8 Hz); Anal. -(CSZHS$N40,~0.5 H20) C, H, N.

Preparation of Product - Ethyl-3-(CBZ-IrLeu-LrN-Me-Phe-IrGln)-E-Propenoate.
Ethyl-3-[CBZ-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.056 g, 0.066 mmol) was deprotected using the procedure described in Example 1 for the formation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate to provide ethyl-3-[CBZ-L-Leu-L-N-Me-Phe-L-GInJ-E-propenoate (after chromatography, 5%
MeOH
in CHZCIz) as a glass (0.029 g, 73%): IR (thin film) 3401, 3298, 3225, 1678, 1652 cm-'; 'H
NMR (CDC13) (mixture of isomers) b 0.62-0.69 (m, 6H), 0.87-0.94 (m, 6H), 1.15-1.32 (m, 8H), 1.37-1.49 (m, 2H), 1.61-1.86 (m, 4H), 1.90-2.03 (m, 2H), 2.10-2.20 (m, 4H), 2.93 (s, 3 H), 2.95 (s, 3 H), 2.97-3.11 (m, 1 H), 3.17-3.28 (m, 2H), 3.41-3.49 (m, 1 H), 4.16-4.29 (m, SH), 4.42-4.52 (m, 2H), 4.55-4.71 (m, 3H), 4.95-5.12 (m, 4H), 5.39-5.52 (m, 4H), 5.78 (d, 1 H, J = 15.9 Hz), 5.89 (s, 1 H), 6.00 (dd, 1 H, J = 15.9, 1.2 Hz), 6.08 (s, 1 H), 6.73-6.91 (m, 3H), 7.12-7.37 (m, 20H), 7.98 (d, 1H, J= 8.1 Hz); Anal. (C33HaaNaO,~0.5 HZO) C, H, N.
Example 3 - Preparation of Compound 3~ Ether=(CBZ-L-Leu-L-N-Me-~OMey Tyr-L-Gln]-E-Propenoate Preparation of Intermediate Ethyl-3-(BOC-L-N-Me-(OMe)-Tyr-L-(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-(Tr-Gln)J-E-propenoate (0.545 g, 1.00 mmol) was deprotected and coupled with the dicyclohexylamine salt of BOC-L-N-Me-(OMe)-Tyr (0.630 g, 1.28 mmol) using the procedure described in Example 1 for the formation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)J-E-propenoate to provide ethyl-3-[BOC-L-N-Me-(OMe)-Tyr-1.-(Tr-Gln)]-E-propenoate (after chromatography, 33%
EtOAc in hexanes) as a white foam (0.380 g, 52%): IR (thin film) 3307, 1708, 1672 cm';
'H NMR (CDC13) 8 1.28 (t, 3H, J'= 7.2 Hz), 1.38 (s, 9H), 1.60-1.77 (m, 1H), 1.94-2.07 (m, 1H), 2.27-2.36 (m, 2H), 2.67 (s, 3H), 2.89-2.99 (m, 1H), 3.18-3.27 (m, 1H), 3.78 (s, 3H), 4.18 (q, 2 H, J = 7.2 Hz), 4.44-4.6 5 (m, 2H), S .73 (d, 1 H, J = 15 .6 Hz), 6.3 S (d, 1 H, J = 8.7 Hz), 6.69-6.84 (m, 3H), 6.94 (s, 1 H), 7.04-7.12 (m, 2H), 7.17-7.34 (m, 1 SH);
Anal.
(CaaHsiN30~) C, H, N.
Preparation of Intermediate Ethyl-3-[CBZ-IrLeu-L-N-Me-(OMe)-Tyr-Ir(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-N-Me-(OMe)-Tyr-L-(Tr-Gln)]-E-propenoate (0.360 g, 0.491 mmol) was dissolved in 1,4-dioxane (2 mL). A solution of HCl in 1,4-dioxane (4.0 M, 2 mL) was added dropwise. The reaction solution was stirred for 2 h, and then the solvent was evaporated to provide the amine salt as a foam which was used without purification.
The crude amine salt was dissolved in dry CHZC12 (12 mL) under argon.
4-Methylmorpholine (0.208 mL, 1.89 mmol), CBZ-L-Leu (0.125 g, 0.471 mmol), hydroxybenzotriazole hydrate (0.096 g, 0.71 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.136 g, 0.709 mmol) were added successively. After stirring overnight, 4-methylmorpholine (0.208 mL, 1.89 mmol), hydroxybenzotriazole hydrate (0.096 g, 0.71 mmol), CBZ-L-Leu (0.125 g, 0.471 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.136 g, 0.709 mmol) were added again. Then 4-dimethylaminopyridine (0.010 g, 0.082 mmol) was added.
After stirring 48 h more, the reaction mixture was poured into water (15 mL).
The resulting mixture was extracted with CH2C12 (3x 75 mL). The combined organic phases were dried over NazS04 and evaporated. The residue was purified by chromatography (38% to 50% EtOAc in hexanes) to provide ethyl-3-[CBZ-L-Leu-L-N-Me-(OMe)-Tyr-L-(Tr-Gln)]- E-propenoate (0.210 g, S l %) as a colorless glass: IR (thin film) 3295, 1708, 1660 cm'; 'H NMR (CDCl3) (mixture of rotamers) b 0.65 (d, J= 6.5 Hz), 0.68 (d, J= 6.8 Hz), 0.82-0.91 (m), 1.14-1.50 (m), 1.52-1.66 (m), 1.68-1.81 (m), 1.87-2.02 (m), 2.16-2.28 (m), 2.89 (s), 2.92 (s), 2.95-3.09 (m), 3.14-3.23 (m), 3.24-3.33 (m), 3.76 (s), 3.76 (s), 4.08-4.25 (m), 4.41-4.49 (m), 4.54-4.63 (m), 4.83-5.16 (m), 5.73 (d, J= 15.6 Hz), 5.95 (dd, J= 15.7, 1.1 Hz), 6.40 (d, J=
8.4 Hz), 6.74 (dd, J= 15.6, 5.0 Hz), 6.78-6.87 (m), 6.99-7.06 (m), 7.16-7.34 (m), 7.97 (d, J
= 7.8 Hz); Anal. (C53H6oN408~0.5 H20) C, H, N.
Preparation of Product -Ethyl-3-[CBZ-L-Leu-L-N-Me-(OMe)-Tyr-L-Gln]-E-Propenoate.
Ethyl-3-[CBZ-1.-Leu-L-N-Me-(OMe)-Tyr-L-(Tr-Gln)]-E-propenoate (0.128 g, 0.145 mmol) was deprotected using the procedure described in Example 1 for the formation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate to provide ethyl-3-[CBZ-L-Leu-L-N-Me-(OMe)-Tyr-L-Gln]-E-propenoate (after chromatography, 5%
MeOH in CHZCIZ) as a colorless glass (0.083 g, 89%): IR (thin film) 3401, 3295, 3201, 1708, 1666, 1637 cm '; 'H NMR (CDCI,) (mixture of rotamers) b 0.64-0.71 (m), 0.87-0.94 (m), 1.27 (t, J= 7.2 Hz), 1.28 (t, J= 7.2 Hz), 1.38-1.51 (m), 1.61-1.85 (m), 1.87-2.02 (m), 2.07-2.21 (m), 2.80-2.92 (m), 2.94 (s), 2.96 (s), 2.97-3.06 (m), 3.08-3.21 (m), 3.36 (dd, J=
14.0, 6.2 Hz), 3.76 (s), 4.16-4.28 (m), 4.18 (q, J= 7.2 Hz), 4.45-4.66 (m), 4.94-5.12 (m), 5.52 (d, J= 7.8 Hz), 5.58 (d, J= 7.8 Hz), 5.69 (s), 5.77 (d, J= 15.9 Hz), 5.99 (s), 6.00 (dd, J= 15.9, 1.2 Hz), 6.21 (s), 6.76 (dd, J= 15.9, 5.3 Hz), 6.79-6.91 (m), 7.02-7.10 (m), 7.26-7.37 (m), 7.97 (d, J= 8.1 Hz); (C3~H46N408~0.5 H20) C, H, N.

Example 4 - Preparation of Compound 5: Ethy~Cyclopentylthiocarbon ~~1-L-Leu-L-N-Me-Phe-L-Gln)-E-Propenoate.
Preparation of Cyclopentyl Chlorothiolformate.
Cyclopentanethiol (10.7 mL, 0.1 mol) was dissolved in 200 mL of CHZCIz.
Triphosgene (11.13 g, 37.5 mmol) was added, and the reaction mixture was cooled to 0 'C.
Et3N (14.1 mL, 0.1 mol) was added dropwise, and the reaction was allowed to warm to room temperature over a period of one hour. The solvent was carefully removed under reduced pressure at 20 'C due to the volatility of the product. The resulting residue was taken up in Et20, and the solids were filtered and washed with more Et20. The solvent was again carefully removed under reduced pressure, and the product was purified by distillation (85% yield): colorless liquid (bp 70-74 °C; 1 torr):
IR(neat) 1756, 830 crri';'H
NMR (benzene-db) 8 1.01-1.23 (m, 6H), 1.49-1.60 (m, 2H), 3.20-3.29 (m, 1H).
Preparation of Intermediate Cyclopentylthiocarbonyl-LrLeu-OBn.
The p-toluenesulfonic acid salt of L-Leu-OBn (3.14 g, 8.0 mmol) was dissolved in 70 mL of CHZC12, followed by 2.25 mL (16 mmol) of Et,N. Cyclopentyl chlorothiolformate (1.32 g, 8.0 mmol) was dissolved in 10 mL of CHZC12 and added dropwise to the reaction. The reaction was stirred one hour, and the solvent was removed in vacuo. The product was purified by flash silica gel chromatography eluting with 5%
EtOAc/ hexanes to give 2.48 g (71 %) of a clear oil; IR(KBr) 3318, 2959, 2870, 1744, 1649, 1516, 1186, 854, 746, 696 cm'; 'H NMR (DMSO-d6) b 0.82 (d, 3H, J= 6.0 Hz), 0.86 (d, 3H, J= 6.0 Hz), 1.39-1.70 (m, 9H), 1.97 (m, 2H), 3.55 (quint, 1H, J= 7.0 Hz), 4.23 (m, 1 H), S .09 (d, 1 H, J = 12.5 Hz), 5.13 (d, 1 H, J = 12.5 Hz), 7.3 5 (m, 5 H), 8.48 (d, 1 H, J = 7.7 Hz). Anal. (C,9HZ,N03S) C, H, N.
Preparation of Intermediate Cyclopentylthiocarbonyl-L-Leu.
Cyclopentylthiocarbonyl-L-Leu-OBn (2.42 g, 6.92 mmol) was dissolved in 35 mL
of CHZC12, followed by 4.51 mL (41.5 mmol) of anisole. The reaction was cooled to 0'C, and AlCl3 (2.88 g, 21.6 mmol), dissolved in 35 mL of nitromethane, was added dropwise via pipet. The ice bath was removed, and the reaction was allowed to stir at rt for 5 h. The reaction was diluted with EtOAc and washed with 10% HCI. The organic phase was washed with a sat. NaHCO, solution. The basic solution was then reacidified to a pH = 1 with 10% HCI, and the product was extracted with EtOAc. The organic layer was dried (MgS04), filtered, and concentrated under reduced pressure to give 0.23 g (93%) of an opaque oil: IR(neat) 3302-2473 (bs), 1715, 1652, 1532, 1202, 925, 852, 673, 563 cm'; 'H
NMR (DMSO-d6) 8 0.82 (d, 3H, J= 6.6 Hz), 0.86 (d, 3H, J= 6.6 Hz), 1.40-1.70 (m, 9H), 1.98 (m, 2H), 3.53 (quint, 1H, J= 7.0 Hz), 4.18 (m, IH), 8.29 (d, IH, J= 8.0 Hz), 12.58 (bs). Anal. (C,ZHz,N03S) C, H, N.
Preparation of Intermediate CBZ-L-(Tr-Gln).
CBZ-L-Gln (28.03 g, 100 mmol) was dissolved in 300 mL of glacial acetic acid.
To this solution was added triphenylmethanol (26.83 g, 100 mmol), acetic anhydride (18.87 mL, 200 mmol), and 0.5 mL of conc. sulfuric acid. The reaction was heated to 55 °C and stirred for one hour. After cooling to room temperature, the mixture was concentrated under reduced pressure to one-third the original volume. Ice water was added, and the product extracted with EtOAc. The organic layer was washed with water and brine, dried over MgS04, and concentrated. The crude product was recrystallized from CHZCIz/hexane, and the resulting crystals washed with EtzO, yielding 37.27 g (71%) as a white solid: IR
(KBr) 3418, 3295, 3059, 3032, 2949, 2515, 1699, 1628, 1539, 1504, 1447, 1418, 1341, 1242, 1209, 1061, 748, 696 cm''; 'H NMR (DMSO-d6) b 1.71 (m, 1 H), 1.88 (m, 1 H), 2.38 (m, 2 H), 3.97 (m, 1 H), 5.04 (s, 2 H), 7.14-7.35 (m, 20H), 7.52 (d, 1 H, J= 7.7 Hz), 8.60 (s, 1 H).
Preparation of Intermediate CBZ-L-(Tr-Gln)OMe.
CBZ-L-(Tr-Gln) (0.26 g, 0.5 mmol) was added to a stirnng solution of 0.25 mL
of acetyl chloride in S mL of MeOH, and stirring was continued at room temperature for 1 h.
The solvent was removed in vacuo, and the residue dissolved in 100 mL CHZCIz.
The organic layer was washed with water, saturated NaHC03, and brine, followed by drying over NazS04. The crude product was purified on a short flash silica gel column, eluting with 20% EtOAc/hexane. The product (0.23 g, 84%) was obtained as a white solid:
IR (KBr) 3405, 3277, 3057, 3034, 2953, 1724, 1643, 1532, 1493, 1447, 1207, 1042, 750, 698 crri';'H NMR (DMSO-db) S 1.16 (t, 1 H, J= 7.0 Hz), 1.77 (m, 1 H), 1.97 (m, 1H), 3.61 (s, 3H), 4.99 (m, 1H), 5.03 (s, 2H), 7.02-7.55 (m, 20H), 7.69 (d, 1H, J=
7.7 Hz), 8.59 (s, 1 H). Anal. (C33H3zNzOs) C, H, N.
Preparation of Intermediate CBZ-L-('Tr-Glutaminol). - -CBZ-L-(Tr-Gln)OMe (1.50 g, 2.79 mmol) was dissolved in 20 mL of THF and 10 mI, of EtOH. LiCI (0.24 g, 5.6 mriiol) was added, and the mixture stirred for 10 minutes until all solids had dissolved. NaBH4 (0.21 g, 5.6 mmol) was added, and the reaction was stirred overnight at room temperature. The solvents were removed in vacuo, the residue taken up in water, and the pH was adjusted to 2-3 with 10% HCI. The product was extracted with EtOAc, and the organic layer was washed with water and brine before drying over MgS04. The crude product was purified on a short flash silica gel column, eluting with an increasing gradient of EtOAc/benzene, yielding 1.02 g (72%) of a white glassy solid: IR (KBr) 3408, 3318, 3057, 3032, 2947, 1699, 1674, 1516, 1447, 1240, 1059, 752, 698 crti';'H NMR (DMSO-d6) 8 1.40 (m, 1H), 1.72 (m, 1H), 2.26 (m, 2H), 3.17-3.50 (m, 3H), 4.64 (t, 1H, J= S.0 Hz), 5.00 (s, 2H), 7.00-7.40 (m, 20H), 6.96 (d, 1H, J= 8.5 Hz), 8.54 (s, 1 H). Anal. (C3zH32N204) C~ H, N.
Preparation of Intermediate L-(Tr-Glutaminol).
10% Pd on carbon (0.03 g) was added to a solution of CBZ-L-(Tr-Glutaminol) (0.51 g, 1.0 mmol) in 20 mL MeOH, with stirring, and under an argon atmosphere. The reaction vessel was evacuated under vacuum and then put under an atmosphere of hydrogen using a balloon. The mixture was stirred far 4 h. At this time the hydrogen gas was evacuated and the catalyst was removed by filtration. The solvent was removed under vacuum to give a white solid in 98% yield which was used without further purification: IR (KBr) 3255, 3057, 3016, 2916, 1642, 1527, 1491, 1446, 1057, 1036, 750, 700, 636 cm'; 'H NMR
(DMSO-d6) 8 1.29 (m, 1H), 1.53 (m, 1_H), 2.29 (m, 2H), 3.08 (m, 1H), 3.18 (m, 2H), 3.38 (bs, 2H), 4.43 -(bs, 1H), 7.14-7.28 (m, 15H), 8.62 (s, 1H). Anal. (Cz4Hz6NzOz) C, H, N. --Preparation of Intermediate CBZ-LrN-Me-Phe-L-(Tr-Glutaminol).
CBZ-N-Me-L-Phe (2.24 g, 7.14 mmol) was dissolved in 70 mL of THF.
Carbonyldiimidazole (1.16 g, 7.14 mmol) was added, and the reaction was stirred for one hour at rt. t,-(Tr-Glutaminol) (2.80 g, 7.5 mmol) was added, and the reaction was stirred overnight. At this time the solvent was removed in vacuo, and the product was purified by column chromatography on silica gel using a gradient solvent system (0-2%
MeOH/CHC13) to give 3.37 g (70%) of a white amorphous solid: IR(KBr) 3304, 3057, 3028, 2949, 1668, 1495, 1447, 1142, 750, 698 cm-'; 'H NMR (DMSO-db) 8 1.51 (m, 1H), 1.73 (m, 1H), 2.23 (m, 2H), 2.79 (s, 3H), 2.84 (m, 1H), 3.29 (m, 3H), 3.70 (m, 1H), 4.66 (m, 1H), 4.88 (m, 3H), 7.15-7.28 (m, 25H), 7.69 (m, 1H), 8.55 (m, 1H). MS calcd for C4zH43N305+H
670, found 670.
Preparation of Intermediate L-N-Me-Phe-L-(Tr-Glutaminol).
CBZ-L-N-Me-Phe-L-(Tr-glutaminol) (3.33 g, 4.97 mmol) was dissolved in 35 mL
of MeOH. The reaction was placed under slight vacuum, and then under an argon atmosphere. With care, 10% Pd/C (0.33 g) was added. The flask was purged of argon which was replaced by hydrogen gas using a balloon. The reaction mixture was stirred at room temperature for 4.5 h, at which time the flask was purged of hydrogen and the catalyst was filtered off. Solvent was removed in vacuo to give 2.36 g (89%) of a white amorphous solid: IR(KBr) 3302, 3057, 3024, 2937, 1655, 1522, 1493, 1447, 750, cm'; 'H NMR (DMSO-db) 8 1.44 (m, 1H), 1.67 (m, 1H), 2.13 (m, 1H), 2.16 (s, 3H), --2.24 (m, 1H), 2.68 (dd, 1H, J = 13.5, 7.3 Hz), 2.82 (dd, 1H, J = 13.5, 5.8 Hz), 3.10 (m, 2H), 3.25 (m, 1H), 3.67 (m, 1H), 4.63 (t, 1H, J = 5.5 Hz), 7.13-7.28 (m, 21H), 7.54 (d, 1H, J = 8.8 Hz), 8.54 (s, 1H). Anal. (C34H3,N3O3) C, H, N.
Preparation of Intermediate Cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gtutaminol).
This preparation was carried out following the procedure of L. A. Carpino, J.
Am.
Chem. Soc. 1993, 115, 4397, the disclosure of which is entirely incorporated herein by reference. Cyclopentylthiocarbonyl-L-Leu (0.27 g, 1.05 mmol) was dissolved in 3.5 mL of DMF. Diisopropylethylamine (0.37 mL, 2.10 mmol) was added, followed by 0.56 g (1.05 mmol) of L-N-Me-Phe-L-(Tr-glutaminol). The reaction was cooled to 0 'C and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (0.398 g, I.OS mmol) was added. The reaction mixture was allowed to warm to room temperature whereupon the DMF was removed in vacuo. The residue was dissolved with EtOAc, and the organic phase washed consecutively with 10% HCI solution, saturated NaHC03 solution, H20, and brine. The solvent was dried (MgS04), filtered, and concentrated to give a residue which was subjected to flash column chromatography on silica gel (gradient; 0-1% MeOH/CHC13) to give 0.49 g (60%) of a white amorphous solid:
IR(KBr) 3293, 3057, 3024, 2955, 2868, 1634, 1493, 1447, 1205, 752, 700 cm'';'HNMR
(DMSO-db) (mixture of rotamers) b -0.18 (m), 0.62 (m), 0.79 (d, J= 6.3 Hz), 1.00-2.05 (m), 2.08-2.40 (m), 2.81 (s), 2.88 (m), 2.95 (s), 3.05-3.53 (m), 3.65 (m), 3.79 (m), 4.27 (m), 4.61 (m), 5.11 (m), 7.14-7.28 (m), 7.43 (d, J= 8.0 Hz), 7.64 (d, J= 8.8 Hz), 8.17 (d, J= 8.0 Hz), 8.43 (d, J= 7.0 Hz), 8.51 (s). MS calcd for C46Hs6Na0sS+Cs 909, found 909.

Preparation of Intermediate C~clopentylthiocarbonyt-L-Leu-L-N-Me-Phe-L-(Tr-Glutaminal).
To cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-glutaminol) (0.57 g, 0.73 mmol) dissolved in 7 mL of DMSO was added o-iodoxybenzoic acid (0.61 g, 2.19 mmol).
The reaction mixture was stirred at rt for 1.5 h. The DMSO was then removed under reduced pressure, and the residue was diluted with CHZC12 and reconcentrated to remove any residual DMSO. Dilution with CHZCl2 and reconcentration was repeated, and the residue was diluted with EtOAc to give a white precipitate which was filtered off. The solvent was washed with a S% Na2S203/5% NaHCO, solution, water, and brine before drying over MgS04. Removal of the solvent under vacuum gave 0.41 g (72%) of a white glassy solid which was used immediately without further purification: 'H NMR
(DMSO-d6) (mixture of rotamers) 8 -0.03 (m), 0.62 (m), 1.04-2.10 (m), 2.20-2.45 (m), 2.82 (s), 2.90 (m), 2.94 (s), 3.21 (m), 4.00 (m), 4.14 (m), 4.34 (m), 4.62 (m), 4.81 (m), 5.17 (m), 7.14-7.28 (m), 8.1 S (d, J= 7.0 Hz), 8.25 (d, J= 7.0 Hz), 8.35 (d, J= 7.0 Hz), 8.41 (d, J=
7.0 Hz), 8.57 (s), 8.62 (s), 9.27 (s), 9.43 (s).
Preparation of Intermediate Ethyl-3-[Cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-Propenoate.
Cyclopentylthiocarbonyl-L-Leu-N-Me-L-Phe-L-(Tr-glutaminal) (0.19 g, 0.25 mmol) was dissolved in S mL of THF. (Carbethoxymethylene)triphenylphosphorane (0.10 g, 0.30 mmol) was added, and the reaction was stirred overnight at rt. The solvent was removed in vacuo, and the residue purified by flash column chromatography on silica gel (gradient;
0-0.75 % MeOH/CHCl3) to give 0.25 g of material that was contaminated by triphenylphosphine oxide. This material was used without further purification:
'H NMR
(DMSO-db) (mixture of rotamers) b -0.16 (m), 0.62 (m), 0.79 (d, J= 6.3 Hz), 1.10 (m), 1.20 (t, J= 7.0 Hz), 1.30-1.78 (m), 1.95 (m), 2.10-2.42 (m), 2.80 (s), 2.88 (m), 2.95 (s), 3.16 (m), 3.48 (m), 4.10 (q, J= 7.0 Hz), 4.11 (q, J= 7.0 Hz), 4.37 (m), 4.53 (m), 4.63 (m), 4.81 (m), 5 .06 (m), S .66 (d, J = 16.0 Hz), 5.93 (d, J = 16.0 Hz), 6.71 (dd, J = 16.0, 6.0 Hz), 6.80 (d, J= 16.0, 6.O~Hz), 7.13-7.28 (m), 7.97 (d, J= 8.0 Hz), 8.07 (d, J= 8.0 Hz), 8.16 (d, J= 7.0 Hz), 8.49 (d, J= 6.0 Hz), 8.55 (s), 8.60 (s).
Preparation of Product Ethyl-3-(Cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-Propenoate.
Ethyl-3-[cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.25 g) was dissolved in S mL of CHZC12. Trifluoroacetic acid (0.5 mL) was added, and the reaction was stirred at rt for 4 h. The solvent was removed in vacuo, and the residue purified by flash column chromatography on silica gel (gradient; 0-2 %
MeOH/CHC13) to give 0.11 g (74% for two steps from the aldehyde intermediate) as a white amorphous solid: mp = 68-72 °C; IR(KBr) 3283, 2955, 1634, 1531, 1277, 1205 cm'';'H NMR
(DMSO-db) (mixture of rotamers) 8 -0.26 (m), 0.61 (m), 0.82 (d, J= 6.3 Hz), 0.83 (d, J=
6.3 Hz), 1.13 (m), 1.20 (t, J= 7.0 Hz), 1.30-2.12 (m), 2.77 (s), 2.90 (m), 2.94 (s), 3.11 (m), 3.47 (m), 4.10 (q, J= 7.0 Hz), 4.11 (q, J= 7.0 Hz), 4.38 (m), 4.50 (m), 4.67 (m), 4.81 (m), 5.04 (m), 5.69 (d, J= 15.0 Hz), 5.99 (d, J= 15.0 Hz), 6.72 (dd, J= 15.0, 5.5 Hz), 6.76 (bs), 6.83 (d, J= 15.0, S.5 Hz), 7.12-7.30 (m), 7.99 (d, J= 8.0 Hz), 8.04 (d, J= 8.0 Hz), 8.19 (d, J= 8.0 Hz), 8.52 (d, J= 6.0 Hz). HRMS calcd for C"H,~N,06S+Cs 735.2192, found 735.2174. Anal. (C31H46N406S) C, H, N.

Example 5 - Preparation of Compound 6: 2-(Cvclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-(a-Vinyl-y-Butyrolactoney.
Preparation of Intermediate 2-[Cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)J- E-(a-Vinyl-y-Butyrolactone).
Using the procedure described in Example 4 for the preparation of ethyl-3-[cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, this intermediate was synthesized from cyclopentylthiocarbonyl-L-Leu-L-N-Me-L-Phe-L-(Tr-glutaminal) (0.205 g, 0.264 mmol) and a-(triphenylphosphoranylidene)-y-butyrolactone (0.12 g, 0.343 mmol) (prepared from a-bromo-y-butyrolactone according to the procedure of J. E. Baldwin, et al., Tetrahedron;
1992, 48, 9373, the disclosure of which is entirely incorporated herein by reference) in 5 mL THF to give 0.28 g of product contaminated with triphenylphosphine oxide which was used without further purification: 'H NMR (DMSO-d6) (mixture of rotamers) b -0.12 (m), 0.60 (m), 0.79 (d, J= 6.3 Hz), 1.10-2.18 (m), 2.10-2.49 (m), 2.80 (s), 2.89 (m), 2.94 (s), 3.09-3.57 (m), 4.30 (m), 4.42 (m), 4.85 (m), S.O1 (m), 6.26 (m), 6.42 (m), 7.10-7.29 (m), 8.01 (d, J= 8.0 Hz), 8.06 (d, J= 8.0 Hz), 8.18 (d, J= 7.0 Hz), 8.48 (d, J= 7.0 Hz), 8.53 (s), 8.59 (s).
Preparation of Product - 2-(Cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-(a-Vinyl-yButyrolactone).
Using the procedure described in Example 4 for the preparation of ethyl-3-(cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-propenoate, 2-(cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-(a-vinyl-'y-butyrolactone) was synthesized from 2-[cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Tr-Gln)]-E-(a-vinyl-y-butyrolactone) in 49% yield (two steps from the aldehyde): white amorphous solid: mp = 87-91 'C: IR(KBr) 3286, 2963, 1749, 1668, 1634, 1531, 1452, 1205, 1138 cni';
'H NMR (DMSO-db) (mixture of rotamers) b -0.12 (m), 0.58 (m), 0.83 (m), 1.08 (m), 1.20-1.79 (m), 2.01 (m), 2.77 (s), 2.84 (m), 2.94 (s), 3.12 (m), 3.53 (m), 4.26-4.43 (m), 4.68 (m), 4.96 (m), 6.26 (m), 6.39 (m), 6.76 (bs), 7.12-7.27 (m), 8.04 (m), 8.19 (d, J= 8.0 Hz), 8.50 (d, J= 7.0 Hz). HRMS calcd for C"H"N,O6S+Cs 733.2036, found 733.2053.
Anal.
(C3,H~N406S ~0.75 CHC13) C, H, N.
Example 6 - Preparation of Compound 7' 1-(2'.3'-Dihydroindolin 111 3-lEthylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-Pronenone Preparation of Intermediate BOC-lrLeu-L-N-Me-Phe-OMe.
N-Me-Phe-OMe~HCl (1.4 g) was dissolved in CH,CI= (SO mL) and poured into a combination of 1 N NaOH (aq, 7 mL) and sat. NaHC03 (25 mL). After mixing, the organic phase was separated, and the aqueous phase was washed with CHZCIz (3 x SO mL).
The combined organic phases were dried over Na2S0; and evaporated to give the free amine as a clear colorless oil (1.14 g, 5.90 mmol). A solution of this amine and diisopropylethylamine (1.13 mL, 6.49 mmol) in DMF (10 mL) was added dropwise to a 0 °C solution of BOC-L-Leu (1.50 g, 6.49 mmol) and hydroxybenzotriazole hydrate (0.877 g, 6.49 mmol) in DMF (10 mL). Dicyclohexylcarbodiimide (1.47 g, 7.12 mmol) was added. The reaction mixture was stirred at 0 °C for 1 h, and was then stirred at rt for _ 48 h. The mixture was filtered to remove the precipitate, and the filtrate was evaporated. '-The residue was dissolved in CHZCIz (200 mL), washed with sat. NaHC03 (40 mL), dried over Na2S04, and evaporated. The residue was purified by chromatography (25%
EtOAc _70_ in hexanes) to give BOC-L-Leu-L-N-Me-Phe-OMe as a white solid (2.04 g, 85%):
mp =
126-127 °C; IR (thin film) 3401, 3319, 1743, 1708, 1649 cm'; 'H NMR
(CDCl3) (major rotamer) 8 0.92 (d, 3H, J= 6.8 Hz), 0.95 (d, 3H, J= 6.5 Hz), 1.32-1.48 (m, 2H), 1.41 (s, 9H), 1.61-1.77 (m, 1H), 2.90 (s, 3H), 3.04 (dd, 1H, J= 14.5, 10.5 Hz), 3.37 (dd, 1H, J=
14.5, 5.5 Hz), 3.72 (s, 3H), 4.48-4.57 (m, 1H), 4.98-5.04 (m, IH), 5.20 (dd, 1H, J= 10.5, 5.5 Hz), 7.16-7.32 (m SH); Anal. (CzzH34N20s) C, H, N.
Preparation of Intermediate BOC-L-Leu-L-N-Me-Phe.
BOC-L-Leu-L-N-Me-Phe-OMe (0.625 g, 1.54 mmol) was dissolved in MeOH (20 mL) and cooled to 0 °C. A solution of 2 N NaOH (aq, 6.15 mL, 12.3 mmol) was added dropwise. The reaction mixture was stirred for 3 h at rt and poured into 10%
aq ICHS04 (150 mL). This mixture was extracted with CHZCIz (3 x 100 mL), and the combined organic phases were dried over NazS04 and evaporated to give BOC-L-Leu-L-N-Me-Phe as a white foam (0.617 g, quantitative yield) which was used without purification.
Preparation of Intermediate [2-(2,3-Dihydroindol-1-yl)-2-oxo-ethylJ-Phosphonic Acid Diethyl Ester.
Oxalyl chloride (5.96 mL, 68.3 mmol) was added to a solution of diethylphosphonoacetic acid (12.8 g, 65.0 mmol) and DMF (0.03 mL, 0.39 mmol) in benzene (150 mL) at 23 °C. The reaction mixture was stirred at 23 °C for 1 °h and then was concentrated under reduced pressure. The resulting oil was dissolved in THF (30 mL) and was added via cannula to a solution of indoline (7.38 g, 61.9 mmol) and triethylamine (10.9 mL, 78.0 mmol) in THF (200 mL) at 0 °C. The reaction mixture was stirred at 0 °C

for 1 S min, and then it was partitioned between 0.5 M HC1 (150 mL) and EtOAc (2 x 150 mL). The combined organic layers were dried over NazS04 and concentrated to afford a tan solid. Recrystallization from Et20 provided [2-(2,3-dihydroindol-1-yl)-2-oxo-ethyl]-phosphonic acid diethyl ester (12.2 g, 63%) as a light brown solid: mp = 97-99 °C; IR
(KBr) 3460, 1657, 1597, 1482 cm''; 'H NMR (CDC13) 8 1.35 (t, 6H, J= 7.2), 3.14 (d, 2H, J
= 22.4), 3.22 (d, 2H, J= 8.4), 4.15-4.30 (m, 6H), 7.04 (t, 1H, J= 7.0), 7.17-7.28 (m, 2H), 8.21 (d, 1H, J= 9.0); Anal. (C,4HzoN04P) C, H, N.
Preparation of Intermediate 1-(2',3'-Dihydroindolin-1-yl)-3-(BOC-L-(Tr-Gln)]-E-Propenone.
Sodium bis(trimethylsilyl)amide (11.9 mL of a 1.0 M solution in THF, 11.9 mmol, 1.0 equiv) was added to a solution of [2-(2,3-dihydroindol-1-yl)-2-oxo-ethyl]-phosphoric acid diethyl ester (3.54 ~g, 11.9 mmol, 1.0 equiv) in THF ( 150 mL) at -78 °C, and the resulting solution was stirred for 20 min at that temperature. Crude BOC-L-(Tr-Glutaminal) (5.63 g, 11.9 mmol, 1 equiv) in THF (40 mL) was added via cannula, and the reaction mixture was stirred for 1 h at -78 °C, warmed to 0 °C for 10 min, and partitioned between 0.5 M HCI (150 mL) and EtOAc (2 x 150 mL). The organic layers were dried over NazS04 and concentrated. Purification of the residue by flash column chromatography (50% EtOAc in hexanes) provided 1-(2',3'-dihydroindolin-1-yl)-3-[BOC-L-(Tr-Gln)]-E-propenone as an off white foam: IR
(thin film) 3401, 3307, 1690, 1665 cni';'H NMR (CDC13) b 1.44 (s, 9H), 1.76-2.05 (m, 2H), 2.37-4.06 (m, 2H), 3.11-3.22 (m, 2H), 4.02-4.16 (m, 2H), 4.27-4.40 (m, 1H), 4.91-4.97 (m, 1H), 6.29 (d, 1H, J= 14.9), 6.77-6.96 (m, 2H), 6.98-7.OS (m, 1H), 7.14-7.37 (m, 17H), 8.25 (d, 1H, J= 7.S); Anal. (C39H4,N3O4) C, H, N.
Preparation of Intermediate 1-(2',3'-Dihydroindolin-1-yl)-3-[BOC-L-Leu-L-N-Me-Phe- L-(Tr-Gln)]-E-Propenone.
1-(2',3'-Dihydroindolin-1-yl)-3-[BOC-L-(Tr-Gln)]-E-propenone (0.420 g, 0.682 mmol) was dissolved in 1,4-dioxane (3 mL). A solution of HCl in 1,4-dioxane (4.0 M, 3 mL) was added dropwise. After stirring for 2 h, the solvent was evaporated to give the amine salt which was used without purification. This crude amine salt was coupled to BOC-L-Leu-L-N-Me-Phe (0.302 g, 0.769 mmol) using the procedure described in Example 6 for the formation of BOC-L-Leu-L-N-Me-Phe-OMe to give 1-(2',3'-Dihydroindolin-1-yl)-3-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenone (after chromatography, 43% EtOAc in hexanes to 100% EtOAc) as an off white foam (0.323 g, S3%): IR (thin film) 3401, 3295, 1660 cm'; 'H NMR (CDCl3) (mixture of isomers) b 0.65 (d, J= 6.S Hz), 0.85 (d, J= 6.8 Hz), 0.88 (d, J= 6.S Hz), 1.04-1.21 (m), 1.23-1.48 (m), 1.34 (s), 1.41 (s), 1.56-1.67 (m), 1.82-1.94 (m), 1.95-2.09 (m), 2.26-2.36 (m), 2.90 (s), 2.99 (dd, J= 14.3, 10.4 Hz), 3.13-3.22 (m), 3.30 (dd, J= 14.3, 3.6 Hz), 3.97-4.18 (m), 4.38-4.47 (m), 4.SS-4.77 (m), 4.83-4.90 (m), 6.18 (d, J= 14.0 Hz), 6.35-6.46 (m), 6.72 (s), 6.82-6.91 (m), 6.99-7.35 (m), 8.17 (d, J= 8.4 Hz), 8.25 (d, J= 8.1 Hz); Anal.
(CSSH63N506~U~7S HZO) C, H, N.

Preparation of Intermediate 1-(2',3'-Dihydroindolin-1-yl)-3-[Ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-Propenone.
1-(2',3'-Dihydroindolin-1-yl)-3-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenone (0.315 g, 0.355 mmol) was dissolved in 1,4-dioxane (6 mL). A solution of HCl in 1,4-dioxane (4.0 M, 4 mL) was added dropwise. After stirring for 2 h, the solvent was evaporated to give the amine salt which was used without purification. This crude amine salt was dissolved in dry CHZCIZ (8 mL) under argon, and diisopropylethylamine (0.136 mL, 0.781 mmol) was added. Ethyl chlorothiolformate (0.044 mL, 0.422 mmol) was added. The reaction solution was stirred 2 h and then poured into water (15 mL). The resulting mixture was extracted with CHZCIZ (3 x 50 mL). The combined organic phases were dried over Na2S04 and evaporated. The residue was purified by chromatography (50%-67% EtOAc in hexanes) to give 1-(2',3'-Dihydroindolin-1-yl)-3-[Ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-Propenone as a white foam (0.127 g, 41 %): IR
(thin film) 3284, 1660, 1637, 1596 cm'';'H NMR (CDCl3) (mixture of isomers) 8 0.59-0.76 (m), 0.82-0.89 (m), 1.15 (t, J= 7.3 Hz), 1.24 (t, J= 7.3 Hz). 1.32-1.44 (m), 1.52-1.76 (m), 1.83-2.11 (m), 2.04 (s), 2.25-2.36 (m), 2.63-3.41 (m), 2.88 (s), 2.89 (s), 3.94-4.19 (m), 4.34-4.44 (m), 4.50-4.72 (m), 5.82 (d, J= 7.5 Hz), 5.92 (d, J= 7.5 Hz), 6.22 (d, J= 14.6 Hz), 6.38 (d, J= 15.0 Hz), 6.65 (d, J= 8.4 Hz), 6.72-6.95 (m), 6.99-7.06 (m), 7.08-7.34 (m), 8.03 (d, J= 7.8 Hz), 8.22-8.28 (m); Anal. (C53HS9NSOSS) C, H, N.
Preparation of Product 1-(2',3'-Dihydroindolin-1-yl)-3-(Ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-Propenone.
1-(2',3'-Dihydroindolin-1-yl)-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenone (0.110 g, 0.125 mmol) was deprotected using the procedure described in Example 1 for the formation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate to give 1-(2',3'-dihydroindolin-1-yl)-3-(ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-propenone (after chromatography, 8% MeOH in CHZC12 , and evaporation from EtzO) as a white waxy material (0.044 g, 55%): IR (thin film) 3389, 3284, 3213, 1660, 1631 cm-';'H
NMR
(CDCl3) (mixture of isomers) b 0.61-0.78 (m), 0.91 (d, J= 6.5 Hz), 0.92 (d, J=
6.2 Hz), 1.18-1.34 (m), 1.39-1.57 (m), 1.58-1.85 (m), 1.87-2.11 (m), 2.15-2.33 (m), 2.72-3.31 (m), 2.96 (s), 3.41-3.50 (m), 4.03-4.20 (m), 4.42-4.77 (m), 5.78 (d, J= 12.4 Hz), 6.01 (s, bs), 6.26-6.49 (m), 6.57 (d, J= 7.2 Hz), 6.80-6.97 (m), 6.99-7.35 (m), 7.91 (d, J=
8.1 Hz), 8.22-8.30 (m); Anal. (C34HasNsOsS) C, H, N.
Example 7 - Preparation of Compound 8' 2-(Ethylthiocarbonyl-L-Leu L N Me Phe-L-Gln)-E-(a-Vinyl-y-Butyrolactone~
Preparation of Intermediate 2-(BOC-L-(Tr-Gln)]-E-(a-Vinyl-y-Butyrolactone).
BOC-L-(Tr-glutaminal) (290 mg, 0.614 mmol) and a-(triphenylphosphoranylidene)- y-butyrolactone (255 mg, 0.737 mmol) (prepared from a-bromo-y-butyrolactone according to the procedure of J. E. Baldwin, et al., Tetrahedron;
1992, 48, 9373, the disclosure of which is entirely incorporated herein by reference) were refluxed in DME (15 mL) / DMF (2 mL) for 2 h. Solvents were removed under vacuum, and the residue was purified by flash chromatography eluting with 50% EtOAc /
hexane on silica gel to give 235 mg of 2-[BOC-L-(Tr-Gln)]- E-(a-vinyl-y-butyrolactone) as a white solid in 71% yield: IR (KBr) 3399, 3059, 2976, 2926, 1752, 1688, 1493, 1366, 1248, 1169 cni';'H NMR (CDC13) 8 1.41 (s, 9 H), 1.84 (m, 2 H), 2.38 (q, 2 H, J= 6.4 Hz) 2.80 (m, 1 H), 2.97 (m, 1 H), 4.22 (m, 1 H), 4.33 (t, 2 H, J= 7.2 Hz), 4.81 (m, 1 H), 6.43 (m, 1 H), 6.80 (s, 1 H), 7.19-7.32 (m, 1 S H). Anal. (C33H36NZO5~HzO) C, H, N.
Preparation of Intermediate 2-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-(a-Vinyl-y-Butyrolactone).
2-[BOC-L-(Tr-Gln)]-E-(a-vinyl-y-butyrolactone) (0.577 g, 1.03 mmol ) was dissolved in 1,4-dioxane (3 mL). A solution of HCl in 1,4-dioxane (4.0 M, 3 mL) was added dropwise. The solution was stirred at rt for 2 h, at which time the solvent was evaporated to provide the amine HCl salt which was used without purification.
The crude salt and BOC-L-Leu-L-N-Me-Phe (0.288 g, 1.03 mmol) were dissolved in dry CHZCl2 (15 mL). Hydroxybenzotriazole-hydrate (0.209 g, 1.55 mmol), 4-methylmorpholine (0.34 mL, 3.09 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbarbodiimide hydrochloride (0.296 g, 1.55 mmol) were added successively. The reaction mixture was stirred at rt overnight and poured into water (50 mL). The resulting mixture was extracted with CHzCIZ
(2 x 50 mL). The combined organic layers were dried over Na2S04, concentrated, and purified by flash column chromatography (2% MeOH in CH2C12) to afford 2-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-(a-vinyl-y-butyrolactone) (0.691 g, 82 %) as white foam: IR (thin film) 3301, 2958, 1753, 1675, 1494, 1173, 728 cm'';'H NMR
(mixture of rotamers) (CDCl3) b 0.63-0.66 (m), 0.71-0.75 (m), 1.03-1.13 (m), 1.37 (s), 1.38 (s), 1.41 (s), 1.42 (s), 1.81-2.00 (m), 2.26-2.29 (m), 2.73-3.06 (m), 3.27 (d, J= 3.3 Hz), 3.32 (d, J= 3.3 Hz), 3.60-3.68 (m), 4.27-4.38 (m), 4.87 (d, J= 7.2 Hz), 6.50 (t, J= 3.3 Hz);
6.53 (t, J= 3.3 Hz), 6.70 (s), 7.09-7.13 (m), 7.19-7.34 (m), 7.44-7.50 (m), 7.64-7.71 (m), 8.21 (d, J= 3.6 Hz). Anal. (C49HSgN40,~0.45 H20) C, H, N.

Preparation of Intermediate 2-[Ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-(a-Vinyl-y-Butyrolactone).
2-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-(a-vinyl-y-butyrolactone) (0.652 g, 0.8 mmol) was dissolved in 1,4-dioxane (3 mL). A solution of HCl in 1,4-dioxane (4.0 M, 3 mL) was added dropwise. The solution was stirred at rt for 2 h, and the solvent was evaporated to provide the amine HCl salt which was used without purification.
The crude amine HCl salt was dissolved in dry CHZCIZ (10 mL), and Et3N (0.335 mL, 2.4 mmol) was added. The reaction mixture was cooled to 0 °C, and ethyl chlorothiolformate (0.083 mL, 0.8 mmol) was added. The reaction mixture was stirred at 0 °C for 2 h and then poured into Hz0 (25 mL) and extracted with CHZC12 (3 x 25 mL). The combined organic layers were dried over NazS04, concentrated, and purified by flash column chromatography (2%
MeOH in CHZC12) to afford 2-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-(a-vinyl-y-butyrolactone) as a white foam (0.389 g, 60%): IR (thin film) 3294, 2361, 1752, 1636, 1522, 1206 cni';'H
NMR (mixture of rotamers) (CDC13): b 0.62-0.68 (m), 0.87 (d, 6.6 Hz), 1.19-1.29 (m), 1.37-1.42 (m), 1.89-1.94 (m), 2.28-2.31 (m), 2.71-3.12 (m), 3.65-3.78 (m), 4.31-4.34 (m), 4.55-4.58 (m), 5.66 (d, J= 6.3 Hz), 5.72 (d, J= 7.5 Hz), 6.40-6.43 (m), 6.51 (t, J= 3.0 Hz), 5.54 (t, J= 3.0 Hz), 6.75 (s), 7.09-7.12 (m), 7.21-7.34 (m), 7.44-7.50 (m), 7.53-7.58 (m), 7.64-7.71 (m), 8.06 (d, J= 7.5 Hz). Anal. (C4~H54N4O6S) C, H, N.
_77_ Preparation of Product 2-(Ethylthiocarbonyl-~Leu-L-N-Me-Phe-t,-Gln)-E-(a-Vinyl-y-Butyrolactone).
2-[Ethylthiocarbonyl-L-Leu-1.-N-Me-Phe-L-(Tr-Gln)]-E-(a-vinyl-y-butyrolactone) (202 mg, 0.25 mmol) was dissolved in 5 mL of dry CHzCl2. Trifluoroacetic acid (4 mL) and triisopropylsilane (2 drops) were added sequentially to give a bright yellow solution.
After stirring for 20 min, no yellow color remained. The reaction mixture was concentrated, and the residue was purified by flash column chromatography (2%
MeOH in CH2C12) to afford 2-(ethylthiocarbonyl-L-Leu-L-N-Me-Phe-1.-Gln)-E-(a-vinyl-y-butyrolactone) as a white solid (0.62 g, 42%): IR (thin film) 3239, 1638, 1526, 1209 cm''; 'H NMR
(mixture of rotamers) (DMSO-db) 8 0.57-0.65 (m), 0.82-0.85 (m), 1.11-1.17 (m), 1.35-1.50 (m), 1.68-1.80 (m), 1.98-2.06 (m), 2.71-2.97 (m), 3.10-3.17 (m), 4.26-4.46 (m), 4.69-4.71 (m), 5.00 (t, J= 7.5 Hz), 5.75 (s), 6.25-6.28 (m), 6.38-6.41 (m), 6.77 (s), 7.16-7.27 (m), 7.94 (d, J= 8.1 Hz), 8.03 (d, J= 7.5 Hz), 8.26 (d, J= 7.5 Hz), 8.54 (d, 6.9 Hz). Anal.
(CZgH4°N4O6S~O.7S H2O) C, H, N. HRMS calcd for CzgH4oN4O6S+Cs 693.1723, found 693.1739.
Example 8 - Preparation of Compound 9' Ethvl-3-(Benz~lthiocarbonyl-L-hPhe L-N-Me-Phe-L-Gln)-E-Propenoate.
Preparation of Intermediate CBZ-L-hPhe-L-N-Me-Phe-L-(Tr-Glutaminol).
Using the procedure described in Example 4 for the preparation of cyclopentylthiocarbonyl- L-Leu-L-N-Me-L-Phe-L-(Tr-glutaminol), CBZ-L-hPhe-L-N-Me-Phe-L-(Tr-Glutaminol) was synthesized from CBZ-L-hPhe and L-N-Me-Phe-L-(Tr-Glutaminol) iri 71% yield: white amorphous solid: IR(KBr) 3295, 3061, _78_ 3027, 2936, 1659, 1495, 1447, 1261, 1043, 750, 698 cm''; 'H NMR (DMSO-d6) (mixture of rotamers) b 0.51 (m), 1.47 (m), 1.77 (m), 2.10-2.70 (m), 2.78 (s), 2.85 (s), 2.89 (m), 3.20 (m), 3.78 (m), 3.83 (m), 4.22 (m), 4.60-5.10 (m), 7.03-7.36 (m), 7.48 (m), 7.72 (d, J= 9.0 Hz), 7.84 (d, J= 7.0 Hz), 8.49 (s), 8.51 (s). Anal. (CSZHsaNaOs) C~ H, N.
Preparation of Intermediate L-hPhe-I~-N-Me-Phe-L-(Tr-Glutaminol).
Using the procedure described in Example 4 for the preparation of L-N-Me-Phe-L-(Tr-glutaminol), L-hPhe-L-N-Me-Phe-L-(Tr-Glutaminol) was synthesized from CBZ-L-hPhe-L-N-Me-Phe-L-(Tr-Glutaminol) in 96% yield: white amorphous solid:
IR(KBr) 3331, 3057, 3029, 2936, 1657, 1493, 1449, 752, 700 clri';'H NMR (DMSO-db) b (mixture of rotamers) 1.38-1.60 (m), 1.73 (m), 2.05-2.40 (m), 2.58 (m), 2.70 (s), 2.78 (s), 2.90 (m), 3.10-3.33 (m), 3.51 (m), 3.72 (m), 4.63 (m), 4.74 (m), 4.95 (m), 7.02-7.28 (m), 7.51 (d, J= 8.0 Hz), 8.50 (m), 8.55 (s). Anal. (C44H4gN4O4) C, H, N.
Preparation of Intermediate Benzyl chlorothiolformate.
Using the procedure described in Example 4 for the preparation of cyclopentyl chlorothiolformate, benzyl chlorothiolformate was synthesized from benzylmercaptan in 71% yield: colorless liquid (bp 95-100 °C; 8 ton): IR(neat) 1755 cm'';'H NMR (CDC13) b 4.19 (s, 2H), 7.30-7.34 (m, SH). This compound is reported in the literature, for example, in J.J Willard et al., J. Am. Chem. Soc. 1960, 82, 4347, the disclosure of which is entirely -incorporated herein by reference. - -Preparation of Intermediate Benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-Glutaminol).
L-hPhe-L-N-Me-Phe-L-(Tr-Glutaminol) (0.62 g, 0.88 mmol) was dissolved in 7 mL
of CHZCIZ. Benzyl chlorothiolformate (0.134 mL, 0.88 mmol) dissolved in 2 mL
of CHZCIz was added dropwise followed by 0.13 mL (0.90 mmol) of Et3N. The reaction mixture was stirred for 1 S minutes at rt, and the solvent was removed in vacuo. The residue was purified by flash column chromatography on silica gel (gradient: 0-1.5%
MeOH/CHC13) to give 0.70 g (94%) of a white amorphous solid: IR(KBr) 3287, 3061, 3026, 2936, 1641, 1495, 1449, 1213, 750, 698 cm-'; 'H NMR (DMSO-db) (mixture of rotamers) b 0.56 (m), 1.30-1.90 (m), 2.10-2.44 (m), 2.79 (s), 2.84 (s), 2.95 (m), 3.1 S (m), 3.83 (d, J= 13.6 Hz), 3.98 (d, J= 13.6 Hz), 4.04 (m), 4.41 (m), 4.57-4.70 (m), 4.82 (m), 5.07 (m), 7.02-7.29 (m), 7.48 (d, J= 8.0 Hz), 7.64 (d, J= 8.0 Hz), 8.47 (m), 8.52 (s), 8.76 (d, J= 7.0 Hz). Anal.
(CszHsaNaOsS'0.5 HZO) C, H, N.
Preparation of Intermediate Benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-Glutaminal).
Using the procedure described in Example 4 for the preparation of cyclopentylthiocarbonyl- L-Leu-L-N-Me-L-Phe-L-(Tr-glutaminal), benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-glutaminal) was synthesized from benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-glutaminol) in 75% yield and used without further purification: white amorphous solid: 'H NMR (DMSO-db) (mixture of rotamers) 8 -0.60 (m), 2.20-2.49 (m), 2.81 (s), 2.84 (s), 2.95 (m), 3.24 (m), 3.80-4.05 (m), 4.17 (m), 4.42 (m), 4.59 (m), 4.95 (m), 5.24 (m), 7.03-7.29 (m), 8.29 (d, J= 9.0 Hz), 8.34 (d, J= 8.0 Hz), 8.47 (d, J= 8.0 Hz), 8.55 (s), 8.63'(s), 8.75 (d, J= 7.0 Hz), 9.26 (s), 9.39 (s).

Preparation of Intermediate Ethyl-3-(Benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-Gln)]- E-Propenoate.
Using the procedure described in Example 4 for the preparation of ethyl-3-[cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, ethyl-3-[benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate was synthesized from benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-glutaminal) to give material contaminated with triphenyphosphine oxide after chromatography which was used without further purification: 'H NMR (DMSO-db) (mixture of rotamers) 8 0.46 (m), 1.19 (t, J= 7.0 Hz), 1.63-1.91 (m), 2.26 (m), 2.44 (m), 2.80 (s), 2.82 (s), 2.94 (m), 3.17 (m), 3.82 (d, J = 14.0 Hz), 3 .97 (d, J = 13 .6 Hz), 4.09 (q, J = 7.0 Hz), 4.10 (q, J =
7.0 Hz), 4.45 (m), 4.98 (m), 5.12 (m), 5.67 (d, J= 14.0 Hz), 5.93 (d, J= 15.5 Hz), 6.71 (dd, J=
16.0, 5.5 Hz), 6.83 (dd, J= 15.5, 5.0 Hz), 7.02-7.29 (m), 8.05 (m), 8.44 (d, J= 8.0 Hz), 8.54 (s), 8.62 (s), 8.84 (d, J= 6.0 Hz).
Preparation of Product - Ethyl-3-(Benzylthiocarbonyl-lrhPhe-L-N-Me-Phe-L-Gln)-E-Propenoate.
Using the procedure described in Example 4 for the preparation of ethyl-3-(cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-propenoate, ethyl-3-(benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-Gln)-E-propenoate was synthesized from ethyl-3-[benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate in yield as a white amorphous solid (two steps from the aldehyde intermediate):
mp = --64-67°C: IR(KBr) 3285, 1641, 1537, 1454, 1208, 700 cm'','H NMR (DMSO-db) (mixture of rotamers) b 0.42 (m), 1.19 (t, J'= 7.0 Hz), 1.60-2.70 (m), 2.79 (s), 2.80 (s), 2.87 (m), 3.20 (m), 3.94-4.14 (m), 4.36-4.60 (m), 4.99 (rn), 5.07 (m), 5.69 (d, J= 15.5 Hz), 5.99 (d, J
= 15.5 Hz), 6.72 (dd, J= 1 S.S, 5.5 Hz), 6.76 (bs), 6.86 (dd, J= 15.5, 5.5 Hz), 6.98-7.30 (m), 8.03 (m), 8.50 (d, J= 8.0 Hz), 8.85 (d, J= 6.0 Hz). HRMS calcd for C3,H44N4O6S+Cs 805.2036, found 805.2054. Anal. (C3,H44N4O6S~O.4S CHCl3) C, H, N.
Example 9 - Preparation of Compound 10: 2-fBenzylthiocarbonxl-L-hPhe-L-N-Me-Phe-L-Gln -~ E-(a-Vinyl-y-Butyrolactone~
Preparation of Intermediate 2-[Benzylthiocarbonyl-L-hPhe-LrN-Me-Phe-L-(Tr-Gln)]-E-(a-Vinyl-'y-Butyrolactone).
Using the procedure described in Example S for the preparation of 2-[cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-(a-vinyl-y-butyrolactone), 2-[benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-Gln)]-E-(a-vinyl-y-butyrolactone) was synthesized from benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-glutaminal) and (triphenylphosphoranylidene)-y-butyrolactone to give material contaminated with triphenyphosphine oxide after column chromatography which was used without further purification: 'H NMR (DMSO-d6) (mixture of rotamers) 8 0.63 (m), 1.39 (m), 1.62-1.90 (m), 2.80 (s), 2.82 (s), 2.10-2.95 (m), 3.10-3.28 (m), 3.85-4.05 (m), 4.24-4.40 (m), 4.45 (m), 4.62 (m), 4.82 (m), 5.07 (m), 6.26 (m), 6.39 (m), 7.02-7.30 (m), 8.05 (m), 8.49 (d, J=
8.0 Hz), 8.51 (s), 8.60 (s), 8.82 (d, J= 6.0 Hz).
Preparation of Product - 2-(Benzylthiocarbonyl-lrhPhe-L-N-Me-Phe-LrGln)-E-(a-Vinyl-y-Butyrolactone). --Using the procedure described in Example S for the preparation of 2-(cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-(a-vinyl-y-butyrolactone), 2-(benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-Gln)-E-(a-vinyl-y-butyrolactone) was synthesized in 70% overall yield based on two steps from benzylthiocarbonyl-L-hPhe-L-N-Me-Phe- L-(Tr-glutaminal): white amorphous solid (mp =
75-79 'C): IR(KBr) 3289, 1751, 1638, 1528, 1208, 700 cm'; 'H NMR (DMSO-d6) (mixture of rotamers) b 0.54 (m), 1.32 (m), 1.80 (m), 2.01-2.46 (m), 2.60 (m), 2.79 (s), 2.80 (s), 2.72-2.98 (m), 3.14 (m), 4.01 (d, J= 13.6 Hz), 4.05 (s), 4.12 (d, J= 13.6 Hz), 4.30-4.57 (m), 4.62 (m), 4.82 (m), 5.01 (m), 6.27 (m), 6.40 (m), 6.77 (m), 6.98-7.30 (m), 8.02 (d, J=
8.0 Hz), 8.08 (d, J= 9.0 Hz), 8.49 (d, J= 8.0 Hz), 8.83 (d, J= 6.0 Hz). HRMS
calcd for C3,H42N4O6S+Cs 803.1879, found 803.1863. Anal. (C3,H42N4O6S~O.3S CHC13) C, H, N.
Example 10 - Preparation of Compound 11: Eth~~thylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-Propenoate.
Preparation of Intermediate Ethyl-3-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-Propenoate.
This material was prepared from ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (0.397 g, 0.732 mmol) and BOC-L-Leu-L-N-Me-Phe (0.287 g, 0.731 mmol) as described in Example 6 for the formation of 1-(2',3'-dihydroindol-1-yl)-3-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenone to give ethyl-3-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (after chromatography, 44%
EtOAc in hexanes) as a white foam (0.412 g, 69%): IR (thin film) 3295, 1713, 1672, 1649 crri';'H NMR (CDCI,) (mixture of isomers) b 0.65 (d, J= 6.2 Hz), 0.66 (d, J=
6.5 Hz), 0.84 (d, J= 6.5 Hz), 0.88 (d, J= 6.5 Hz), 1.02-1.22 (m), 1.23-1.38 (m), 1.33 (s), 1.41 (s), 1.55-1.82 (m), 1.89-2.07 (m), 2.23-2.30 (m), 2.90 (s), 2.94 (s), 3.01 (dd, J=14.6, 10.9 Hz), 3.03-3.13 (m), 3.26-3.37 (m), 3.27 (dd, J= 14.6, 3.4 Hz), 3.42-3.54 (m), 4.00-4.22 (m), 4.37-4.73 (m), 4.82-4.89 (m), 5.63-5.70 (m), 5.95 (dd, J= 15.9, 1.2 Hz), 6.23-6.28 (m), 6.66-6.75 (m), 6.79-6.89 (m), 7.09-7.34 (m), 8.14 (d, J= 8.7 Hz); Anal.
(C49H6°N4O.,) C, H, N.
Preparation of Intermediate Ethyl-3-[Ethylthiocarbonyl-IrLeu-L-N-Me-Phe-L-(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.390 g, 0.477 mmol) was deprotected and coupled with ethyl chlorothiolformate (0.063 mL, 0.60 mmol) as described in Example 6 for the formation of 2,3-dihydroindole-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe- L-(Tr-Gln))-E-propenamide to give ethyl-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]- E-propenoate (after chromatography, 44% EtOAc in hexanes) as a white foam (0.261 g, 68%): IR (thin filin) 3295, 1708, 1648 cni'; 'H NMR (CDC13) (mixture of isomers) 8 0.61-0.75 (m), 0.92 (d, J=
6.8 Hz), 0.68 (d, J= 6.5 Hz), 0.82-0.98 (m), 0.86 (d, J= 6.5 Hz), 0.87 (d, J=
6.2 Hz), 1.04-1.43 (m), 1.51-1.84 (m), 1.88-2.08 (m), 2.21-2.32 (m), 2.66-3.53 (m), 2.86 (s), 2.89 (s), 4.08-4.24 (m), 4.28-4.53 (m), 4.54-4.68 (m), 4.83-4.89 (m), 5.65-5.76 (m), 5.74 (d, J=
15.7 Hz), 5.96 (d, J= 15.7 Hz), 6.35-6.40 (m), 6.75 (dd, J= 15.7, 5.3 Hz), 6.80-6.89 (m), 7.09-7.35 (m), 8.03 (d, J= 7.5 Hz); Anal. (C4,HS6N4O6S) C, H, N.
Preparation of Product Ethyl-3-(Ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-Propenoate.
Ethyl-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.220 g, 0.273 mmol) was deprotected using the procedure described in Example 1 for the formation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate to give ethyl-3-(ethylthiocarbonyl-L-Leu- L-N-Me-Phe-L-Gln)-E-propenoate (after chromatography, SO% acetone in hexanes) as a white foam (0.111 g, 72%): IR
(thin film) 3284, 1660 cm''; 'H NMR (CDC13) (mixture of isomers) b 0.62 (d, J= 6.5 Hz), 0.67 (d, J=
6.5 Hz), 0.89 (d, J = 6.5 Hz), 0.93 (d, J = 6.5 Hz), 1.22 (t, J = 7.2 Hz), 1.29 (t, J = 7.2 Hz), 1.37-2.04 (m), 2.13-2.44 (m), 2.58-3.36 (m), 2.93 (s), 3.12 (s), 4.17 (q, J=
7.2 Hz), 4.19 (q, J= 7.2 Hz), 4.37-4.90 (m), 4.96-5.15 (m) , 5.67 (d, J= 15.6 Hz), 6.00 (d, J=
15.6 Hz), 6.12 (s, bs), 6.62-6.72 (m), 6.87 (dd, J= 15.6, 5.9 Hz), 6.95 (bs), 7.12-7.35 (m), 7.47 (bs), 7.83 (d, J= 7.2 Hz); Anal. (CZgH42N4S~0.5 HZO) C, H, N.
Example 11 - Pre~laration of Compound 12:
2-(Ethylthiocarbonyl-L-Val-L-N-Me-Phe-L-Gln)- E-(a-Vinyl-y-Butyrolactoney.
Preparation of Intermediate BOC-L-Val-L-N-Me-Phe-OMe.
N-Me-Phe-OMe~HCI (2.0 g) was dissolved in 50 mL of CHzCIz and poured into a combination of 1N NaOH (aq. 7 mL) and sat. NaHC03 (25 mL). After mixing, the organic phase was separated, and the aqueous phase was extracted with CHzCIz (3 x SO
mL). The combined organic phases were dried over Na2S04 and concentrated to give the free base of the amine as a clear colorless oil (1.69 g, 8.75 mmol). A solution of this amine and diisopropylethylamine (1.68 mL, 9.62 mmol) in 10 mL of DMF was added dropwise to a solution of BOC-L-Val (2.09 g, 9.62 mmol) and hydroxybenzotriazole-hydrate (1.30 g, 9.62 mmol) in 10 mL DMF cooled to 0 °C. 1,3-Dicyclohexylcarbodiimide (2.18 g, 10.59 minol) was then added. The reaction mixture was stirred at 0 °C for 1 h, and then stirred at rt. for 48 h. The mixture was filtered to remove the precipitate, and the filtrate was evaporated. The residue was dissolved in CHzCl2 (200 mL), washed with sat.
NaHC03 (100 mL), dried over Na2S04, concentrated, and purified by flash column chromatography (15 % EtOAc in hexane) to give BOC-L-Val-L-N-Me-Phe-OMe as a white solid (2.56 g, 75 %). IR (thin film) 2972, 1743, 1710, 1646, 1497, 1172 cni';'H NMR (mixture of rotamers) (CDC13): b 0.34 (d, J= 6.9 Hz), 0.66 (d, J= 6.9 Hz), 0.89 (d, J= 6.9 Hz), 0.95 (d, J= 6.9 Hz), 1.41 (s), 1.87-1.98 (m), 2.92 (s), 2.94 (s), 2.99-3.01 (m), 3.37 (d, J= 5.7 Hz), 3.42 (d, J= 5.7 Hz), 3.72 (s), 3.73 (s), 4.35 (dd, J= 9.3, 6.0 Hz); 4.94-5.02 (m), 5.07 (d, J=
9.3 Hz), 5.34 (dd, J= 9.9, 3.0 Hz), 7.17-7.32 (m). Anal. (CZ,H32NZO5) C, H, N.
Preparation of Intermediate BOC-IrVal-L-N-Me-Phe.
BOC-L-Val-L-N-Me-Phe-OMe (0.396 g, 1.01 mmol) was dissolved in 10 mL of MeOH and cooled to 0 °C. A solution of 2 N NaOH (aq 4.04 mL, 8.08 mmol) was added dropwise. The reaction mixture was stirred for 2 h at rt. and poured into 10%
aq ICHSO, (80 mL) and extracted with CHZC12 (2 x 100 mL,). The combined organic layers were dried over NazS04 and concentrated to give BOC-L-Val-L-N-Me-Phe (0.38 g, quant.) which was used without purification.
Preparation of Intermediate 2-[BOC-L-Val-L-N-Me-Phe-L-(Tr-Gln))-E-(a-Vinyl-y-Butyrolactone).
2-[BOC-L-(Tr-Gln)]-E-(a-vinyl-y-butyrolactone) (0.546 g, 1.01 mmol ) was deprotected and coupled with BOC-L-Val-L-N-Me-Phe (0.38 g, 1.01 mmol) using the procedure described in Example 7 for the formation of the 2-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]- E-(a-vinyl-'y-butyrolactone) to give 2-[BOC-L-Val-L-N-Me-Phe-L-(Tr-Gln)]- E-(a-vinyl-'y-butyrolactone) as a white foam (0.613 g, 76%): IR (thin film) 3307, 2965, 1752, 1677, 1493, 1171 cni'; 'H NMR
(mixture of rotamers) (CDC13) 8 0.68 (d, J= 8.1 Hz), 0.81 (d, J= 6.6 Hz), 0.86 (d, J= 6.9 Hz), 1.38-1.45 (m), 1.78-2.00 (m), 2.25-2.27 (m), 2.64-2.99 (m), 3.28-3.47 (m), 3.55 (s), 3.59-3.76 (m), 4.04-4.07 (m), 4.24-4.31 (m), 4.42-4.46 (m), 4.74-4.80 (m), 4.90 (d, J= 6.9 Hz), 4.94-5.03 (m), 6.27-6.31 (m), 6.46-6.49 (m), 6.84 (s), 6.96 (s), 7.02 (s), 7.12-7.33 (m), 7.46-7.49 (m), 7.53-7.55 (m), 7.64-7.70 (m), 7.93 (d, J= 8.1 Hz); Anal.
(C48Hs6N4O,~O.S
H20) C, H, N.
Preparation of Intermediate 2-[Ethylthiocarbonyl-L-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-(a-Vinyl-y-Butyrolactone).
2-[BOC-L-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-(a-vinyl-y-butyrolactone) (0.376, 0.47 mmol) was deprotected and coupled with ethyl chlorothiolformate (0.06 mL, 0.47 mmol) as described in Example 7 for the formation of 2-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]- E-(a-vinyl-y-butyrolactone) to give 2-[ethylthiocarbonyl-L-Val-L-N-Me-Phe-L-(Tr-Gln)]- E-(a-vinyl-y-butyrolactone) as a white foam (0.150 mg, 40%): IR (thin film) 3299, 2965, 2360, 1751, 1493, 1205 cm'';'H
NMR (mixture of rotamers) (CDC13) b 0.36 (d, J= 6.9 Hz), 0.54 (d, J= 6.6 Hz), 0.71 (d, J
= 6.9 Hz), 0.85 (d, J= 6.3 Hz), 1.21-1.31 (m), 1.82-1.84 (m), 2.28-2.30 (m), 2.64-3.03 (m), 3.31-3.41 (m), 3.62-3.78 (m), 4.24-4.33 (m), 4.45-4.52 (m), 4.60-4.66 (m), 5.81-5.89 (m), 6.33-6.36 (m), 6.41-6.49 (m), 6.86(s), 7.06 (s), 7.11-7.33 (m), 7.46-7.50 (m), 7.54-7.55 (m), 7.64-7.70 (m), 7.79 (d, J= 7.5 Hz). Anal. (C46Hs2NaOss'0.5 HZO) C, H, N.
_87_ Preparation of Product - 2-(Ethylthiocarbonyl-L-Val-L-N-Me-Phe-L-Gln)-E-(a-Vinyl-y-Butyrolactone).
2-[Ethylthiocarbonyl-L-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-(a-vinyl-y-butyrolactone) was deprotected using the procedure described in Example 7 for the formation of 2-(ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-(a-vinyl-y-butyrolactone) to give 2-(ethylthiocarbonyl-L-Val-L-N-Me-Phe-L-Gln)-E-(a-vinyl-y-butyrolactone) as a white solid (0.068 g, 96%): IR (thin film) 3748, 1625, 1541, 1200 cni'; 'H NMR
(mixture of rotamers) (DMSO-db) 8 0.27 (d, J= 6.6 Hz), 0.38 (d, J= 6.3 HZ), 0.55-0.59 (m), 0.79-0.84 (m), 1.11-1.17 (m), 1.70-1.83 (m), 1.88-1.95 (m), 1.98-2.07 (m), 2.72-3.26 (m), 4.05-4.10 (m), 4.25-4.44 (m), 4.64-4.66 (m), 5.12-5.18 (m), 5.33-5.36 (m), 6.23-6.26 (m), 6.34-6.39 (m), 6.75-6.78 (m), 7.12-7.26 (m), 7.78-7.84 (m), 8.13 (d, J= 7.5 Hz), 8.24-8.30 (m).
HRMS calcd. for (M+Cs), 679.1566, found 679.1591. Anal. (Cz,H38N406S~0.3 H20) C,H,N.
Erample 12 - Preparation of Compound 13:
Ethyl-3-lBenzylthiocarbonyl-L-hPhe-L-N-Me- (4-Me-Phe)-L-Gln~-E-Propenoate Preparation of Intermediate FMOC-L-N-Me-(4-Me)-Phe.
This N-protected amino acid was prepared in approximately 80% yield from FMOC-L-(4-Me)-Phe, purchased from Neosystem Laboratories, Strasbourg, France, using the procedure described by R.M. Friedinger, et al.; J. Org. Chem. 1983, 48, 77-81, the disclosure of which is entirely incorporated by reference herein. The crude product, _ isolated as an oil, was used without further purification: IR (thin film) 3452, 2953, 1713, --1 S 16, 1451, 1404, 1321, 1194, 1040, 738 cm''; 'H NMR (CDC13) mixture of rotamers; 8 2.27 (m), 2.77 (s), 2.79 (s), 2.85 (s), 3.08-3.32 (m), 3.37-3.49 (m), 4.10-4.26 (m), 4.30-4.45 _88_ (m), 4.80-4.89 (m), S.OS (m), 6.87 (d, J= 11.0 Hz), 6.95 (d, J= 11.0 Hz), 7.09 (m), 7.25-7.55 (m), 7.75 (d, J= 7.4 Hz). MS calcd for C26HZSN04+Na 438, found 438.
Preparation of Intermediate FMOC-L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol).
FMOC-L-N-Me-(4-Me)-Phe (1.90 g, 4.6 mmol) was dissolved in 12 mL of CHzCl2 and 2 mL of DMF. To this solution was added N-hydroxysuccinimide (0.53 g, 4.6 mmol) was added to this solution. Stirring was continued until all the solids were dissolved.
N,N'-Dicyclohexylcarbodiimide (0.95 g, 4.6 mmol) was added to the reaction mixture, and the reaction was stirred at room temperature for two hours. The mixture was then filtered into a separate flask containing L-(Tr-Glutaminol) (1.72 g, 4.6 mmol) dissolved in 15 mL
of DMF, removing the N,N'-dicyclohexylurea precipitate. The reaction mixture was stirred overnight at room temperature. The solvents were removed under vacuum, and the resulting crude product was purified by flash chromatography (5% saturated anhydrous NH3 in MeOH/ CHZCIZ) on silica gel to give 3.72 g (90%) of a white solid: IR
(KBr) 3407, 3312, 3059, 3032, 2932, 1665, 1516, 1491, 1447, 1319, 1188, 741, 700 cm''; 'H
NMR
(DMSO-db) mixture of rotamers; 8 1.55 (m), 1.67 (m), 2.16 (bs), 2.23 (bs), 2.79 (s), 3.00-3.29 (m), 3.75 (m), 4.01-4.10 (m), 4.25 (m), 4.50-4.64 (m), 4.85 (m), 6.98-7.39 (m), 7.49 (d, J= 7.4 Hz), 7.60-7.75 (m), 7.87 (d, 1 H, J= 7.4 Hz), 8.50 (bs). MS
calcd for CSOH49N305+Na 794, found 794.
Preparation of Intermediate L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol) FMOC-L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol) (3.32 g, 4.3 mmol) was dissolved in 11 mL of DMF. Piperidine (0.44 g, 5.2 mmol) was added dropwise to this solution. The solution was stirred for 30 min. At this time, the solution was concentrated under vacuum, and the resulting crude amine was purified by flash chromatography (7% MeOH/
CHZC12) on silica gel to give 2.12 g (90%) of a white tacky foam: IR (thin film) 3302, 3057, 3025, 2934, 2865, 1956, 1925, 1809, 1659, 1516, 1265, 1035, 737, 700 cm '; 'H NMR
(CDC13) b 1.73 (m, 1H), 1.89 (m, 1H), 2.26 (s, 3H), 2.30 (s, 3H), 2.37 (m, 2H), 2.67 (dd, 1H, J= 13.8, 9.0 Hz), 3.09 (dd, 1H, J= 13.4, 4.6 Hz), 3.20 (dd, 1H, J= 8.8, 4.4 Hz), 3.42 (m, 2H), 3.52 (m, 1 H), 3.82 (m, 1 H), 3.91 (m, 1 H), 6.94 (m, 2H), 7.09 (m, 2H), 7.23-7.32 (m, 16H), 7.44 (d, 1 H, J= 7.7 Hz). MS calcd for C35H39N3O3+Cs 682, found 682.
Preparation of Intermediate CBZ-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol).
Following the procedure of L. A. Carpino, J. Am. Chem. Soc. 1993, 11 S, 4397, the disclosure of which is entirely incorporated herein by reference, CBZ-L-hPhe was coupled with L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol) as follows. To CBZ-L-hPhe (0.32 g, 1.0 mmol) was added 3 mL of DMF. To this solution was added L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol) (0.55 g, 1.0 mmol) and diisopropylethylamine (0.26 g, 2.0 mmol). This solution was then cooled to 0 °C, and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (0.38 g, 1.0 mmol) was added.
The solution instantly turned yellow, and the mixture was allowed to warm to rt. Once the starting materials were consumed as indicated by TLC, the reaction mixture was concentrated under vacuum. The residue was taken up in an excess of EtOAc (200 mL), _ and washed with 25 mL of HzO, 25 mL 10% HCl twice, and then 5% aq NaHC03. The --organic layer was dried over anh NaZS04 and concentrated. The residue was subjected to flash chromatography (5% MeOH/ CHzCl2) on silica gel to give 0.68 g (80%) of a white solid: IR (KBr) 3403, 3059, 3030, 2947, 1662, 1516, 1448, 1264, 752, 700 cm-';
'H NMR
(DMSO-db) mixture of rotamers; b 0.45 (m), 1.27-1.65 (m), 1.77-1.95 (m), 1.97 (s), 2.07-2.15 (m), 2.18 (s), 2.19-2.25 (m), 2.37 (m), 2.68-2.94 (m), 3.05-3.35 (m), 3.75 (m), 3.80 (m), 4.20-4.40 (m), 4.54-5.03 (m), 6.92-7.34 (m), 7.43-7.85 (m), 8.49 (m). MS calcd for C53Hs6Na06+Cs 977, found 977.
Preparation of Intermediate L-hPhe-LrN-Me-(4-Me)-Phe-L-(Tr-Glutaminol).
Using the catalytic hydrogenation procedure described in Example 4 for the preparation of L-(Tr-Glutaminol), the amine was prepared in quantitative yield from CBZ-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol) . White glassy solid: IR (K.Br) 3378, 3057, 3027, 2938, 1659, 1516, 1493, 1447, 1180, 752, 700 cm'; 'H NMR (DMSO-db) mixture of rotamers; 8 .1.30-1.60 (m), 1.68 (m), 2.07 (m), 2.16 (s), 2.22 (m), 2.57 (m), 2.68 (s), 2.77 (s), 2.82-3.30 (m), 3.7~ (m), 4.30-4.80 (m), 4.90-5.00 (m), 6.97-7.43 (m), 8.35-8.55 (m). MS calcd for C45HsoNaOa+Na 733, found 733.
Preparation of Intermediate Benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol).
Using the procedure described in Example 8 for the preparation of benzylthiocarbonyl-L-hPhe-L-N-Me-Phe-L-(Tr-Glutaminol), benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-glutaminol) was prepared from L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-glutaminol) and benzyl chlorothiolformate in 96%
yield. White solid: IR (KBr) 3418, 3316, 3054, 3023, 2947, 1678, 1666, 1643, 1530, 1493, 1451, 1211, 700 cm'; 'H NMR (DMSO-db) mixture of rotamers; 8 0.55 (m), 1.25-1.60 (m), 1.80-1.93 (m), 1.96 (s), 2.19 (s), 2.22 {m), 2.40 (m), 2.68 (s), 2.72-2.96 {m), 3.17-3.27 (m), 3.40 (m), 3.65 (m), 3.80-4.10 (m), 4.54-5.03 (m), 6.84-7.29 (m), 7.47 (d, J=
8.1 Hz), 7.55 (d, J= 7.5 Hz), 7.66 {d, J= 8.4 Hz), 8.44-8.52 (m), 8.76 (d, J= 7.5 Hz). MS
calcd for Cs3Hs6NaOsS+Na 883, found 883.
Preparation of Intermediate Benzylthiocarbonyl-IrhPhe-L-N-Me-(4-Me)-Phe-Lr(Tr-Glutaminal).
Benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol) was oxidized using o-iodoxybenzoic acid in anh. DMSO as described in Example 4 for the preparation of cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-glutaminal). Upon workup, the aldehyde was used immediately without further purification. 'H NMR (CDC13) mixture of rotamers; b 0.89 (m), 1.26 (m), 1.67 (m), 1.85-2.05 (m), 2.13 (s), 2.22 (m), 2.28 (s), 2.35 (m), 2.60 (m), 2.70 (s), 2.83 (s), 2.89-2.95 (m), 2.99 (s), 3.01 (m), 3.25 (m), 3.90 (m), 4.04-4.25 (m), 4.30 (m), 4.61-4.66 (m), 5.85 (d, J= 7.0 Hz), 5.95 (d, J= 7.0 Hz), 6.22 (d, J
= 7.0 Hz), 6.70-7.36 (m), 8.15 (d, J= 7.0 Hz). 9.35 (s), 9.40 (s).
Preparation of Intermediate Ethyl-3-[Benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-1r(Tr-Gln)]-E-Propenoate.
This intermediate was prepared from benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-glutaminal) and (carbethoxymethylene)triphenylphosphorane as described in Example 4 for the preparation of ethyl-3-[cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]- E-propenoate. White solid: IR (thin film) 3297, 3057, --3027, 2980, 2928, 1714, 1651, 1516, 1495, 1447, 1267, 1213, 1035, 735, 700 cm';'H
NMR (CDC13) mixture of rotamers; b 0.88 (m), 1.26 (t, J= 7.2 Hz), 1.44 (m), 1.61-1.80 (m), 1.94 (m), 2.10 {s), 2.23 (m), 2.29 (s), 2.54 (m), 2.67 (s), 2.85 (s), 2.90 (m), 2.98 (s), 3.03 (m), 3.17-3.29 (m), 3.84-4.07 (m), 4.14 (m), 4.35 (m), 4.58 (m), 5.73 (dd, J= 15.8, 1.5 Hz), 5.91-5.99 (m), 6.04 (d, J= 7.7 Hz), 6.47 (d, J= 8.5 Hz), 6.72 (dd, J=
15.5, S.1 Hz), 6.82 (m), 6.87-7.08 (m), 7.14-7.31 (m), 7.77 (d, J= 7.0 Hz). MS calcd for CS,H6oN406S+Na 951, found 951.
Preparation of Product -Ethyl-3-[Benzylthiocarhonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-Glnj- E-Propenoate.
This product was prepared in 69% overall yield (3 steps) from intermediate benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol) by the deprotection of ethyl-3-[benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-Gln)]-E-propenoate using the procedure described in Example 4 for the synthesis of ethyl-3-(cyclopentylthiocarbonyl-L-Leu-L-N-Me-Ph.e-L-Gln)-E-propenoate. White solid:
IR (KBr) 3414, 3327, 3293, 3205, 3025, 2980, 2930, 1717, 1674, 1644, 1537, 1454, 1283, 1217, 1194, 700 cm''; 'H NMR (DMSO-db) mixture of rotamers; 8 0.30 (m), 0.84 (m), 1.19 (t, J= 7.0 Hz), 1.33 (m), 1.77 (m), 1.92 (s), 2.05 (m), 2.20 (s), 2.40 (m), 2.57 (m), 2.77 (s), 2.80 (s), 2.84-2.90 (m), 3.05 (m), 3.94-4.14 {m), 4.36-4.60 (m), S.OI (m), 5.63-5.73 {m), 6.01 (dd, J= 15.8, 1.1 Hz), 6.68-6.91 (m), 6.93-7.35 (m), 7.70 (m), 8.02 {m), 8.48 (d, J=
8.1 Hz), 8.65 (d, J= 8.0 Hz), 8.85 (d, J= 5.9 Hz). HRMS calcd for C3gH46N~O6S+Cs 819.2192, found 89.2177. Anal. (C3BH4bN4O6S) C, H, N, S.

Egamnle 13 - Preparation of Compound 14~ Ethyl-2-Methvl-3 fBenzvlthiocarbonyl L-hPhe-L-N-Me-(4-Mel-Phe-L-Gln~-E-Pro~enoate Preparation of Intermediate Ethyl-2-Methyl-3-(Benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-Ght)]-E-Propenoate.
This intermediate was prepared from benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-glutaminal) using (carbethoxyethylidene)triphenylphosphorane in place of (carbethoxymethylene)triphenylphosphorane in the procedure described in Example 4 for the preparation of ethyl-3-[cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate. After column chromatography on silica gel (5%
MeOH/CHZC12), two fractions were collected, one impure with triphenylphosphine oxide.
(Analytical sample) White solid: IR (thin film) 3289, 3057, 3027, 2978, 2928, 1707, 1676, 1642, 1516, 1495, 1449, 1253, 1215, 750, 700 cm'; 'H NMR (CDCI,) mixture of rotamers; b 0.83 (m), 1.26 (m), 1.47-1.50 (m), 1.63-1.70 (m), 1.78 (m), 1.85 (d, J= 1.5 Hz), 1.87 (m), 1.92 (d, J
= 1.5 Hz), 2.10 (s), 2.20 (m), 2.30 (s), 2.35-2.61 (m), 2.71 (s), 2.88 (s), 2.92 (m), 2.99 (s), 3.03-3.29 (m), 3.93 (d, J= 13.6 Hz), 4.06-4.23 (m), 4.35 (m), 4.52-4.69 (m), 5.94 (d, J=
7.4 Hz), 6.23 (d, J = 8.5 Hz), 6.28 (d, J = 7.7 Hz), 6.42 (dd, J = 9.0, 1.3 Hz), 6. S 8 (dd, J =
9.4, 1.3 Hz), 6.89 (bs), 6.92-7.17 (m), 7.20-7.33 (m), 7.64 (d, J= 7.7 Hz). MS
calcd for CSgH62N4O6S+Na 965, found 965.
Preparation of Product - Ethyl-2-Methyl-3-[Benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-Gln]-E-Propenoate.
This product was prepared in 89% overall yield (3 steps) from intermediate benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-Glutaminol) by the deprotection of ethyl-2-methyl-3-[benzylthiocarbonyl-L-hPhe-L-N-Me-(4-Me)-Phe-L-(Tr-Gln)]-E-propenoa -w to using the procedure described in Example 4 for the synthesis of ethyl-3-(cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-propenoate. White solid:
IR (KBr) 3302, 3223, 2984, 2928, 1709, 1672, 1642, 1535, 1453, 1256, 1217, 1132, 700 crri';'H NMR (DMSO-db) mixture of rotamers; b 0.34 (m), 1.17(m), 1.30 (m), 1.72 (m), 1.78 (s), 1.87 (s), 1.93 (s), 1.97-2.04 (m), 2.19 (s), 2.40 (m), 2.59 (m), 2.77 (s), 2.79 (s), 2.83 (m), 3.05 (m), 4.07 (m), 4.39 (m), 4.64 (m), 4.85 (m), 4.91 (m), 6.40 (d, J= 9.6 Hz), 6.54 (d, J= 8.5, 1.1 Hz), 6.74 (m), 6.76-7.30 (m), 7.99 (d, J= 8.1 Hz), 8.47 (d, J= 6.6 Hz), 8.84 (d, J= 6.3 Hz). HRMS calcd for C39H48N4O6S+CS 833.2349, found 833.2329.
Anal.
(C39H48N4~6'~) C~ H~ N, S.
Example 14 - Preparation of Compound 15~
Ethvl-3-(Benzvlthiocarbonyl-L-Leu-L-N-Me- Phe-L-Gln~-E-Propenoate Preparation of Intermediate Benzylthiocarbonyl-L-Leu-OMe.
To 2-isocyanato-4-methylvaleric acid methyl ester (0.86 g, S.0 mmol) dissolved in 50 mL of THF was added benzyl mercaptan (0.59 mL, 5.0 mmol). The reaction mixture was stirred at rt overnight, and the solvent was removed in vacuo to give a yellow liquid which was purified by flash column chromatography on silica gel (gradient; 5-10% of EtOAc/hexanes) to give 1.39 g (94%) of benzylthiocarbonyl-L-Leu-OMe as a clear oil: IR
(neat) 3320, 2957, 1746, 1651, 1520, 1454, 1200, 839, 702 cm'; 'H NMR (DMSO-db) b 0.97 (m, 6H), 1.65 (m, 3H), 3.74 (s, 3H), 4.16 (s, 2H), 4.60 (m, 1H), 5.72 (d, 1H, J= 8.0 Hz), 7.32 (m, SH). Anal. (C,SHz,N03S) C, H, N.

Preparation of Intermediate Benzylthiocarbonyl-L-Leu.
Benzylthiocarbonyl-L-Leu-OMe (0.85 g, 2.88 mmol) was dissolved in 30 mL of THF. To this solution was added 1N LiOH (3.0 mL, 3.0 mmol), and the reaction mixture was stirred at rt overnight. At this time an additional 1.5 mL of 1N LiOH was added, and the reaction mixture was further stirred for 4 h. At this time, an additional 1.5 mL of 1N
LiOH was added. After another 3 h at room temperature, the pH was adjusted to 7 with 10% HCI, and the THF was removed in vacuo. The aqueous phase was washed with Et20 and separated, then adjusted to pH 1-2. The product was extracted with CHzCIz, and the organic phase washed with brine, dried over MgS04, filtered, and then concentrated to give 0.29 g of benzylthiocarbonyl-L-Leu as a clear liquid that was contaminated with benzyl mercaptan: 'H NMR (DMSO-d6) 8 0.83 (d, 3H, J= 6.0 Hz), 0.87 (d, 3H, J= 6.0 Hz), 1.45 (m, 3H), 4.04 (s, 2H), 4.22 (m, 1H), 7.27 (m, SH), 8.46 (d, 1H, J= 7.0 Hz). MS calcd for C,4H,9N03S+H 282, found 282.
Preparation of Intermediate Benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Glutaminol).
Using the procedure described in Example 4 for the preparation of cyclopenylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-glutaminol), benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-glutaminol) was synthesized from L-N-Me-Phe-L-(Tr-glutaminol) and benzylthiocarbonyl-L-Leu in 58% yield: white amorphous solid: IR(KBr) 3289, 3057, 3027, 2953, 1638, 1493, 1449, 1206, 700 crri';'H __ NMR (DMSO-db) (mixture of rotamers) b -0.19 (m), 0.60 (m), 0.79 (d, J= 6.2 Hz), 0.80 (d, J= 6.2 Hz), 1.12-1.77 (m), 2.12-2.36 (m), 2.84 (s), 2.90 (m), 2.96 (s), 3.12-3.40 (m), 3.63 (m), 3.84 (d, J = 13.6 Hz), 3.96 (d, J = 13.6 Hz), 4.02 (s), 4.33 (m), 4.66 (m), 5.06 (m), 7.10-7.28 (m), 7.47 (d, J = 9 Hz), 7.61 (d, J= 8.5 Hz), 8.35 (d, J= 7.0 Hz), 8.51 (s), 8.56 (d, J= 7.0 Hz). Anal. (C4gH54N4O5S) C, H, N.
Preparation of Intermediate Benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Glutaminal).
Using the procedure described in Example 4 for the preparation of cyclopenylthiocarbonyl- L-Leu-L-N-Me-Phe-L-(Tr-glutaminal), benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-glutaminal) was synthesized from benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-glutaminol) in 93% yield and was used without further purification: white amorphous solid: 'H NMR (DMSO-d6) (mixture of rotamers) 8 0.02 (m), 0.61 (d, J = 6.6 Hz), 0.64 (d, J = 6.6 Hz), 0.81 (d, J =
6.2 Hz), 1.05-1.75 (m), 1.98 (m), 2.23-2.48 (m), 2.84 (s), 2.93 (m), 2.96 (s), 3.23 (m), 3.84 (d, J=
13.6 Hz), 3.95 (d, J= 14.0 Hz), 4.U1 (m), 4.12 (m), 4.42 (m), 4.71 (m), 4.83 (m), 5.18 (m), 7.11-7.28 (m), 8.27 (d, J= 8.0 Hz), 8.31 (m), 8.57 (m), 8.62 (s), 9.27 (s), 9.40 (s).
Preparation of Intermediate Ethyl-3-(Benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Tr-Gln)J- E-Propenoate.
Using the procedure described in Example 4 for the preparation of ethyl-3-[cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, ethyl-3-[benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate was synthesized from benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-glutaminal) to give 0.30 g of material contaminated with triphenylphosphine oxide after chromatography which was used without further purification: white amorphous solid: 'H NMR (DMSO-db) (mixture of rotamers) b -0.12 (m), 0. 8 6 (d, J = 6.2 Hz), 0. 8 7 (d, J = 6.2 Hz), 1.23 (t, J = 7.0 Hz), 1.26 (t, J = 7.0 Hz), 1.49 (m), 1.72 (m), 2.10-2.45 (m), 2.88 (s), 2.96 (m), 3.03 (s), 3.17 (m), 3.83 (d, J=
13.6 Hz), 3.96 (d, J= 13.6 Hz), 4.03 (s), 4.08 (m), 4.39 (m), 4.50 (m), 4.66 (m), 4.81 (m), 5.08 (m), 5.72 (d, J = 16.0 Hz), 6.01 (d, J = 15. 8 Hz), 6.77 (dd, J = 15.6, 6.0 Hz), 6.89 (dd, J= 15.8, 6.0 Hz), 7.16-7.34 (m), 8.09 (d, J= 8.0 Hz), 8.43 (d, J= 8.0 Hz), 8.63 (s), 8.68 (s), 8.70 (d, J= 7.0 Hz).
Preparation of Product Ethyl-3-(Benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-Propenoate.
Using the procedure described in Example 4 for the preparation of ethyl-3-(cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-propenoate, ethyl-3-(benzylthiocarbonyl-L-Leu-L-N-Me=Phe-L-Gln)-E-propenoate was synthesized from ethyl-3-(benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)-E-propenoate in 41%
yield (two steps from the aldehyde intermediate): white amorphous solid: mp =
60-63 'C):
IR(KBr) 3289, 2957, 1638, 1533, 1453, 1277, 1209, 700 clri';'H NMR (DMSO-db) (mixture of rotamers) b -0.26 (m), 0.60 (m), 0.83 (d, J= 6.2 Hz), 1.17 (t, J=
7.0 Hz), 1.20 (t, J= 7.0 Hz), 1.03-1.60 (m), 1.66-1.98 (m), 2.01 (m), 2.80 (s), 2.92 (m), 2.96 (s), 3.25 (m), 3.92-4.18 (m), 4.38 (m), 4.48 (m), 4.68 (m), 4.86 (m), 5.08 (m), 5.69 (d, J= 16.0 Hz), 5.99 (d, J= 16.0 Hz), 6.69-6.76 (m), 6.86 (dd, J= 16.0, 6.0 Hz), 7.14-7.29 (m), 8.00 (m), 8.36 (d, J= 8.5 Hz), 8.64 (d, J= 6.6 Hz). HRMS calcd for C"H"N,O6S+Cs 757.2036, _ _ found 757.2008. Anal. (C33Ha4Na06S) C, H, N.

Example 15 - Preparation of Compound 16' Ethyl-2-Methyl-3-(Benzylthiocarbont~l-L-Leu-L-N-Me-Phe-L-Glnl-E-Propenoate Preparation of Intermediate Ethyl-2-Methyl-3-[Benzylthiocarbonyl-L-.Leu-L-N-Me-Phe- L-(Tr-Gln)]-E-Propenoate.
Using the procedure described in Example 4 for the preparation of ethyl-3 -[cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)J-E-propenoate, ethyl-2-methyl-3-[benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)J-E-propenoate was synthesized from benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-glutaminal) (0.2 g, 0.25 mmol) and (carbethoxyethylidene) triphenylphosphorane (0.11 g, 0.3 mmol) in 5 mL THF
to give 0.12 g of material contaminated with triphenylphosphine oxide after column chromatography on silica gel (gradient; 0-1% MeOH/CHCI,) which was used without further purification. White amorphous solid: 'H NMR (DMSO-d6) (mixture of rotamers) 8 -.012 (m), 0.61 (m), 0.80 (d, J = 6.2 Hz), 1.10-1.34 (m), 1.3 8-1.74 (m), 1.76 (s), 1.81 (s), 2.10-2.48 (m), 2.83 (s), 2.94 (s), 3.13 (m), 3.85 (d, J= 14.0 Hz), 3.98 (d, J=
14.0 Hz), 4.02 (s), 4.09 (m), 4.35 (m), 4.57 (m), 4.73 (m), 4.97 (m), 6.38 (d, J= 10.0 Hz), 6.53 (d, J= 9.0 Hz), 7.10-7.28 (m), 7.98 (m), 8.35 (d, J= 8.0 Hz), 8.51 (s), 8.58 (s), 8.63 (d, J= 6.0 Hz).
Preparation of Product Ethyl-2-Methyl-3-(Benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)- E-Propenoate.
Using the procedure described in Example 4 for the preparation of ethyl-3-(cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-propenoate, ethyl-2-methyl-3-(benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-propenoate was synthesized from ethyl-2-methyl-3-[benzylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate in 24% yield (two steps from the aldehyde intermediate). White amorphous solid: 'H NMR (DMSO-db) {mixture of rotamers) b -0.16 (m), 0.59 {m), 0.84 (m), 1.08-1.83 (m), 1.78 (s), 1.86 (s), 2.03 (m), 2.79 (s), 2.94 (s), 3.16 (m), 3.97-4.21 (m), 4.35 (m), 4.53-4.78 (m), 5.08 (m), 6.39 (d, J= 9.0 Hz), 6.55 (d, J= 9.0 Hz), 6.82 (m), 7.12-7.29 {m), 7.96 (m), 8.35 (d, J= 6.6 Hz), 8.65 (d, J= 7.0 Hz). HRMS calcd for C"H,6N,O6S+Cs 771.2192, found 771.2172. Anal. {C34H46N4~6S) C, H, N.
Example 16 - Preparation of Compound 17: 1-(2'-Oxazolidon-3' ;yll-3_~Ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-Propenone.
Preparation of Intermediate 1-[2'-Oxazolidon-3'-yl]-3-[BOC-L-(Tr-Gln)]-E-Propenone.
To 3-[BOC-L-(Tr-Gln)]-E-propenoic acid (1.0 g, 1.94 mmol) in 12.0 mL of anh THF was added triethylamine (0.68 mL, 4.86 mmol). The mixture was cooled to -20 °C
and pivaloyl chloride (0.24 mL, 1.94 mmol) was added. The reaction mixture was stirred at -20 °C for 2.5 h, at which time solid lithium chloride (0.091 g, 2.14 mmol) and 2-oxazolidone (0.17 g, 1.94 mmol) were added. The reaction mixture was allowed to warm to rt and further stirred overnight. The mixture was then concentrated to dryness, and the residue was taken up in CHZCIz and washed with 5% hHS04. The organic layer was separated, and the aqueous layer was reextracted twice with CHzCl2. The combined organic layers were dried over MgS04, concentrated and purified by column chromatography on silica gel (S% MeOH/CHC13) to yield 1-[2'-oxazolidon-3'-yl]-3-[BOC-L-(Tr-Gln)]-E-propenone (0.61 g, 54 %) as an off white solid foam. 'H NMR (CDCI,) b 1.23 {s, 4.5 H), 1.43 (s, 4.5 H), 1.81 (m, 1H), 1.98 (m, 1H), -2.40 (t, 2H, J= 7.2 Hz), 4.02-4.08 (m, 2H), 4.37-4.44 (m, 3H), 4.88 (d, 1H, J=
8.1 Hz), 6.87 (bs, 1H), 6.99 (dd, 1H, J= 15.8, 5.2 Hz), 7.18-7.32 (m, 16H). MS calcd for C34H3,N3O6+H 584, found 584.
Preparation of Intermediate 1-[2'-Oxazolidon-3'-yl]-3-(BOC-L-Leu-L-N-Me-Phe-(Tr-Gln)]- E-Propenone.
To 1-[2'-oxazolidon-3'-yl]-3-[BOC-t,-(Tr-Gln)]-E-propenone (0.60 g, 1.02 mmol) dissolved in isopropyl alcohol (17.25 mL), HC10,(S.0 mL, 79.63 mmol) was added, and the reaction mixture was stirred at rt for 1.5 h. The mixture was then poured into an aq solution of 1N NaOH (3.0 mL) along with a sat. NaHC03 solution (30.0 mL) and was extracted twice with CHZCIz. The organic phase was dried over MgS04 and concentrated to give the free amine (0.46 g, 0.96 mmol), which was coupled immediately with BOC-L-Leu-L-N-Me-Phe (0.38 g, 0.96 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]- E-propenoate to provide 1-[2'-oxazolidon-3'-yl]-3-[BOC-L-Leu-1,-N-Me-Phe-(Tr-Gln)]- E-propenone (0.33 g, 41 %) as a tan solid foam after column chromatography on silica (2% methanol/CHC13).
'H NMR
(CDC13) b 0.65 (t, J= 6.8 Hz), 0.72 (m), 0.84-0.89 (m), 1.07 (m), 1.24-1.44 (m), 1.63 (m), 1.84 (m), 2.08 (m), 2.28-2.36 (m), 2.90 (s), 3.01 (m), 3.34 (m, 4.01-4.06 (m), 4.16 (m), 4.38-4.42 (m), 4.64 (m), 4.73 (m), 4.85 (m), 6.76 (bs), 7.04 (dd, J= 15.5, 6.1 Hz), 7.12-7.41 (m), 8.29 (d, J= 8.4 Hz). MS calcd for CSOH59N50g+H 858, found 858.
Preparation of Intermediate 1-[2'-Oxazolidon-3'-yl]-3-[Ethylthiocarbonyl-L-Leu-L-N-Me-Phe-(Tr-Gln)]-E-Propenone. --1-[2'-Oxazolidon-3'-yl]-3-[BOC-L-Leu-L-N-Me-Phe-(Tr-Gln)]-E-propenone (0.32 g, 0.37 mmol) was deprotected with HC10~ using the procedure described in the previous preparation and was subsequently coupled to ethylchlorothiolformate (0.042 mL, 0.40 mmol) using the procedure described in Example 6 for the preparation of 2,3-dihydroindole-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenamide to provide I-[2'-oxazolidon-3'-yl]-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-(Tr-Gln)]-E-propenone (0.22 g, 78 %) as an off=white solid foam after column chromatography on silica (2% methanol/CHC13). 'H NMR (CDC13) 8 0.62-0.76 (m), 0.85-0.87 (m), 1.13-1.26 (m), 1.37 (m), 1.62 (m), 1.85 (m), 2.06 (m), 2.58-2.72 (m), 2.67-2.89 (m), 3.18-3.40 (m), 4.02-4.07 (m), 4.39-4.44 (m), 4.64-4.67 (m), 5.71 (m), 6.76 (bs), 7.00 (m), 7.14-7.35 (m), 8.06 (d, J= 8.4 Hz). MS calcd for C48HSSNSO,S+Cs 978, found 978.
Preparation of Product - 1-[2'-Oxazolidon-3'-y1J-3-(Ethylthiocarbonyl-L-Leu-L-N-Me-Phe-Gln)-E-Propenone.
1-[2'-Oxazolidon-3'-yl]-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-(Tr-Gln)]-E-propenone (0.22 g, 0.26 mmol) was deprotected using the procedure described in Example 1 for the preparation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate to provide 1-[2'-oxazolidon-3'-yl]-3-(ethylthiocarbonyl-L-Leu-L-N-Me-Phe-Gln)-E-propenone (0.056 g, 35 %) as a white solid: mp = 110-111 °C; IR (thin film) 3272, 1677 cm ''; 'H
NMR (CDC13) b 0.64-0.70 (m), 0.89-0.91 (m), 1.19-I .28 (m), 1.40 (m), 1.65 (m), 2.03 (m), 2.23-2.25 (m), 2.76-2.96 (m), 3.48 (q, J= 7.2 Hz), 4.04-4.10 (m), 4.41-4.46 (m), 4.65-4.67 (m), 5.48 (m), 6.12 (m), 6.24 (bs), 7.02 (m), 7.15-7.36 (m), 7.91 (m). HRMS
calcd for CZ9H4,NSO,S+Cs 736.1780, found 736.1803; Anal (Cz9H4,N50~S) C, H, N.

Example 17 - Preparation of Compound 18~
Ethvl-3-1CBZ-L-Leu-L-(3R-Phenyl)-Pro-L-Gln]- E-Propenoate Preparation of Intermediate BOC-L-(3R-Phenyl)-Pro.
(2S, 3R)-3-Phenylpyrrolidine-2-carboxylic acid (0.10 g, 0.52 mmol) was suspended in 1,4-dioxane and 800 mL of 1N NaOH was added to form a clear solution. Di-tert-butyl dicarbonate (0.13 g, 0.58 mmol) was added over a period of 30 minutes, and the reaction mixture was stirred overnight at rt. At this time, the reaction mixture was concentrated in vacuo, and the resulting residue was taken up in a saturated solution of NaHC03. This solution was washed with ether, and the aqueous layer was acidified with 1N
HCl and extracted with ethyl acetate. The organic phase was separated and dried over MgS04 and concentrated to provide BOC-L-(3R-phenyl)-Pro (0.15 g, 97%) as a white solid.
'H NMR
(CDCl3) b 1.52 (s, 9H), 2.03 (m, 1H), 2.35 (m, 1H), 3.49-3.83 (m, 4H), 7.33-7.35 (m, SH).
MS calcd for C,6Hz,N04+H 292, found 292.
Preparation of Intermediate Ethyl-3-[BOC-L-(3R-Phenyl)-Pro-L-(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (0.28 g, 0.52 mmol) was deprotected and coupled to BOC-L-(3R-phenyl)-Pro using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(T'r-Gln)]-E-propenoate, to provide ethyl-3-[BOC-L-(3R-phenyl)-Pro-L-(Tr-Gln)]-E-propenoate (0.27 g, 73%) as a white glassy solid after column chromatography on silica (2% methanol/CHCl3). 'H NMR
(CDCl3) 8 -1.25-1.31 (m, 3H), 1.40 (bs, 9H), 2.03 (m, 2H), 2.41 (m, 2H), 3.48 (m, 2H), 3.67 (m, 2H), 4.14-4.21 (m, 4H), 4.68 (m, 1 H), 5.62 (d, 1 H, J = 16.5 Hz), 6.32 (m, 1 H), 6.75 (dd, 1 H, J =

15.9, 5.0 Hz), 6.96 (s, bs, 1H), 7.20 - 7.33 (m, 20H). MS calcd for C44Ha9N30s+H 716, found 716.
Preparation of Intermediate - Ethyl-3-[CBZ-L-Leu-L-(3R-Phenyl)-Pro-L-(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-(3R-phenyl)-Pro-L-(Tr-Gln)]-E-propenoate was deprotected and coupled to CBZ-Leu (0.10 g, 0.37 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, to provide ethyl-3-[CBZ-L-Leu-L-(3R-phenyl)-Pro-L-(Tr-Gln)J-E-propenoate (0.19 g, 60%) as a white glassy solid. 'H NMR (CDCl3) b 0.84 (d, 3H, J= 6.5 Hz), 0.93 (d, 3H, J= 6.5 Hz), 1.94 (m, 1H), 1.29 (t, 3H, J= 7.2 Hz), 1.34 - 1.51 (m, 2H), 2.07 (m, 1H), 2.23 (m, 1H), 2.37 (m, 1 H), 2.44 - 2.48 (m, 2H), 3.50-3.52 (m, 2H), 3.67-3.69 (m, 2H), 4.04 - 4.19 (m, 4H), 4.45-4.52 (m, 2H), 4.80 (d, 1H, J= 9.0 Hz), S.OS (d, 1H, J= 12.1 Hz), 5.12 (d, 1H, J= 12.1 Hz), 5 .44 (dd, 1 H, J = 15.6, 1.9 Hz), 5 .6 S (d, 1 H, J = 8.7 Hz), 6.66 (dd, 1 H, J = 1 S .7, 4. 5 Hz), 7.17-7.38 (m, 25H); MS calcd for C53HSgN40~+H 863, found 863.
Preparation of Product -Ethyl-3-[CBZ-L-Leu-L-(3R-Phenyl)-Pro-L-Gln]-E-Propenoate.
Ethyl-3-[CBZ-L-Leu-L-(3R-phenyl)-Pro-L-(Tr-Gln)J-E-propenoate was deprotected using the procedure described in Example 1 for the preparation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)- E-propenoate, to provide ethyl-3-[CBZ-L-Leu-L-(3R-phenyl)-Pro-L-Gln]-E-propenoate (0.098 g, 70%) as a white solid after column chromatography on silica (5% methanol/CHC13). mp = 72-75 'C; IR
(thin film) 3311, 1709 cm'; 'H NMR (CDC13) b 0.97 (t, 6H, J= 7.2 Hz), 1.30 (t, 3H, J=

7.0 Hz), 1.44-1.57 (m, 4H), 1.75 (m, 1H), 2.10 (m, 1H), 2.17-2.28 (m, 2H), 2.34-2.43 (m, 2H), 3.51 (m, 1 H), 3.73 (m, 1 H), 4.13-4.20 (m, 3H), 4.59-4.66 (m, 2H), S.11 (bs, 2H), 5.25 (bs, 1 H), 5.3 7-5.47 (m, 2H), 5.71 (d, 1 H, J = 9.0 Hz), 6.57 (bs, 1 H), 6.70 (dd, 1 H, J = 15.7, 4.5 Hz), 7.25-7.41 (m, lOH). HRMS calcd for C"H"N,O,+Cs 753.2264, found 753.2240.
Anal (C34H44N407) C~ H, N.
E_xamnle 18 - Preparation of Compound 19' Ethyl-~CBZ-L-Leu-L Pro-L-Gln) E-Prc~penoate.
Preparation of Intermediate Ethyl-3-[BOC-L-Pro-L-(Tr-Gln))-E-Propenoate.
Ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (0.30 g, 0.55 mmol) was deprotected and coupled to BOC-L-Pro (0.11 g, 0.55 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, to provide ethyl-3-[BOC-L-Pro-L-(Tr-Gln)]-E-propenoate (0.30 g, 85%) as a white glassy solid after column chromatography on silica (S% methanol/CHC13). 'H NMR (CDCl3) 8 1.27 (t, 3H, J
= 7.2 Hz), 1.43 (bs, lOH), 1.82-2.00 (m, 6H), 2.34 (t, 2H, J= 7.2 Hz), 3.34 (m, 2H), 4.14-4.21 (m, 3H), 4.62 (m, 1H), 5.92 (dd, 1H, J= 15.6, 1.5 Hz), 6.80 (dd, 1H, J= 15.7, 5.1 Hz), 7.18-7.33 (m, 16H). MS calcd for C3gH45N3O6+Cs 772, found 772.
Preparation of Intermediate Ethyl-3-[CBZ-L-Leu-L-Pro-L-(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-Pro-L-(Tr-Gln)]-E-propenoate (0.30 g, 0.47 mmol) was deprotected and coupled with CBZ-Leu (0.12 g, 0.47 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, to provide ethyl-3-[CBZ-L-Leu-L-Pro-L-('rr-Gln)]-E-propenoate (0.24 g, 64%) as a white foamy solid after column chromatography on silica (2% methanoUCHCl3). 'H NMR
(CDCI3) 8 0.84 (d, 3H, J= 6.5 Hz), 0.92 (d, 3H, J= 6.2 Hz), 1.27 (t, 3H, J=
7.0 Hz) 1.35 (m, 1H), 1.63-1.75 (m, 2H), 1.99-2.10 {m, 5H), 2.39 (m, 2H), 3.53 (m, 1H), 3.73-3.76 (m, 3H), 4.17 (q, 2H, J= 7.2 Hz), 4.26 (m, 1H), 4.49-4.51 (m, 3H), 5.02-5.12 (m, 3H), 5.85 (dd, 1 H, J = 15.9, 1.6 Hz), 6.78 (dd, 1 H, J = 15.7, 5.1 Hz), 7.07 (bs, 1 H), 7.19-7.3 3 (m, 20H). MS calcd for C4,H54N40,+Cs 919, found 919.
Preparation of Product - Ethyl-3-(CBZ-L-Leu-L-Pro-L-Gln)-E-Propenoate.
Ethyl-3-[CBZ-L-Leu-L-Pro-L-(Tr-Gln)]-E-propenoate (0.22 g, 0.28 mmol) was deprotected using the procedure described in Example 1 for the preparation of ethyl-3-(CBZ-L-N-Me-Phe- L-Gln)-E-propenoate, to provide ethyl-3-(CBZ-L-Leu-L-Pro-L-Gln)-E-propenoate (0.092 g, 61%) as a white solid after preparative TLC (10% methanoUCHCl3): mp = SS-60 'C; IR (thin film) 3300, 1707 cm';
'H NMR (CDCI3) 8 0.94 (d, 3H, J= 6.5 Hz), 0.98 (d, 3H, J= 6.5 Hz) 1.28 (t, 3H, J=7.2 Hz), 1.46 (t, 2H, J= 7.0 Hz), 1.70-1.75 (m, 2H), 2.03-2.33 (m, 7H), 3.60 (m, 1H), 3.79 (m, 1H), 4.19 (q, 2H, J= 7.2 Hz), 4.41 (m, 1H), 4.54-4.65 (m, 2H), 5.08 (dd, 2H, J= 15.4, 12.3 Hz), 5 .54 (m, 1 H), 5 .44 (d, 1 H, J = 8 .4 Hz), 5 .91 (dd, 1 H, J = 15 .7, 1.4 Hz), 6.3 6 (m, 1 H), 6.77 (d, 1H, J= 8.7 Hz), 6.84 (dd, 1H, J= 15.9, S.0 Hz), 7.34 (bs, SH). HRMS
calcd for CZ8H4°N40,+Cs 677.1951, found 677.1972. Anal (CZgH4°N40,~O.SHZO) C, H, N.

Example 19 - Preparation of Compound 20: Ethyl-3-[CBZ-IrLeu-Ir.(4R-Benz~loa~y~-Pro-L-Gln~-E-Propenoate.
Preparation of Intermediate Ethyl-3-[BOC-L-(4R-Benzyloxy)-Pro-L-(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (0.50 g, 0.92 mmol) was deprotected and coupled to BOC-L-(4R-benzyloxy)-Pro (0.30 g, 0.92 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate to provide ethyl-3-[BOC-L-(4R-benzyloxy)-Pro-L-(Tr-Gln)]-E-propenoate (0.54 g, 78%) as a white foamy solid after column chromatography on silica (2% methanol/CHCl3).
'H
NMR (CDC13) 8 1.27 (t, 3H, J= 7.16 Hz), 1.39 (bs, lOH), 1.80 (m, 1H), 1.80 (m, 1H), 2.16 (m, 1H), 2.32 - 2.39 (m, 2H), 3.46-3.51 (m, 2H), 4.18 (q, 2H, J= 7.2 Hz), 4.26-4.35 (m, 2H), 4.46-4.49 (m, 2H), 4.56-4.66 (m, 2H), 5.90 (dd, 1H, J= 15.7 Hz), 6.80 (dd, 1H, J=
15.6, 4.8 Hz), 6.97 (m, 1H), 7.18-7.37 (m, 20H). MS calcd for C45HS,N30~+H
746, found 746.
Preparation of Intermediate Ethyl-3-[CBZ-L-Leu-L-(4R-Benzyloxy)-Pro-L-(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-(4R-benzyloxy)-Pro-L-frr-Gln)]-E-propenoate (0.49 g, 0.72 mmol) was deprotected and coupled to CBZ-Leu (0.19 g, 0.72 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, to provide ethyl-3-[CBZ-L-Leu-L-(4R-benzyloxy)-Pro-L-(Tr-Gln)]-E-propenoate (0.47 g, 72%) as a white foamy solid after column chromatography on silica (2% methanol/CHCl3).
'H NMR
(CDC13) 8 0.84 (d, 3H, J= 6.5 Hz), 0.91 (d, 3H, J= 6.5 Hz), 1.29-1.35 (m, 4H), 1.75 (m, 1 H), 2.45 (m, 1 H), 2.19-2.23 (m, 2H), 2.40-2.46 (m, 2H), 3.60 (m, 1 H), 3.87 (m, 1 H), 4.18 (q, 2H, J= 7.2 Hz), 4.27-4.37 (m, 2H), 4.48-4.54 (m, SH), 4.97-5.09 (m, 4H), 5.83 (dd, 1H, J = 15.7, 1.7 Hz), 6.673 (d, 1 H, J = 7.5 Hz), 6.78 (dd, 1 H, J = 15.7, 5.1 Hz), 7.09 (bs, 1 H), 7.15-7.36 (m, 25I-n. MS calcd for C54HsoNaCs+H 893, observed 893.
Preparation of Product -Ethyl-3-[CBZ-L-Leu-L-(4R-Benzyloxy)-Pro-L-Gln]-E-Propenoate.
Ethyl-3-[CBZ-L-Leu-L-(4R-benzyloxy)-Pro-L-(Tr-Gln)]-E-propenoate (0.47 g, 0.52 mmol) was deprotected using the procedure described in Example 1 for the preparation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate, to provide ethyl-3-[CBZ-L-Leu-L-(4R-benzyloxy)-Pro-L-Gln]-E-propenoate (0.27 g, 81%) as a white foamy solid after column chromatography on silica (S% methanoUCHCI3). IR (thin film) 3296, 1716 cm'; 'H NMR (CDC13) 8 0.90- 0.96 (m, 6H), 1.28 (t, 3H, J= 7:0 Hz), 1.44-1.46 (m, 2H), 1.69-1.71 (m, 2H), 2.07-2.37 (m, SH), 3.67 (dd, 1H, J=
10.7, 4.5 Hz), 4.03 (d, 1 H, J = 10.9 Hz), 4.16 (d, 1 H, J = 7.2 Hz), 4.21 (d, 1 H, J = 7.2 Hz), 4.32 (m, 1 H), 4.46-4.55 (m, 4H), 4.62 (m, 1H), 5.02 (d, 1H, J= 12.3 Hz), 5.09 (d, 1H, J=
12.3 Hz), 5.31 (m, 1H), 5.46 (d, 1H, J= 9.0 Hz), 5.89 (dd, 1H, J= 15.9, 1.6 Hz), 6.43 (m, 1H), 6.65 (d, 1H, J= 9.0 Hz), 6.83 (dd, 1H, J= 15.7, 5.1 Hz), 7.33 (bs, lOH). HRMS calcd for C35H46N4~8+CS 783.2370, found 783.2390; Anal (C,SH46N4~8~O.S HZO) C, H, N.

Ezample 20 - Preparation of Compound 21:
Ethyl-3-jCB~L-Leu-L-(3S-Methyl)-Pro-L-Gln]- E-Propenoate.
Preparation of Intermediate BOC-L-(3S-Methyl)-Pro.
(2S, 3S)-3-Methyl pyrrolidine-2-carboxylic acid (0.25 g, 1.94 mmol) was protected with a BOC group following the procedure described in Example 17 for the preparation of BOC-L-(3R-Phenyi)-Pro to provide BOC-L-(3S-methyl)-Pro (0.43 g, 98%) as a white solid.
'H NMR (CDCl3) b 1.16-1.21 (m, 6H), 1.42 (s, 9H), 1.48 (s, 9H), 1.52-1.61 (m, 2H), 2.01-2.12 (m, 2H), 2.41 (m, 1H), 2.61 (m, 1H), 3.41-3.62 (m, 4H), 3.77 (m, 1H), 3.90 (m, 1H). MS calcd for C"H,9N04+H, 230, found 230.
Preparation of Intermediate Ethyl-3-[BOC-Ir(3S-Methyl)-Pro-Ir(Tr-Gln)]
-E-Propenoate.
Ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (0.53 g, 0.97 mmol) was deprotected and coupled to BOC-L-(3S-methyl)-Pro (0.22 g, 0.97 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, to provide ethyl-3-[BOC-L-(3S-methyl)-Pro-L-(Tr-Gln)]-E-propenoate (0.27 g, 43%) as a glassy off white solid foam after column chromatography on silica (5%
methanol/CHCl3).
'H NMR (CDC13) 8 1.10-1.17 (m, 3H), 1.27 (t, 3H, J= 7.2 Hz), 1.41 (hs, lOH), 1.58 (bs, 2H), 1.80 (m, 1 H), 2.00 (m, 1 H), 2.36 (m, 2H), 3.30 (m, 1 H), 3.40-3.66 (m, 2H), 3.70 (d, 1 H, J = 5.0 Hz), 4.14-4.21 (m, 2H), 4.64 (m, 1 H), 5.92 (d, 1 H, J = 15.9 Hz), 6.78-6.84 (m, 2H), 7.19-7.29 (m, 15H)._ MS calcd for C39H4~N3O6+H, 654, found 654.

Preparation of Intermediate Ethyl-3-[CBZ-L-Leu-L-(3S-Methyl)-Pro-L-(Tr-Gln)1-E-Propenoate.
Ethyl-3-[BOC-L-(3S-methyl)-Pro-L-(Tr-Gln)]-E-propenoate (0.27 g, 0.42 mmol) was deprotected and coupled to CBZ-Leu (0.11 g, 0.42 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, to provide ethyl-3-[CBZ-L-Leu-L-(3S-methyl)-Pro-L-(Tr-Gln)]-E-propenoate (0.18 g, 52%) as a white solid foam after column chromatography on silica (4% methanol/CHCl3). 'H NMR
(CDCl3) S 0.83 (d, 3H, J= 6.2 Hz), 0.92 (d, 3H, J= 6.2 Hz), 1.10 (d, 3H, J=
7.2 Hz), 1.34 (m, 1H), 1.60-1.74 (m, 2H), 2.04-2.17 (m, 3H), 2.38-2.48 (m, 3H), 3.53 (m, 1H), 3.68 (d, 1H, J= 6.2 Hz), 3.91 (m, 1H), 4.17 (dd, 2H, J= 14.9, 6.8 Hz), 4.48-4.52 (m, 2H), 4.96-5.12 (m, 4H), 5 . 84 (d, 1 H, J = 15.6 Hz), 6.49 (d, 1 H, J = 8.1 Hz), 6.79 (dd, 1 H, J =
16.2, 4.7 Hz), 7.13 (bs, 1H), 7.19-7.33 (m, 20H). MS calcd for C4gH56N40,+H, 801, found 801.
Preparation of Product - Ethyl-3-[CBZ-IrLeu-L-(3S-Methyl)-Pro-L-Gln]-E-Propenoate.
Ethyl-3-[CBZ-L-Leu-L-(3S-methyl)-Pro-L-(Tr-Gln)]-E-propenoate (0.18 g, 0.22 mmol) was deprotected using the procedure described in Example 1 for the preparation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate, to provide ethyl-3-[CBZ-L-Leu-L-(3S-methyl)-Pro-L-Gln]-E-propenoate (0.078 g, 64%) as a white solid foam after column chromatography on silica (4% methanoUCHCI3). IR (thin film) 3392, 1708 cm-';'H
NMR
(CDC13) 8 0.92-0.98 (m, 6H), 1.17 (d, 3H, J= 6.9 Hz), 1.28 (t, 3H, J= 7.2 Hz), 1.41-1.49 (m, 2H), 1.64-1.76 (m, 3H), 2.10-2.28 (m, 3H), 2.35-2.48 (m, 2H), 3.59 (m, 1H), 3.85 (d, 1 H, J = 6.5 Hz), 3 .96 (m, 1 H), 4.19 (dd, 1 H, J = 14.3, 7.2 Hz), 4.54 (m, 1 H), 4.68 (m, 1 H), 5.04- 5.13 (m, 2H), 5 .31 (d, 1 H, J = 9.0 Hz), 5.91 (dd, 1 H, J = 15.6, 1.6 Hz), 6. S 1- 6.54 (m, 2H), 6.85 (dd, 1H, J= 15.7, S.1 Hz), 7.34 (bs, SH). HRMS calcd for C29H42N407+Na, 581.2951, found 581.2937. Anal (Cz9H~ZN40,~0.5 HZO) C, H, N.
Example 21 - Preparation of Compound 22' N-Methoxy, N-Methyl 3 I~CBZ L Leu L
(3R-Phenyl)~-Pro-L-Gln~]-EPro~enamide.
Preparation of Intermediate 3-[BOC-L-(Tr-Gln)]-E-Propenoic Acid.
Ethyl-3-[BOC-r.-(Tr-Gln)]-E-propenoate (1.874 g, 3.46 mmol) was taken up in 20 mL EtOH, and 1N aq NaOH (7.95 mL, 7.95 mmol) was added dropwise via an addition funnel over 2 h. The resulting solution was stirred at room temperature for 1.5 h, whereupon the reaction mixture was poured into water and washed with ether.
The aqueous layer was acidified to pH 3 with 1 N HC 1, and extracted 3 times with EtOAc. The organic phase was dried over MgS04 and concentrated to provide 3-[BOC-L-('Tr-Gln)]-E-propenoic acid (1.373 g, 77%) as a glassy off-white solid. No further purification was needed: IR (ICBr) 3315, 1698, 1666 cm-';'H NMR (CDC13) 8 1.42 (s, 9H), 1.76 (m, 1H), 1.83-1.98 (m, 1H), 2.37 (t, 2H, J= 7.0 Hz), 4.30 (m, 1H), 4.88 (m, 1H), 5.85 (d, 1H, J=
15.3 Hz), 6.86 (dd, 1 H, J = 15. S, 5.1 Hz), 6.92 (s, 1 H), 7.25 (m, 1 SH).
Preparation of Intermediate N-Methoxy-N-Methyl-3-[BOC-L-(Tr-Gln)]-E-Propenamide.
This intermediate was prepared from 3-[BOC-L-(Tr-Gln)]-E-propenoic acid and N, O-dimethylhydroxylamine hydrochloride as described in Example 1 for the synthesis of intermediate BOC-L-(Tr-Gln)-N(OMe)Me. This intermediate can alternatively be prepared by the reaction of BOC-L-(Tr-glutaminal) with N-methoxyl-N-methyl-(2-triphenylphosphoranylidene)-acetamide in THF as described for the preparation of ethyl-3- [cyclopentylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, or by the reaction of BOC-L-(Tr-glutaminal) with the anion of diethyl (N-methoxy-N-methylcarbamoylmethyl)phosphonate as described in Example 6 for the 1 preparation of 1-(2',3'-dihydroindolin-1-yl)-3-[BOC-L-(Tr-Gln)]-E-propenone.
IR (thin film) 3307, 1704 cm-';'H NMR (CDCl3) b 1.43 (s, 9H), 1.80 (m, 1H), 1.95 (m, 1H), 2.36-2.40 (m, 2H), 3.24 (s, 3H), 3.67 (s, 3H), 4.31 (m, 1H), 4.83 (m, 1H), 6.48 (d, 1H, J=
15.6 Hz), 6.79 (dd, 1H, J= 15.6, 5.6 Hz), 6.92 (m, 1H), 7.19-7.32 (m, 15H).
HRMS calcd for C33H39N3O5+Cs, 690.1944, found 690.1967.
Preparation of Intermediate N-Methoxy-N-Methyl-3-[BOC-L-(3R-Phenyl)-Pro-L-(Tr-Gln)]-E-Propenamide.
N-Methoxy-N-methyl-3-[BOC-L-(Tr-Gln)]-E-propenamide (0.24 g, 0.49 mmol) was deprotected and coupled to BOC-L-(3R-phenyl)-Pro (0.14 g, 0.49 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate to provide N-methoxy-N-methyl-[BOC-L-(3R-phenyl)-Pro-L-(Tr-Gln)]-E-propenamide (0.22 g, 63%) as a white solid foam after column chromatography on silica (3% methanol/CHC13). 'H NMR (CDC13) 8 1.40 (s, 9H), 1.48 (m, 1H), 1.73 (m, 1H), 1.91-2.02 (m, 2H), 2.25 (m, 1H), 2.35-2.45 (m, 2H), 3.22 (s, 3 H), 3.43 - 3.46 (m, 2H), 3 .61- 3.72 (m, 4H), 4.20 (m, 1 H), 4.70 (m, 1 H), 6.44 (m, 1H), 6.74 (m, 1H), 6.99 (m, 1H), 7.16 - 7.33 (m, 20H). MS calcd for C44HsoNa06+Na 753, found 753.

Preparation of Intermediate N-Methoxy-N-Methyl-3-[CBZ-L-Leu-L-(3R-Phenyl)-Pro L-(Tr-Gln)]-E-Propenamide.
N-Methoxy-N-methyl-3-[BOC-L-(3 R-phenyl)-Pro-L-(Tr-Gln)]-E-propenamide (0.18 g, 0.26 mmol) was deprotected and coupled to CBZ-L-Leu (0.070 g, 0.26 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, to provide N-methoxy-N-methyl-3-[CBZ-L-Leu-L-(3 R-phenyl)-Pro-L-(Tr-Gln)]-E-propenamide (0.076 g, 33%) as a clear glass after column chromatography on silica (3% methanol/CHC13). 'H NMR (CDC13) 8 0.79-0.93 (m, 6H), 1.01 (m, 1H), 1.22 (m, 1 H), 1.40 (m, 1 H), 1.51-1.95 (m, 2H), 2.01 (m, 1 H), 2.19 (m, 1 H), 2.31-2.52 (m, 2H), 3.15-3.20 (m, 3H), 3.53-3.68 (m, 6H), 3.92 (m, 1H), 4.08 (m, 1H), 4.57 (m, 1H), 5.02-5.15 (m, 2H), 6.25-6.35 (m, 2H), 6.63 (m, 1H), 7.15-7.35 (m, 25H). MS
calcd for Cs3HsvNsO,+H 878, found 878.
Preparation of Product -N-Methoxy-N-Methyl-3-[CBZ-L-Leu-L-(3R-Phenyl)-Pro-L-Gln]-E-Propenamide.
N-Methoxy-N-methyl-3-[CBZ-L-Leu-L-(3R-phenyl)-Pro-L-(Tr-Gln)]-E-propenamide (0.076 g, 0.090 mmol) was deprotected using the procedure described in Example 1 for the synthesis of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate, to provide N-methoxy-N-methyl-3-[CBZ-L-Leu-L-(3R-phenyl)-Pro-L-Gln]-E-propenamide (12.0 mg, _ 21%) as a clear glass after column chromatography (S% methanol/CHC13). IR
(thin film) --3290, 1708 cm-'; 'H NMR (CDC13) b 0.94 (d, 3H, J= 6.5 Hz), 0.99 (d, 3H, J= 6.7 Hz), 1.44-1.74 (m, 3H), 2.05 (m, 1 H), 2.15-2.22 (m, 2H), 2.32 (m, 1 H), 2.41 (m, 1 H), 3.21 (m, 1 H), 3.51- 3.74 (m, SH), 4.14 (m, 1 H), 4.23 (m, 1 H), 4.62- 4.66 (m, 2H), 5.09- 5.10 (m, 2H), 5.27 (m, 1 H), 5.48 (d, 1 H, J = 13 .8 Hz), 6.17 (d, 1 H, J = 9.0 Hz), 6.3 6 (d, 1 H, J = 15.3 Hz), 6.59 (m, 1H), 6.65 (dd, 1H, J= 15.6, 5.9 Hz), 7.21 (m, 1H), 7.24-7.35 (m, lOH).
HRMS calcd for C34H45N507+CS 768.2373, found 768.2395.
Example 22 - Preparation of Compound 24~
Ethvl-3-(Ethvlthiocarbonyl-L-Leu-L-Pro-L-Glny-E-Propenoate.
Preparation of intermediate Ethyl-3-[BOC-L-Leu-L-Pro-Ir(T'r-Gln)]-E-Propenoate.
A solution of HC1 in 1,4-dioxane (4.5 mL of a 4.0 M solution) was added to a solution of ethyl-3-[BOC-L-Pro-L-(Tr-Gln)J-E-propenoate (0.39 g, 0.61 mmol) in the same solvent (4.5 mL) at room temperature. The reaction mixture was stirred for 2 h at rt and then concentrated. The resulting foamy solid was dissolved in dry CHZCIz, and BOC-L-Leu (0.14 g, 0.61 mmol), l-hydroxybenzotriazole hydrate (0.12 g, 0.92 mmol), 4-methylmorpholine (0.27 mL, 2.45 mmol), and 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (0.18 g, 0.92 mmol) were added sequentially. The reaction mixture was stirred for 12 h at 23°C, and then it was partitioned between 1N HCI and CHzC 12. The organic layer was washed with aq sat solution of NaHC03, dried over MgS04, concentrated, and purified by column chromatography on silica gel (2 MeOH/CHC13) to provide ethyl-3-[BOC-L-Leu-L-Pro-L-(Tr-Gln)J-E-propenoate (0.31 g, 68%) as a foamy white solid. 'H NMR (CDC 13) b 0.84 (d, 3H, J= 6.5 Hz), 0.92 (d, 3H, J
=-6.5 Hz), 1:27 (t, 3H, J= 7.2 Hz), 1.43 (s, 9H), 1.63-1.72 (m, 3H), 1.97-2.09 (m, 6H), 3.52 (m, 1H), 3.75 (m, 1H), 4.14-4.21 (m, 2H), 4.27 (m, 1H), 4.42-4.52 (m, 2H), 4.86 (m, 1H), 5.85 (dd, 1H, J= 15.6, 1.6 Hz), 6.75-6.82 (m, 2H), 7.07 (s, 1H), 7.19-7.32 (m, 15H).
MS calcd for C~,H56N40,+Cs 885, found 885.
Preparation of Intermediate Ethyl-3-(Ethylthiocarbonyl-L-Leu-L-Pro-L-(Tr-Gln)]
-E-Propenoate.
A solution of anh HC 1 in 1,4-dioxane (3.0 mL of a 4.0 M solution) was added to a solution of ethyl-3-[BOC-L-Leu-L-Pro-L-(Tr-Gln)]-E-propenoate (0.31 g, 0.42 mmol) in 3 mL 1,4-dioxane at 23°C. The reaction mixture was stirred for 2 h at 23°C, and it was then concentrated. The resulting foamy white solid was dissolved in dry CHIC 12 and diisopropylethylamine (0.16 mL, 0.91 mmol), and ethylchlorothiolformate (0.052 mL, 0.91 mmol) were added sequentially. The reaction mixture was poured into HZO, extracted with CHIC 1 Z twice, and dried over MgS04. The solution was concentrated and purified by column chromatography on silica gel (2% MeOH/CHC13) to provide ethyl-3-[ethylthiocarbonyl-L-Leu-1.-Pro-L-(Tr-Gln)]-E-propenoate (0.24 g, 78%) as a glassy white foamy solid. 'H NMR (CDC13) b 0.83 (d, 3H, J= 6.7 Hz), 0.91 (d, 3H, J=
6.7 Hz), 1.27 (t, 6H, J= 7.4 Hz), 1.34 (m, 1 H), 1.70-1.72 (m, 2H), 1.96-2.10 (m, 6H), 2.37-2.42 (m, 2H), 2.88 (dd, 2H, J= 14.6, 7.5 Hz), 3.54 (m, 1H), 3.72 (m, 1H), 4.18 (dd, 2H, J=
14.3, 7.2 Hz), 4.25 (m, 1 H), 4.52 (m, 1 H), 4.75 (m, 1 H), 5.78 (m, 1 H), 5.85 (dd, 1 H, J=
15.8, 1.8 Hz), 6.79 (dd, 1 H, J = 15. 8, 5.2 Hz), 6. 8 8 (d, 1 H, J = 8.1 Hz), 7.11 (s, 1 H), 7.20-7.33 (m, 15H). MS calCd C4zH52N4O6S+Cs 873, found 873.

Preparation of Product -Ethyl-3-(Ethylthiocarbonyl-IrLeu-L-Pro-L-Gln)-E-Propenoate.
Trifluoroacetic acid (2.0 mL) was added to a solution of ethyl-3-[ethylthiocarbonyl-L-Leu-L-Pro-L-(Tr-Gln)]-E-propenoate (0.24 g, 0.32 mmol) in chloroform (2.0 mL) and stirred at 23 °C for 1 h. The yellow solution evaporated to dryness, and the residue was purified by column chromatography on silica gel (5%
MeOH/CH13) to provide ethyl-3-(ethylthiocarbonyl-L-Leu-L-Pro-L-Gln)-E-propenoate (0.096 g, 60%) as a glassy white foamy solid. IR (thin film) 3292, 1717 cm-';
'H NMR
(CDC13) b 0.92 (d, 3H, J= 6.5), 0.98 (d, 3H, J= 6.7 Hz), 1.29 (t, 6H, J= 7.4 Hz), 1.46-1.51 (m, 2H), 1.69-1.79 (m, 3H), 2.00-2.34 (m, 6H), 2.86-2.94 (m, 2H), 3.62 (m, 1 H), 3.80 (m, 1 H), 4.20 (dd, 2H, J = 14.3, 7.2 Hz), 4.42 (m, 1 H), 4.65 (m, 1 H), 4.80 (m, 1 H), 5.5 7 (m, 1 H), 5.93 (dd, 1 H, J = 15.8, 1.5 Hz), 6.41 (m, 1 H), 6.49 (m, 1 H), 6.86 (dd, 1H, J= 15.8, 5.2 Hz), 7.06 (d, 1H, J= 8.7 Hz). HRMS calcd for C23H38N4O6S+Cs 499.2590, found 499.2596; Anal (C23H38N4O6S) C, H, N.
Example 23 - Preparation of Compound 25' Ethxl-3 '[CBZ-L Leu L Pip L Glnl E
Propenoate.
Preparation of Intermediate CB~L-Leu-L-Pip-OtBu.
A suspension of CBZ-L-Pip-OtBu (0.52 g, 1.6 mmol) and Pd on C (10%, 0.10 g) in EtOAc was stirred under a hydrogen atmosphere (balloon) for 1 h. The reaction mixture was filtered through Celite, and the filtrate was concentrated. The resulting oil was coupled _ with CBZ-L-Leu (0.43 g, 1.6 mmol) using the procedure described in Example 1 for the --preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, to provide CBZ-L-Leu-L-Pip-OtBu (0.57 g, 83%) as a colorless oil after column chromatography on silica (20% EtOAc/hexanes): IR (thin film) 3300, 1726, 1642 cm-';'H NMR (CDC13) b 0.93 (d, 3H, J= 6.5 Hz), 1.03 (d, 3H, J= 6.5 Hz), 1.46 (s, 9H), 1.50-1.60 (m, 2H), 1.64-1.83 (m, 2H), 2.23-2.27 (m, 2H), 3.19-3.28 (m, 2H), 3.77-3.81 (m, 2I-n, 4.76-4.83 (m, 2H), 5.10 (s, 2H), 5.26 (d, 1H, J= 4.7 Hz), 5.60 (d, 1H, J= 8.7 Hz), 7.27-7.36 (m, SH);
Anal.
(C24H36N2~5) C~ H~ N.
Preparation of Intermediate CBZ-L-Leu-L-Pip Trifluoroacetic acid (3 mL) was added to a solution of CBZ-L-Leu-L-Pip-OtBu (0.57 g, 1.3 mmol) in CHzC 1 z (6 mL) at 23 ° C. The reaction mixture was stirred at 23 °C
for 1.5 h after which CC 14 (6 mL) was added. The volatiles were then removed under reduced pressure to afford crude CBZ-L-Leu-L-Pip as a colorless oil. The crude acid thus obtained was immediately utilized in the following coupling procedure.
Preparation of Intermediate Ethyl-3-(CBZ-L-Leu-L-Pip-L-(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (0.36 g, 0.67 mmol) was deprotected and coupled with CBZ-L-Leu-L-Pip (0.26 g, 0.67 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propeneate to provide ethyl-3-[CBZ-L-Leu-L-Pip-L-(Tr-Gln)]-E-propenoate (0.20 g, 37%) as a foamy white solid: IR (thin film) 3304, 2954, 1713, 1655 cm-';'H NMR (CDC13, mixture of rotamers) 8 0.86 (d, J= 6.5 Hz), 0.94-0.99 (m), 1.22-1.30 (m), 1.32-1.40(m), 1.43-1.50 --(m), 1.62-1.68 (m), 1.79-1.98 (m), 2.26-2.45 (m), 3.25 (bs), 3.63-3.77 (m), 4.09-4.21 (m), 4.50-4.58 (m), 4.73-4.78 (m), 4.88-5.10 (m), 5.27 (d, J= 7.2 Hz), 5.49 (d, J= 8.7 Hz), 5.82 (dd, J= 15.6, 1.3 Hz), 5.90 (d, J= 15.6 Hz), 6.75 (d, J= 5.3 Hz), 6.79-6.88(m), 7.02-7.36(m); Anal. (C48HS6N4O,) C, H, N.
Preparation of Product-Ethyl-3-(CBZ-L-Leu-L-Pip-L~-Gln)-E-Propenoate.
Ethyl-3-[CBZ-L-Leu-L-Pip-L-(Tr-Gln)]-E-propenoate (0.16 g, 0.18 mmol) was deprotected using the procedure described in Example 1 for the synthesis of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate, to provide ethyl-3-(CBZ-L-Leu-L-Pip-L-Gln)-E-propenoate (0.082 g, 83%) as a foamy white solid: IR (thin film) 3306, 1713, 1667 cm-';
'H NMR (CDC13, mixture of rotamers) b 0.90-1.00(m), 1.23-1.30 (m), 1.41-2.08 (m), 2.12-2.22 (m), 2.44-2.59 (m), 3.41-3.48 (m), 3.80-3.84 (m), 4.12-4.22 (m), 4.54-4.60 (m), 4.79 (bs), 4.99- 5.12 (m), 5.79- 5.98 (m), 6.11 (s), 6.27 (s), 6.79- 6.92 (m), 7.14 (d, J =
7.2 Hz), 7.28-7.34 (m), 7.75 (d, J= 7.8 Hz). Anal. (Cz9H42N40,~0.5 Hz0) C, H, N.
Example 24 - Preparation of Compound 26~ 1-[1', 2'-Oxazin-2' yl] 3 (CBZ-L Leu L
Pip-L-Gln)-E-Propenone Preparation of Intermediate 1,2-Isooxazinane-2-Carboxylic Acid Ethyl Ester.
1,4 Dibromobutane (2.84 mL, 24.0 mmol), N-hydroxyurethane (S.0 g, 48.0 mmol), and KOH (2.67 g, 48.0 mmol) were taken up in 27 mL of EtOH and refluxed for 6 h. The mixture was concentrated in vacuo, and the residue was purified by column chromatography on silica gel (SO% EtOAc/hexanes) to provide 1,2-isooxazinane-2-carboxylic acid ethyl ester (2.38 g, 68%) as a clear, colorless oil. 'H NMR
(CDC13) 8 1.31 (t, 3H, J= 7.0 Hz), 1.69-1.81 (m, 4H), 3.69 (t, 2H, J= 5.5 Hz), 3.98 (t, 2H, J= 5.3 Hz), 4.20-4.27 (m, 2H).
Preparation of Intermediate 1,2-Isooaazinane~HCl salt 1,2-Isooxazinane-2-carboxylic acid ethyl ester (2.38 g, 15.0 mmol) was refluxed in concentrated HCl for 3 h. The reaction mixture was cooled to rt and washed with EtzO.
The organic phase was discarded, and the aqueous layer was concentrated in vacuo. Traces of Hz0 were removed by adding EtOH and reconcentrating. This yielded the HC1 salt of 1,2-isooxazinane as a white solid (1.70 g, 92%) which was dried before subsequent use. 'H
NMR (CD30D) b 1.86-1.90 (m, 2H), 1.96-2.02 (m, 2H), 3.52-3.46 (m, 2H), 4.25-4.29 (m, 2H), 4.88 (bs, 1H). MS calcd for C4H,aN0 87,,found 87.
Preparation of Intermediate 1-[1', 2'-Oxazin-2'-yl]-3-(BOC-L-Gln)-E-Propenone 1,2-Isooxazinane-HCl (0.12 g, 0.97 mmol) was coupled with 3-[BOC-L-(Tr-Gln)]-E-propenoic acid (0.50 g, 0.97 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate to provide 1-[1', 2'-oxazin-2'-yl]-3-(BOC-t,-Gln)-E-propenone (0.43 g, 76%) as a glassy white solid. 'H NMR
(CDC13) 8 1.43 (s, 9H), 1.71-1.83 (m, SH), 1.94 (m, 1H), 2.35-2.39 (m, 2H), 3.80-3.85 (m, 2H), 3.93-3.96 (m, 2H), 4.33 (m, 1H), 4.76 (m, 1H), 6.54 (d, 1H, J= 15.3 Hz), 6.79 (dd, 1H, J= 15.6, 5.6 Hz), 6.96 (m, 1H), 7.20-7.32 (m, 15H); MS calcd for C35H4,N305+H
584, found 584.

Preparation of Intermediate 1-[1', 2'-Oxazin-2'-yl)-3-[CBZ-L-Leu-L-Pip-Ir(Tr-Gln)]-E-Propenone.
1-[1', 2'-oxazin-2'-yl]-3-(BOC-L-Gln)-E-propenone (0.36 g, 0.66 mmol) was deprotected and coupled with CBZ-L-Leu-L-Pip (0.26 g, 0.66 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate to provide 1-[1', 2'-oxazin-2'-yl]-3-[CBZ-L-Leu-L-Pip-L-(Tr-Gln)]-E-propenone (0.14 g, 26%) as a foamy white solid: IR (thin film) 3301, 1658, 1630 cm '; 'H
NMR
(CDC13, mixture of rotamers) 8 0.86 (d, J= 6.9 Hz), 0.94-0.99 (m), 1.28-1.40 (m), 1.52-1.57 (m), 1.64-2.01(m), 2.27-2.55 (m), 3.27 (s, bs), 3.73-3.94 (m), 4.46-4.64 (m), 4.73-4.92 (m), 5.05 (s), 5.10 (s), 5.30 (s), 5.52 (d, J= 9.0 Hz), 6.48-6.61(m), 6.74-6.79 (m), 6.81- 6.95 (m), 7.17- 7.3 7 (m), 7.72 (d, J = 8.4 Hz).
Preparation of Product-1-[1', 2'-Oxazin-2'-yl]-3-(CBZ-L-Leu-L-Pip-L-Gln)-E-Propenone.
1-[f, 2'-Oxazin-2'-yl]-3-[CBZ-L-Leu-L-Pip-L-(Tr-Gln))-E-propenone (0.14 g, 0.17 mmol) was deprotected using the procedure described in Example 1 for the preparation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate, to provide 1-[1', 2'-oxazin-2'-yl]-3-(CBZ-L-Leu-L-Pip-L-Gln)-E-propenone (0.060 g, 59%) as a foamy white solid: IR (thin film) 3305, 1660, 1630 cm-';'H NMR (CDCI3, mixture of rotamers) 8 0.91 (d, J= 6.9 Hz), 0.94-0.97(m), 0.92 (d, J= 6.5 Hz), 1.26-1.82(m), 1.93-2.29(m), 2.45 (d, J=
12.1 Hz), 2.56-2.65 (m), 3.47 (s), 3.73-3.96 (m), 4.49-4.83 (m), 4.99 (s), 5.04 (s), 5.09 (s), 5.13 (s), 5.60-5.66(m), 5.72-5.85(m), 6.18(s), 6.31(s), 6.54-6.63 (m), 6.79-6.91(m), 7.14 (d, J=
7.8 Hz), 7.28-7.34 (m), 7.71 (d, J= 8.1 Hz). Anal. (C3,HasNsO~) C, H, N.

Ezamnle 25 - Preparation of Compound 27~ Eth~(CBZ-L-Leu DL-Pipz E-Propenoate.
Preparation of Intermediate FMOC-L-Leu-DL-(4-BOC)-Pipz.
To a suspension of DL-(4-BOC)-piperazine-3-carboxylic acid (0.20 g, 0.87 mmol) in dry CH2C 12 ( 10 mL) was added 4-methylmorpholine (0.21 mL, 1.91 mmol) and trimethylsilylchloride (0.13 g, 1.04 mmol) at rt. A clear, homogeneous solution formed after ~2 h. To this solution was added the FMOC-L-Leu-Cl (0.32 g, 0.87 mmol) (Advanced ChemTech), and the mixture was stirred at rt overnight. At this time, the reaction mixture was poured into H20 and extracted twice with CHZCIz, dried over MgS04, and concentrated to provide FMOC-L-Leu-DL-(4-BOC)-Pipz (0.45 g, 91%) as a pale yellow foamy solid. 'H NMR (CDC 13) 8 0.87-1.04 (m, 6H), 1.44 (s, 9H), 1.51 (m, 1H), 1.74 (m, 1H), 2.89-3.10 (m, 2H), 3.67 (m, 1H), 4.03 (m, 1H), 4.21-4.42 (m, 7H), 4.56-4.77 (m, 3H), 7.25-7.77 (m, 8H). MS calcd for C3,H39N3O~+CS, 698, found 698.
Preparation of Intermediate Ethyl-3-[FMOC-L-Leu-DL-(4-BOC)-Pipz-L-(Tr-Gln)] -E-Propenoate.
Ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (0.59 g, 1.23 mmol) was deprotected and coupled to FMOC-L-Leu-DL-(4-BOC)-Pipz (0.70 g, 1.23 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate to provide ethyl-3-[FMOC-L-Leu-DL-(4-BOC)-Pipz-L-(Tr-Gln)]- E-propenoate (0.60 g, 49 % ) as a white foamy solid. 'H NMR (CDC 13) 8 0.87-1.03 (m, 6H), -1.18-1.30 (m, 3H), 1.44 (s, 9H), 2.00 (m, 1H), 2.24 (m ,1H), 2.38 (m, 1H), 3.06-3.13 (m, 2H), 3.69-3.77 (m, 2H), 3.89 (m, 1H), 4.07-4.24 (m, 6H), 4.33-4.59 (m, 9H), 5.85 (m, 1H), 6.75-6.88 (m, 2H), 7.19-7.78 (m, 23H). MS calcd for CSgH6,N5O9+CS
1122, found 1122.
Preparation of Intermediate Ethyl-3-[CBZ-~,-Leu-(4-BOC)-DL-Pipz-L-(Tr-Gln)]
E-Propenoate.
To a solution of ethyl-3-[FMOC-L-Leu-DL-(4-BOC)-Pipz-L-(Tr-Gln)J-E-propenoate (0.60 g, 0.60 mmol) in CHC 13 was added 4-(aminomethyl)piperidine (S mL) at rt. The reaction mixture was stirred for 1 h and then sequentially washed twice with sat brine, S times with 10% aq KZHP04 buffer (pH 5.5), and once with a sat solution of NaHC03: The organic phase was dried over MgS04 and concentrated. The resulting oil (0.34 g, 0.44 mmol) was dissolved in dry CHZC12 (30 mL). 4-Methylmorpholine (0.24 g, 2.20 mmol) was added followed by benzylchloroformate (0.13 g, 0.88 mmol), and the mixture was stirred for 4 h at rt. This mixture was then poured into H20 and extracted twice with CHZCIz. The organic phase was dried over MgS04, concentrated, and purified by flash column chromatography on silica gel (S% MeOH/CHC13) providing ethyl-3-[CBZ-L-Leu-(4-BOC)-DL-Pipz-L-(Tr-Gln)]-E-propenoate (0.31 g, 77 %a) as a white solid foam. 'H NMR (CDC 13) S 0.82-1.00 (m, 6H), 1.23-1.28 (m, 3H), 1.40-1.58 (m, 2H), 1.67 (m, 1H), 1.98 (m, 1H), 2.26 (m, 1H), 2.37 (m, 1H), 2.75 (m, 1H), 3.07-3.11 (m, 2H), 3.50-4.06 (m, 4H), 4.13 - 4.20 (m, 2H), 4.52-5.15 (m, 6H), 5.87 (m, 1H), 6.75-7.03 (m, 2H), 7.08-7.41 (m, ZOH). MS calcd for C52H63Ns09+Cs 1034, found 1034.

Preparation of Product Ethyl-3-(CBZ-~Leu-DL-Pipz-I~-Gln)-E-Propenoate.
The BOC and trityl protecting groups were both removed from ethyl-3-[CBZ-L-Leu-(4-BOC)-DL-Pipz-L-(Tr-Gln)]-E-propenoate (0.10 g, 0.11 mmol) with trifluoroacetic acid as described in Example 4 for the preparation of ethyl-3-(cyclopentylthiocarbbnyl-L-Leu-L-N-Me-Phe-L-Gln)-E-propenoate to provide ethyl-3-(CBZ-L-Leu-DL-Pipz-L-Gln)-E-propenoate (24.0 mg, 39 %) as a solid white foam. IR (thin film) 3308, 1704 cm '; 'H NMR (CDC13) 8 0.91-1.01 (m, 6H), 1.24-1.30 (m, 3H), 1.49 (m, 1H), 1.59 (m, 1H), 1.65-1.86 (m, 3H), 1.98 {m, 1H), 2.15-2.24 (m, 2H), 2.67-2:75 (m, 2H), 3.06 (m, 1H), 3.30 (m, 1H), 3.72-3.82 (m, 2H), 4.14-4.21 (m, 2H), 4.57-4.64 (m, 2H), 5.01-5.13 (m, 3H), 5.58 (m, 1H), 5.76 (d, 1H, J = 6.5 Hz), 5.90-5.98 (m, 2H), 6.88 (dd, 1H, J = 15.6, 5.6 Hz), 7.33 (s, lOH), 7.60 (d, 1H, J = 7.2 Hz). HRMS calcd for C28H41N50,+Cs 692.2062, found 692.2040.
Example 26 - Preparation of Compound 28:
Eth~~l-3-(CBZ-L-Leu-DL-(4-Benzyl)-Pi z-.n ~Glrt]-E-Pro enn pate Preparation of Intermediate Ethyl-3-[CBZ-IrLeu-DL-(4-Benzyl)-Pipz-L-(Tr-Gln)]-E-Propenoate.
A solution of anh HC1 in 1,4-dioxane (3.0 mL of a 4.0 M solution) was added to a solution of ethyl-3-[CBZ-L-Leu-(4-BOC)-DL-Pipz-L-(Tr-Gln)]-E-propenoate (0.18 g, 0.20 mmol) in 1,4-dioxane (3.0 mL) at rt. The reaction mixture was stirred for 2 h at rt, and then concentrated under vacuum. The resulting foamy residue was taken up in EtOAc, washed with a sat NaHC03 solution, dried over MgS04, and concentrated.
The resulting yellow oil was dissolved in 3.0 mL of DMF. To this solution was added NaH

(5.0 mg, 0.20 mmol), followed by benzyl bromide (0.024 mL, 0.20 mmol) after a few minutes. The reaction mixture was stirred at rt overnight. The mixture was then concentrated under vacuum and 10 mL Hz0 was added to the residue. CHZC12 was used to extract the aq. phase twice, which was dried over MgS04, concentrated, and purified using prep TLC (5% MeOH/CHC13), providing ethyl-3-[CBZ-L-Leu-DL-(4-benzyl)-Pipz-L-(Tr-Gln)]-E-propenoate (0.10 g, 56 %) as a yellow foamy solid. 1H NMR
(CDC13) 8 0.82-0.94 (m, 6H), 1.21-1.32 (m, 4H), 1.48-1.66 (m, 3H), 1.97-2.13 (m, 2H), 2.25-2.35 (m, 2H), 2.81 (m, 1H), 3.38-3.52 (m, 3H), 3.64-3.76 (m, 3H), 4.14-4.24 (m, 2H), 4.46-5.22 (m, 6H), 5.96 (m, 1H), 6.75-7.04 (m, 2H), 7.15-7.35 (m, 25H), 7.51 (m, 1H). MS calcd for C54H61Ns0,+H 892, found 892.
Preparation of Product-Ethyl-3-[CBZ-L-Leu-DL-(4-Benzyl)-Pipz-irGln]-E-Propenoate.
Ethyl-3-[CBZ-L-Leu-DL-(4-benzyl)-Pipz-L-(Tr-Gln)]-E-propenoate (0.090 g, 0.10 mmol) was deprotected using the procedure described in Example 1 for the preparation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate, to provide ethyl-3-[CBZ-L-Leu-DL-(4-benzyl)-Pipz-L-Gln]-E-propenoate (0.030 g, 45 %) as a solid white foam. 1R (thin film) 3323, 1708 crri'; 'H NMR (CDC13) 8 0.94-0.99 (m, 6H), 1.27-1.32 (m, 3H), 1.48 (m, 1H), 1.56 (m, 1H), 1.71-2.17 (m, 6H), 2.83 (m, 1H), 3.37-3.50 (m, 2H), 3.68-3.72 (m, 2H), 4.19-4.24 (m, 3H), 4.60-4.70 (m, 2H), 5.00-5.28 (m, 2H), 5.61-5.92 (m, 4H), 6.03 (m, d, 1H, J = 15.6 Hz), 6.87-6.92 (m, 2H), 7.26-7.32 (m, lOH), 7.78 (m, 1H). HRMS calcd for C35H4~N50,+Cs 782.2530, found 782.2546.

Example 27 - Preparation of Compound 29~
Ethvl-3-fCBZ-IrLeu-D~(4-Phenyl ulfonyl)-Pi z-L- Irt]-E-Propenoa P.
Preparation of Intermediate Ethyl-3-[CBZ-L-Leu-nL-(4-Phenylsulfonyl)-Pipz-L-('Tr-Gln)]-E-Propenoate.
A solution of anh HC1 in 1,4-dioxane (2.5 mL of a 4.0 M solution) was added to a solution of ethyl-3-[CBZ-L-Leu-(4-BOC)-DL-Pipz-L-(Tr-Gln)]-E-propenoate (0.16 g, 0.18 mmol) in 1,4-dioxane (2.5 mL) at room temperature. The reaction mixture was stirred fQr 2 h at rt, and then it was concentrated under vacuum. The resulting foam was dissolved in dry CHZC12, and phenylsulfonyl chloride (0.046 mL, 0.36 mmol) and 4-methylmorpholine (0.10 mL, 0.91 mmol) were added at rt and stirred for 2 h.
The reaction mixture was poured into H20 and extracted twice with CHZC12. The organic layer was dried over MgS04 and concentrated to give a residue that was purified by column chromatography on silica gel (5 % MeOH/CHC13) to provide ethyl-3-[CBZ-L-Leu-DL-(4-phenylsulfonyl)-Pipz-L-(Tr-Gln)]-E-propenoate (0.057 g, 33 % ) as an off white foamy solid. 1H NMR (CDC13) S 0.86-0.93 (m, 6H), 1.25-1.32 (m, 3H), 1.48 (m, 1H), 1.63 (m, 1H); 2.25-2.36 (m, 4H), 3.52 (m, 1H), 3.71-3.78 (m, 4H), 4.12-4.25 (m, 4H), 4.45 (m, 1H), 4.64 (m, 1H), 4.92-5.39 (m, SH), 5.94 (m, 1H), 6.34 (m, 1H), 7.18-7.31 (m, 20H), 7.48-7.67 (m, SH), 7.77 (m, 1H). MS calcd for C53HS9NSO9S+CS
1074, found 1074.
Preparation of Product Ethyl-3-(CBZ-L-Leu-D~(4-Phenylsulfonyl)-Pipz-L-Gln)]-E-Propenoate.
Ethyl-3-[CBZ-L-Leu-DL-(4-phenylsulfonyl)-Pipz-L-(Tr-Gln)]-E-propenoate (0.057 g, 0.06 mmol) was deprotected using the procedure described in Example 1 for the preparation of ethyl-3-(CBZ-L-N=Me-Phe-L-Gln)-E-propenoate, to provide ethyl-3-[CBZ-L-Leu-DL- (4-phenylsulfonyl)-Pipz-L-Gln)]-E-propenoate (22.0 mg, S2 % ) as a white foamy solid. IR (thin film) 3322, 1667 cm-'; 'H NMR (CDC13) S 0.89-0.98 (m, 6H), 1.22-1.33 (m, 3H), 1.52 (m, 1H), 2.19-2.51 (m, 4H), 3.68-3.78 (m, SH), 4.14-4.25 (m, 4H), 4.59-4.63 (m, 2H), 5.03-5.11 (m, 3H), 5.21 (m, 1H), 5.43 (m, 1H), S.S7 (m, 1H), 5.94 (m, 1H), 6.85 (m, 1H), 7.20-7.34 (m, SH), 7.SS-7.62 (m, 3H), 7.74-7.80 (m, 2H). HRMS calcd for C34HasNs09S+Cs 832.1992, found 832.1982.
Example 28 - Preparation of Compound 32~
Ethyl-3-(~N-((1, -Dihvdro-imidazol-2-on~~~] L-Gln!~ E Pro enoat Preparation of Intermediate Ethyl-3-(~,-N-[(1,3-Dihydro-imidazol-2-one)-Phe]-L-(Tr-Gln)]-E-Propenoate.
A solution of Phe-OtBu~HCl (0.77 g, 2.99 mmol) and triethylamine (0.833 mL, 5.98 mmol) in CHZC12 (10 mL) was added via cannula to a solution of triphosgene (0.295 g, 0.994 mmol) in CHZC12(2S mL) at 23°C. The reaction mixture was stirred at that temperature for S min, and then it was heated to reflux for 1 h. After cooling to 23 °C, a solution of aminoacetaldehyde dimethyl acetal (0.314 g, 2.99 mmol) and triethylamine (0.417 mL, 2.99 mmol) in CHZC12 (10 mL) was added via cannula.
The reaction mixture was stirred for 3 h at 23°C and then partitioned between half-saturated NH4C1 (100 mL) and EtOAc (2 x 1S0 mL). The combined organic layers were dried over Na2S04 and were concentrated. Purification of the residue by flash column -chromatography (S% CH30H/CHzCl~ provided the intermediate urea as a colorless oil (0.36 g, 34%).

This material was dissolved in CHZCIz (20 mL) at 23 °C. Trifluoroacetic acid (10 mL) was added, and the reaction mixture was stirred at 23 °C for 1 h and then concentrated under reduced pressure. The resulting oil was partitioned between NaOH (100 mL) and EtzO (2 x 100 mL). The aqueous layer was acidified with concentrated HC 1 to pH = 2 (as indicated by pH paper) and extracted with EtOAc (2 x 100 mL). The combined organic layers were dried over Na2S04 and concentrated to afford crude L-N-(1,3-dihydro-imidazol-2-one)-Phe (0.125 g, 53%) as a white solid.
This material was dissolved in DMF (10 mL) and crude ethyl-3-[L-(Tr-Gln)]-B-propenoate~HCl (0.603 mmol) (generated as described in the first deprotection step in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate), 1-hydroxybenzotriazole hydrate (0.122 g, 0.903 mmol), 4-methylmorpholine (0.2 mL, 1.81 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.173 g, 0.903 mmol) were added sequentially, and the reaction mixture was stirred for 18 h at 23 °C and then concentrated under reduced pressure. The resulting oil was partitioned between water (100 mL) and EtOAc (2 x 100 mL). The combined organic layers were dried over Na2S04 and concentrated. Purification of the residue by flash column chromatography (S % CH30H/CHZC 1~ provided ethyl-3-[L-N-[(1,3-dihydro-imidazol-2-one)-Phe]-L-(Tr-Gln)]-E-propenoate (0.129 g, 33%) as a solid yellow foam: Rf = 0.42 (10% CH30H in CHZC1~; IR (thin film) 3265, 1671 cW ';'H NMR (CDC13) b 1.30 (t, 3H, J = 7.2), 1.68-1.78 (m, 1H), 1.89-1.95 (m, 1H), 2.27-2.33 (m, 2H), 3.06 (dd, 1H, J = 13.6, 7.3), 3.27 (dd, 1H, J =
13.6, 8.4), 4.18 (q, 2H, J = 7.2), 4.38 (bs, 1H), 4.96-5.02 (m, 1H), 5.62 (dd, 1H,,J
= 15.7, 1.6), 5.87-5.89 (m, 1H), 6.51-6.53 (m, 1H), 6.62 (dd, 1H, J = 15.7, 5.6), 6.90 (s, 1H), 7.00-7.33 (m, 20H), 7.79 (d, 1H, J = 7.5), 8.06 (s, 1H).
Preparation of Product - Ethyl-3-(ir-N-[(1,3-Dihydro-imidazol-2-one)-Phe]-L-Gln)-E-Propenoate.
Ethyl-3-[L-N-[(1,3-dihydro-imidazol-2-one)-Phe]-L-(Tr-Gln)]-E-propenoate (0.129 g, 0.196 mmol) was deprotected according to the procedure described in Example 1 for the preparation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate.
Ethyl-3-(L-N-[(1,3-dihydro-imidazol-2-one)-Phe]-L-Gln)-E-propenoate (0.037 g, 46 % ) was isolated as a solid beige foam after removal of organic solvents and trituration with 4:1 Et~O:CH3CN, followed by filtration and washing with 2 x 10 mL Et~O and air drying. Rt = 0.15 (10% CH30H/CHZC12); 'H NMR (DMSO-d6) b 1.22 (t, 3H, J =
7.2), 1.61-1.80 (m, 2H), 2.01-2.07 (m, 2H), 3.01-3.17 (m, 2H), 4.11 (q, 2H, J
=
7.2), 4.32-4.41 (m, 1H), 4.87-4.92 (m, 1H), 5.68 (dd, 1H, J = 15.7, 1.4), 6.24-6.26 (m, 1H), 6.63-6.72 (m, 2H), 6.~4 (s, 1H), 7.12-7.25 (m, 6H), 8.44 (d, 1H, J =
8.1), 9.83 (s, 1H); Anal. (CZ1H26N405~0~S HZO) C, H, N.
Example 29 - Preparation of Compound 33~ EthXl-3lCBZ-amino-IrN-I11.3-Dih~dro-imidazol-2-one)-Phe~-L-Glr~-E-Propenoate Preparation of Intermediate 1-CBZ-2-(2,2-Dimethoxyethyl)-Hydrazine.
Aminoacetaldehyde dimethyl acetal (0.430 g, 3.95 mmol) was added to a solution of N-CBZ-3-phenyl-oxaziridine (l.l l g, 4.35 mmol) (prepared as described in Tetrahedron Lett. 1993, 6859, the disclosure of which is entirely incorporated herein by reference) in CHIC 1 Z (20 mL) at 23 ° C. The resulting yellow solution was stirred at 23°C for 18 h, and it then was concentrated under reduced pressure.
Purification of the residue by flash column chromatography (3% CH30H/CHZC12) provided 1-CBZ-2-(2,2-dimethoxyethyl)-hydrazine (0.434 g, 43 % ) as a pale yellow oil: Rf = 0.40 (5 CH30H/CHZC12); IR (thin film) 3317, 1721, 1456 cm-~; 'H NMR (C6D6) b 2.96 (bs, 2H), 3.06 (bs, 6H), 3.97 (bs, 1H), 4.37 (bs, 1H), 4.97 (bs, 2H), 5.87 (bs, 1H), 6.98-7.18 (m, SH).
Preparation of Intermediate Ethyl-3-[CBZ-amino-IrN-[(1,3-Dihydro-imidazol-2-one)-Phe]-ir(Tr-Gln)]-E-Propenoate.
A solution of Phe-OtBu~HCl (0.440 g, 1.71 mmol) and triethylamine (0.345 mL, 2.47 mmol) in CHZC12 (20 mL) was added via cannula to a solution of triphosgene (0.168 g, 0.566 mmol) in CHZC12(40 mL) at 23°C. The reaction mixture was stirred at that temperature for 5 min, and then it was heated to reflux for 1 h. After cooling to 23°C, a solution of 1-CBZ-2-(2,2-dimethoxyethyl)-hydrazine (0.434 g, 1.71 mmol) and triethylamine (0.173 mL, 1.24 mmol) in CHZClZ (10 mL) was added via cannula.
The reaction mixture was stirred for 1 h at 23 ° C, and then it was partitioned between half saturated NH4C1 (100 mL) and EtOAc (2 x 150 mL). The combined organic layers were dried over NazS04 and were concentrated. Purification of the residue by flash column chromatography (3 % CH30H/CHZCl~ provided the intermediate urea as a colorless oil (0.56 g, 65 %). This material was dissolved in CHZC12 (20 mL) at 23 °C.
Trifluoroacetic acid (10 mL) was added, and the reaction mixture was stirred at 23°C
for 1.5 h. CC14 (10 mL) was added, and the mixture was concentrated under reduced pressure.
The resulting oil was partitioned between 10% NaOH (100 mL) and Et~O (2 x 100 mL).
The aqueous layer was acidified with concentrated HC1 to pH = 2_ (as indicated by pH paper) and was extracted with EtOAc (2 x 100 mL). The combined organic layers were dried over Na2S04 and concentrated to afford crude CBZ-amino-L-N-(1,3-dihydro-imidazol-2-one)-Phe (0.374 g, 89%) as a solid white foam. This material was dissolved in (10 mL) and crude ethyl-3-[L-(Tr-Gln)]-E-propenoate~HC1 (0.981 mmol) (generated as described in the first deprotection step in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate), 1-hydroxybenzotriazole hydrate (0.172 g, 1.27 mmol), 4-methylinorpholine (0.323 mL, 2.94 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.244 g, 1.27 mmol) were added sequentially.
The reaction mixture was stirred for 18 h at 23°C, and it then was partitioned between water (100 mL) and EtOAc (2 x 100 mL). The combined organic layers were dried over NaZS04 and concentrated. Purification of the residue by flash column chromatography (5% CH30H/CHZC12) provided ethyl-3-[CBZ-amino-L-N-[(1,3-dihydro-imidazol-2-one)-Phe]-L-(Tr-Gln)]-E-propenoate (0.449 g, 57 % ) as a solid white foam: Rf =
0.44 (10 CH30H in CHZC12); IR (thin film) 3284, 1681 cmv; 'H NMR (CDC13) b 1.23 (t, 1H, J
= 7.2), 1.42-1.44 (m, 1H), 2.00-2.16 (m, 3H), 3.08 (dd, 1H, J = 13.4, 7.5), 3.32-3.39 (m, 1H), 4.01-4.18 (m, 3H), 4.47 (bs, 1H), 4.90 (bs, 2H), 4.99-5.04 (m, 1H), 5.60 (dd, 1H, J = 16.0, 1.6), 5.86 (bs, 1H), 6.54 (d, 1H, J = 3.1), 6.66 (dd, 1H, J = 16.0, 4.5), 6.94-7.32 (m, 26H), 7.83 (s, 1H); Anal. (C48H4,N50,~0.5 H20) C, H, N.

Preparation of Product Ethyl-3-(CBZ-amino-IrN-((1,3-Dihydro-imidazol-2-one)-Phe]-~,-Gln)-E-Propenoate.
Ethyl-3-[CBZ-amino-L-N-[(1, 3-dihydro-imidazol-2-one)-Phe]-L-(Tr-Gln)]-E-propenoate (0.147 g, 0.182 mmol) was deprotected according to the procedure described in Example 1 for the preparation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate. Ethyl-3-(CBZ-amino-L-N-[(1,3-dihydro-imidazol-2-one)-Phe]-L-Gln)-E-propenoate (0.042 g, 40%) was isolated as a white solid after removal of organic solvents and trituration with Et~O, followed by filtration and washing with 2 x 10 mL
Et~O and air drying: mp = 216-218°C; Rf = 0.27 (10% CH30H/CHZC1~;

(DMSO-d6) 8 1.22 (t, 3H, J = 7.2), 1.61-2.06 (m, 2H), 2.01-2.06 (m, 2H), 3.11-3.13 (m, 2H), 3.36-3.38 (m, 1H), 4.11 (q, 2H, J = 7.2), 4.34-4.38 (m, 1H), 4.90-4.96 (m, 1H), 5.09 (bs, 2H), 5.66 (d, 1H, J = 15.7), 6.53 (d, 1H, J =
2.8), 6.69 (dd, 1H, J = 15.7, 5.6), 6.75-6.77 (m, 2H), 7.21 (bs, 6H), 7.37 (bs, 4H), 8.52 (d, 1H, J = 8.1), 10.14 (s, 1H); Anal. (CZ9H33NSO~) C, H, N.
Example 30 - Preparation of Compound 34~
Ethyl-3-(Ethvlthiocarbonvl-L-Val-L-N-Me Phe ~- In) E Propenoate Preparation of Intermediate Ethyl-3-[BOC-I~-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-Propenoate.
This material was prepared from ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (0.832 g, 1.53 mmol) and BOC-L-Val-L-N-Me-Phe (0.570 g, 1.51 mmol) using the method described in Example 6 for the formation of 1-(2',3'-dihydroindolin-1-yl)-3-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenone to give ethyl-3-(BOC-L-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate after column chromatography on silica gel (gradient: 43 % -50 %

EtOAc in hexanes) as a white foam (0.789 g, 64%): IR (thin film) 3295, 1708, cm-1; 1H NMR (CDC13) (mixture of isomers) 8 0.66-0.73 (m), 0.81 (d,J = 6.8 Hz), 0.86 (d, J = 6.8 Hz), 1.23-1.37 (m), 1.35 (s), 1.42 (s), 1.62-1.85 (m), 1.88-2.06 (m), 2.20-2.27 (m), 2.83-3.03 (m), 2.88 (s), 2.99 (s}, 3.31 (dd, J = 14.0, 8.2 Hz), 3.41 (dd, J = 14.0, 5.8 Hz), 4.03-4.10 (m), 4.16 (q, J = 7.2 Hz), 4.17 (q, J =
7.2 Hz), 4.27-4.34 (m), 4.45-4.56 (m), 4.57-4.70 (m), 4.88-5.03 (m), 5.59 (d, J =
15.7 Hz), 5.87 (d, J = 15.7 Hz), 6.20 (d, J = 8.4 Hz), 6.66 (dd, J = 15.7, 5.1 Hz), 6.80 (dd, J = 15.7, 6.1 Hz), 6.89-7.05 (m), 7.12-7.34 (m), 7.88 (d, J = 8.1 Hz).
Anal.
(C48HS8N40,~0.5 H20) C, H, N.
Preparation of Intermediate Ethyl-3-[Ethylthiocarbonyl-z-Val-L-N-Me-Phe-Ir(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.366 g, 0.456 mmol) was deprotected and coupled with ethyl chlorothiolformate (0.057 mL, 0.55 mmol) as described in Example 6 for the formation of 1-(2',3'-dihydroindolin-1-yl)-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenone to give ethyl-3-[ethylthiocarbonyl-L-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate after column chromatography on silica gel (gradient: 44%-50% EtOAc in hexanes) as a white foam (0.217 g, 60%): IR (thin film) 3295, 1713, 1655 clri'; 1H NMR (CDC13) (mixture of isomers) b 0.48 (d, J = 6.5 Hz), 0.71 (d, J = 6.8 Hz), 0.80-0.89 (m), 1.17-1.22 (m), 1.58-2.06 (m), 2.19-2.32 (m), 2.65-3.04 (m), 2.84 {s), 2.97 (s), 3.29-3.43 (m}, 4.18 (q, J = 7.2 Hz), 4.49-4.59 (m), 4.65-4.71 (m), 4.75-4.83 (m), 5.65 (dd, J =
15.9, 1.6 Hz), 5.71-5.76 (m), 5.81-5.90 (m), 6.31-6.36 (m), 6.70 (dd, J = 15.9, 5.3 Hz), 6.79 (dd, J = 15.9, 5.9 Hz), 6.88 (s), 7.01(s), 7.12-7.34 (m), 7.75-7.80 (m).
Anal.
(C,~H~N406S~0.5 H20) C, H, N.
Preparation of Product -Ethyl-3-(Ethylthiocarbonyl-~Val-L-N-Me-Phe-IrGln)-E-Propenoate.
Ethyl-3-[ethylthiocarbonyl-L-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.187 g, 0.236 mmol) was deprotected using the procedure described in Example 1 for the formation of ethyl-3-(CBZ-L-N-Me-Phe-L-Gln)-E-propenoate to give ethyl-3-(ethylthiocarbonyl-L-Val-L-N-Me-Phe-L-Gln)-E-propenoate after column chromatography (50% acetone in hexanes, then 6% MeOH in CHZC1~ as a white foam (0.076 g, 58%):
IR (thin film) 3307, 1660 cm-1; 'H NMR (CDC13) (mixture of isomers) b 0.47 (d, J =
6.5 Hz), 0.77 (d, J = 6.8 Hz), 0.92 (d, J = 6.5 Hz), 0.93 (d, J = 6.5 Hz), 1.25 (t, J =
7.2 Hz), 1.29 (t, J = 7.2 Hz), 1.42-1.54(m), 1.64-1.79(m), 1.80-2.03 (m), 2.08-2.31 (m), 2.73-3.01(m), 2.92 (s), 3.04-3.15 (m), 3.07 (s), 3.31-3.47 (m), 4.16-4.26 (m), 4.19 (q, J = 7.2 Hz), 4.51-4.65 (m), 4.70-4.78 (m), 5.72 (dd, J = 15.6, 1.6 Hz), 5.85-6.05 (m), 6.19 (bs), 6.56 (d, J = 8.1 Hz), 6.75 (dd, J = 15.6, 5.3 Hz), .6.80-6.89 (m), 7.15-7.35(m}, 7.46 (d, J = 7.8 Hz). Anal. (C.1~H~N406S) C, H, N.
Example 31 - Preparation of Compound 35~ Ethy~~vc_ loner rlthiocarbonvl L-Val L-N-Me-Phe-IrGln]-E-Pronenoate Preparation of Intermediate Ethyl-3-[Cyclopentylthiocarbonyl-L-Val-L-N-Me-Phe-L- -(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.365 g, 0.455 mmol) was deprotected and coupled with cyclopentyl chlorothiolformate (0.09 mL, about 0.5 mmol) using the procedure described in Example 6 for the formation of 1-(2',3'-dihydroindolin-1-yl)-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenone to give ethyl-3-[cyclopentylthiocarbonyl-L-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate after column chromatography on silica gel (40%-50% EtOAc in hexanes) as a white foam (0.231 g, 61 %): IR (thin film) 3295, 1713, 1655, 1631 cm-'; 'H NMR (CDC13) (mixture of isomers) 8 0.50' (d, J = 6.5 Hz), 0.73 (d, J = 6.8 Hz), 0.80-0.88 (m), 1.22-2.31 (m), 2.84-3.04 (m), 2.86 (s), 2.98 (s), 3.29-3.41 (m), 3.54-3.69 (m), 4.08-4.25 (m), 4.17 (q, J = 7.2 Hz), 4.48-4.63 (m), 4.67-4.82 (m), 5.64 (dd, J
=
15.7, 1.6 Hz), 5.76-5.82 (m), 5.83-5.91 (m), 5.87 (dd, J = 15.7, 1.6 Hz), 6.39-6.45 (m), 6.70 (dd, J = 15.7, 5.3 Hz), 6.79 (dd, J = 15.7, 5.8 Hz), 6.93 (s), 7.06 (s), 7.12-7.33 (m), 7.72 (d, J = 7.8 Hz). Anal. (C49HS8N4O6S~O.S HZO) C, H, N.
Preparation of Product-Ethyl-3-(Cyclopentylthiocarbonyl-L-Val-L-N-Me-Phe-L-Gln)-E-Propenoate.
Ethyl-3-[cyclopentylthiocarbonyl-L-Val-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate (0.179 g, 0.215 mmol) was deprotected using the procedure described in Example 1 for the formation of ethyl-3-[CBZ-L-N-Me-Phe-L-Gln]-E-propenoate to give ethyl-3-(cyclopentylthiocarbonyl-L-Val-L-N-Me-Phe-L-Gln)-E-propenoate after column chromatography on silica gel (SO% acetone in hexanes, then 6% MeOH in CHZC12) as a white foam (0.086 g, 68%): IR (thin film) 3295, 1713, 1666, 1631 cm-~; 'H NMR
(CDC13) (mixture of isomers) 8 0.48 (d, J = 6.5 Hz), 0.77 (d, J = 6.8 Hz), 0.92 (d, J -= 6.5 Hz), 0.93 (d, J = 6.8 Hz), 1.29 (t, J = 7.2 Hz), 1.37-1.79 (m), 1.81-2.29 (m), 2.91-3.00 (m), 2.92 (s), 3.03-3.15 (m), 3.06 (s), 3.34 (dd, J = 14.0, 5.3 Hz), 3.43 (dd, J = 14.0, 6.7 Hz), 3.59-3.69 (m), 4.16-4.26 (m), 4.18 (q, J = 7.2 Hz), 4.52-4.65 (m), 4.68-4.77 (m), 5.72 (dd, J = 15.9, 1.6 Hz), 5.78 (bs), 5.85 (bs), 5.90 (dd, J = 15.6, 1.2 Hz), 6.01 (bs), 6.19 (bs), 6.42 (d, J = 8.1 Hz), 6.67 (d, J
= 9.0 Hz), 6.75 (dd, J = 15.6, 5.3 Hz), 6.80-6.87 (m), 7.16-7.34 (m), 7.42 (d, J =
7.8 Hz).
Anal. (C3oH~N406S) C, H, N.
Example 32 - PrPnaration of Compound 36:
N-Methox~r-N-Methyl-3-(Eth~rlthiocarbonyl-IrLeu-i!-N-Me-Phe-L- ln)-E-Propenamide.
Preparation of Intermediate N-Methoxy-N-Methyl-3-[BOC-L-Leu-IrN-Me-Phe-Ir(Tr-Gln)]-E-Propenamide.
N-Methoxy-N-methyl-3-[BOC-L-(Tr-Gln)]-E-propenamide (0.29 g, 0.58 mmol) was deprotected and coupled to BOC-L-Leu-L-N-Me-Phe (0.23 g, 0.58 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate to provide N-methoxy-N-methyl-3-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenamide (0.23 g, 47%) as a white solid foam after column chromatography on silica (2% methanol/CHC13). 'H NMR (CDC13) b 0.63-0.66 (m, 6H), 0.71 (m, 1H), 0.86-0.95 (m, 3H), 1.06 (m, 1H), 1.31-1.44 (m, 9H), 1.84 (m, 1H), 2.00 (m, 1H), 2.25-2.28 (m, 2H), 2.91-3.00 (m, 3H), 3.23 (s, 3H), 3.66-3.68 (m, 3H), 4.13 (m, 1H), 4.58 (m, 1H), 4.71 (m, 1H), 4.86 (m, 1H), 6.35 (m, 1H), 6.55 (m, 1H), 6.80 (m, 1H), 7.10-7.33 (m, 20H), 8.20 (d, 1H, J = 8.7 Hz). MS calcd for C4gH6'N50,+Na 854, found 854.

Preparation of Intermediate N-Methoxy-N-Methyl 3-[Ethylthiocarbonyl-~Leu-L-N-Me-Phe-~(Tr-Gln))-E-Propenamide.
N-Methoxy-N-methyl-3-[BOC-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenamide (0.098 g, 0. 13 mmol) was deprotected and treated with ethylchlorothiolformate (0.016 mL, 0.15 mmol) using the procedure described in Example 22 for the preparation of ethyl-3-[ethylthiocarbonyl-L-Leu-L-Pro-L-(Tr-Gln)]-E-propenoate, to provide N-methoxy-N-methyl-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenamide (0.041 g, 39 %) as a clear glass. 'H NMR (CDC13) b 0.61-0.75 (m, 3H), 0.80-0.88 (m, 2H), 1.15-1.27 (m, 4H), 1.34-1.44 (m, 2H), 1.65-1.96 (m, SH), 2.25-2.33 (m, 2H), 2.72-3.05 (m, 3H), 3.20 (s, 3H), 3.66 (s, 3H), 4.61 (m, 1H), 5.77 (dd, 1H, J =
17.4, 7.5 Hz), 6.49 (m, 1H), 6.83 (m, 1H), 7.12 (m, 1H), 7.19-7.33 (m, 20H), 8.01 (d, 1H, J = 8.1 Hz). MS calcd for C4,HS,NSO6S+Cs MS calcd for 952, found 952.
Preparation of Product N-Methoxy-N-Methyl-3-(Ethylthiocarbonyl-L-Leu-~N-Me-Phe-L-Gln)-E-Propenamide.
N-Methoxy-N-methyl-3-[ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-(Tr-Gln)]-E-propenamide (0.040 g, 0.049 mmol) was deprotected using the procedure described in Example 1 for the preparation ethyl-3-[CBZ-L-N-Me-Phe-L-Gln]-E-propenoate, to provide N-methoxy-N-methyl-3-(ethylthiocarbonyl-L-Leu-L-N-Me-Phe-L-Gln)-E-propenamide (17.0 mg, 61 %o) as a white foam after column chromatography (2%
methanol/CHC13). IR (thin film) 3274, 1678 cm '; 'H NMR (CDC13) b 0.63-0.64 (m, _ 3H), 0.91 (d, 2H, J = 6.2 Hz), 1.22-1.28 (m, 4H), 1.43 (m, 1H), 1.63 (m, 1H), --1.95-2.02 (m, 2H), 2.80-2.98 (m, 4H), 3.25 (s, 3H), 3.69-3.70 (m, 3H), 4.42 (m, 1H), 4.62-4.66 (m, 2H), 6.09 (m, 1H), 6.18 (dd, 1H, J = 15.0, 7.5 Hz), 6.57 (m, 1H), 6.82 (m, 1H), 7.15-7.34 (m, 7H), 7.89 (d, 1H, J = 8.4 Hz). HRMS calcd for CZ8H43NSO6S+Cs 710.1988, found 710.2014.
Example 33 - Preparation of Compound 30' Ethyl-3-([,(5-CBZ-Amino) 2-Phenyl-6-Oxo-1,6-Dihvdro-1-P,~rimidinyl]-~ In)-E-Pro noate Preparation of Intermediate Ethyl-3-{[(5-CBZ-Amino)-2-Phenyl-6-Oxo-l,6-Dihydro-1-Pyrimi dinyl]-Ir (T r-Gln) }-E-Propenoate.
Ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (0.39 g, 0.72 mmol) was deprotected and coupled with [(5-CBZ-amino)-2-phenyl-6-oxo-1,6-dihydro-1-pyrimidinyl]acetic acid (0.28 g, 0.73 mmol) (prepared according to the procedure of C.A. Veale, et al., J. Med.
Chem. 1995, 38, 98, the disclosure of which is entirely incorporated herein by reference) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate), to give ethyl-3-{[(S-CBZ-amino)-2-phenyl-6-oxo-1,6-dihydro-1-pyrimidinyl)-L-(Tr-Gln)}-E-propenoate (0.43 g, 73 % ) as a white solid after column chromatography on silica (3 % methanol/CHCl3): mp = 106-112°C;
IR (thin film) 3297, 1722, 1658 cm '; 'H NMR (CDC13) b 1.29 (t, 3H, J = 7.2 Hz), 1.76-1.86 (m, 1H), 1.93-2.04 (m, 1H), 2.36-2.52 (m, 2H), 4.07-4.30 (m, SH), 4.51 (bs, 1H), 5.21 (s, 2H), 5.81 (dd, 1H, J = 15.6, 1.6 Hz), 6.73 (dd, 1H, J = 15.6, 4.8 Hz), 6.86 (s, 1H), 7.08-7.23 (m, 15 H), 7.29-7.54 (m, 11H), 8.73 (bs, 1H); Anal.
(CasHasNsO~'1.0 H20) C, H, N.

Preparation of Product Ethyl-3-{[(5-CBZ-Amino)-2-Phenyl-6-Oxo-1,6-Dihydro-1-Pyrimidinyl]-L-Gln}-E-Propenoate.
Ethyl-3-{ [(5-CBZ-amino)-2-phenyl-6-oxo-1, 6-dihydro-1-pyrimidinyl]-L-(Tr-Gln)}-E-propenoate (0.22 g, 0.27 mmol) was deprotected using the procedure described in Example 1 for the preparation of ethyl-3-[CBZ-L-N-Me-Phe-L-Gln]-E-propenoate, to provide ethyl-3-{[(5-CBZ-amino)-2-phenyl-6-oxo-1,6-dihydro-1-pyrimidinyl]-L-Gln}-E-propenoate (0.12 g, 79 % ) as a white solid after removal of organic solvents and trituration with Et~O, followed by filtration and washing with 2 x 10 mL Er20 and air drying: mp = 200-205°C; IR (thin film) 3278, 1719, 1650 cm-~; 1H NMR
(CDC13) 8 1.22 (t, 3H, J = 7.2 Hz), 1.56-1.68 (m, 1H), 1.71-1.77 (m, 1H), 2.01-2.06 (m, 2H), 4.13 (q, 2H, J = 7.2 Hz), 4.39-4.55 (m, 3H), 5.18 (s, 2H), 5.78 (dd, 1H, J =
15.9, 1.6 Hz), 6.70-6.77 (m, 2H), 7.24 (s, 1H), 7.30-7.55 (m, lOH), 8.34 (d, 1H, J =
8.1 Hz), 8.45 (s, 1H), 8.94 (s, 1H); Anal. (CZ9H31Ns0~'0.25 H20) C, H, N.
Example 34 - Preparation of Compound 3I~ Etl~l-3-~[~5-Aminol 2 Phenyl 6-Oxo-1,6-Dihvdro-1-Pvrimidin,~~l]-L-Glr~ -E-Propenoate Preparation of Product Ethyl-3-{[(5-Amino)-2-Phenyl-6-Oxo-1,6-Dihydro-1-Pyrimidinyl]-L-Gln}-E-Propenoate.
Borontribromide (0.18 mL of a 1.0 M solution in CHIC 12, 0.18 mmol) was added to a solution of ethyl-3-{[(5-CBZ-amino)-2-phenyl-6-oxo-1,6-dihydro-1-pyrimidinyl]-L-Gln}-E-propenoate (0.050 g, 0.089 mmol) in trifluoroacetic acid (4 mL) at 23 °C. The reaction mixture was stirred for 2 h at 23°C, then it was quenched with EtOH (2 mL) and concentrated. The residue was then partitioned between NaHC03 (50 mL) and EtOAc (2 x 100 mL). The combined organic layers were dried over NaZS04 and concentrated to afford ethyl-3-{[(5-amino)-2-phenyl-6-oxo-1,6-dihydro-1-pyrimidinyl]-L-Gln}-E-propenoate (0.013 g, 36%) as a white solid: mp = 175°C (dec); IR
(thin film) 3421, 1646 cm '; 'H NMR (DMSO-db) 8 1.23 (t, 3H, J = 7.2 Hz), 1.62-1.64 (m, 1H), 1.71-1.78 (m, 1H), 2.01-2.06 (m, 2H), 4.13 (q, 2H, J = 7.2 Hz), 4.37-4.51 (m, 3H), 5.14 (bs, 1H), 5.79 (d, 1H, J = 15.6 Hz), 6.53-6.78 (m, 2H), 7.09-7.52 (m, 6H), 8.28 (d, 1H, J = 8.4 Hz).
Example 35 - Preparation of Compound 37: Eth~ 1-3-[(S)-~CBZ-Amino)-4-Oxo-4 6,7.8-Tetrah~pyrrolo [1.2-a]Pyrimidine-6-IrGln]-E-Pronenoate Preparation of Intermediate (S)-Pyrrolidin-2-one-5-Carboxylic Acid t-Butyl Ester.
To a suspension of L-pyroglutamic acid (2.00 g, 15.49 mmol) in t-butyl acetate was added 70% HC104(0.46 mL, 17.04 mmol). The suspension was stirred at rt in a tightly closed flask overnight. The resulting solution was poured slowly into a sat.
solution of NaHC03 and extracted twice with EtOAc. The organic phase was dried over MgS04 and concentrated to provide (S)-pyrrolidin-2-one-5-carboxylic acid t-butyl ester.
(2.04 g, 85%) as a white solid 'H NMR (CDC13) b 1.48 (s, 9H), 2.16-2.48 (m, 4H), 4.14 (m, 1H), 5.97 (bs, 1H). MS calcd for CgH,5N03+H 186, found 186.
Preparation of Intermediate (S)-Pyrrolidin-2-thione-5-Carboxylic Acid t-Butyl Ester.
To a solution of (S)-pyrrolidin-2-one-5-carboxylic acid t-butyl ester (2.04 g, 11.01 mmol) in benzene was added Lawesson's Reagent (2.22 g, 5.50 mmol). The reaction mixture was heated at reflux overnight, concentrated under vacuum, and purified by column chromatography on silica gel (5% MeOH/CHC13) to provide (S)-pyrrolidin-2-thione-5-carboxylic acid t-butyl ester (1.75 g, 79 % ) as a tan solid. 1H
NMR (CDC13) b 1.49 (s, 9H), 2.30 (m, 1H), 2.53 (m, 1H), 2.85-3.04 (m, 2H), 4.42 (t, 1H, J = 7.7 Hz), 7.88 (bs, 1H). MS calcd for CgH,5NO2S+H 202, found 202.
Preparation of Intermediate (S)-2-Methylsulfanyl-3,4-Dihydro-5H Pyrrole-5-Carboxylic Acid t-Butyl Ester.
To a solution of (S)-pyrrolidin-2-thione-S-carboxylic acid t-butyl ester (1.75 g, 8.71 mmol) in 35 mL of dry THF was added MeI (2.2 mL, 34.83 mmol) at rt. The mixture was stirred at rt for 3 h and concentrated under vacuum. CHZC12 was added to the resulting oil which was poured into a sat. solution of NaHC03. This was extracted 3 times with CHIC 12, dried over MgS04, and concentrated to provide (S)-2-methylsulfanyl-3,4-dihydro-SH pyrrole-5-carboxylic acid t-butyl ester (1.63 g, 87%) as a brown oil which was used without further purificatiow 'H NMR (CDC13) 8 1.46 (s, 9H), 2.09 (m, 1H), 2.28 (m, 1H), 2.48 (s, 3H), 2.56-2.80 (m, 2H), 4.59 (m, 1H). MS
calcd for C,oH"NOZS+H, 216, found 216.
Preparation of Intermediate (S)-2-Amino-3,4-Dihydro-5H Pyrrole-5-Carboxylic Acid t-Butyl Ester~HCl Salt.
To a solution of (S)-2-methylsulfanyl-3,4-dihydro-SH-pyrrole-5-carboxylic acid t-butyl ester (0.42 g, 1.95 mmol) in 4.0 mL anhydrous MeOH was added anh NH4C1 (0.11 g, 2.05 mmol). The reaction mixture was heated to reflux for 2 h, concentrated in vacuo, and the residue was taken up in CHZC12. The white solids were filtered, and the filtrate was concentrated to provide (S)-2-amino-3,4-dihydro-SH pyrrole-5-carboxylic acid t-butyl ester~HCl (0.41 g, 94%) as a light yellow solid 'H NMR (CDC13) 8 1.49 (s, 9H), 2.24 (m, 1H), 2.52 (m, 1H), 3.06-3.08 (m, 2H), 4.44 (m, 1H), 9.81-9.84 (m, 2H). MS calcd for C~-i,6N2O2+H 185, found 185.
Preparation of Intermediate (S)-4-Oxo-4,6,7,8-Tetrahydropyrrolo [1,2-a] Pyrimidine- 3,6-Dicarboxylic Acid 6-t-Butyl Ester 3-Methyl Ester.
A solution of freshly prepared sodium methoxide (Na, SO % by weight in paraffin, 0.084 g, 1.84 mmol, 2.25 mL anh MeOH) was added slowly to a solution of (S)-2-amino-3,4-dihydro-SH pyrrole-S-carboxylic acid t-butyl ester~HCl (0.41 g, 1.84 mmol) in 2.25 mL anh MeOH cooled to -10°C. After 1 h, the resulting white precipitate (NaCI) was filtered, and the solution of this free base was slowly added to a solution of dimethylmethoxymethylene malonate (0.32 g, 1.84 mmol) in 2.25 mL anh MeOH at -10°C. The reaction mixture was stirred at 0°C overnight at which time it was concentrated under vacuum, and the residue was purified by column chromatography on silica gel (2% MeOH/CHC13) to afford (S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-3,6-dicarboxylic acid 6-t-butyl ester 3-methyl ester (0.22 g, 40 %) as a yellow oil. 1H NMR (CDC13) b 1.49 (s, 9H), 2.31 (m, 1H), 2.57 (m, 1H), 3.09-3.33 (m, 2H), 3.90 (s, 3H), 5.03 (m, 1H), 8.69 (s, 1H). MS calcd C,4H18Nz05+H 295, found 295.
Preparation of Intermediate (S)-4-Oxo-4,6,7,8-Tetrahydropyrrolo-[1,2-a]Pyrimidine-3,6-Dicarboxylic Acid 6-t-Butyl Ester.
To a solution of (S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine- --3,6-dicarboxylic acid 6-t-butyl ester 3-methyl ester (0.22 g, 0.74 mmol) in MeOH cooled to 0°C was added 2N NaOH (0.37 mL, 0.74 mmol) dropwise. The reaction mixture was allowed to warm slowly to rt and stirred overnight. The reaction mixture was washed twicewith Et~O, and the aqueous layer was acidified to pH 2 with 1N HC1, which was then extracted twice with EtOAc. The combined organic layers were dried over MgS04 and concentrated to provide (S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-3,6-dicarboxylic acid 6-t-butyl ester (0.14 g, 70%) as a solid yellow foam 'H NMR
(CDC13) b 1.50 (s, 9H), 2.41.(m, 1H), 2.68 (m, 1H), 3.21-3.41 (m, 2H), 5.10 (m, 1H), 8.94 (s, 1H). MS calcd C13H16NZO5+H, 281, found 281.
Preparation of Intermediate (S)-3-(CBZ-Amino)-4-Oxo-4,6,7,8-Tetrahydropyrrolo-[1,2-a]Pyrimidine-6-Carboxylic Acid t-Butyl Ester.
(S)-4-Oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-3,6-dicarboxylic acid 6-t-butyl ester (0.58 g, 2.07 mmol), triethylamine (0.29 mL, 2.07 mmol) and diphenylphosphoryl azide (0.45 mL, 2.07 mmol) in 1,4-dioxane (10 mL) were heated to reflux for 2 h. Benzyl alcohol (0.24 mL, 2.28 mmol) was added and heating at reflux was continued for another 3 h. The reaction mixture was then concentrated under vacuum, and the residue was purified by column chromatography on silica gel (2%
MeOH/CHC13) to provide (S)-3-(CBZ-amino)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxylic acid t-butyl ester (0.62 g, 77%) as a yellow solid.
'H NMR
(CDC13) b 1.48 (s, 9H), 2.30 (m, 1H), 2.56 (m, 1H), 3.05-3.21 (m, 2H), 4.98 (m, 1H), 5.20 (s, 2H), 7.30-7.40 (m, 6H), 8.67 (bs, 1H). MS calcd for CZOH23N305+H, 386, found 386.

Preparation of Intermediate (S)-3-(CBZ-Amino)-4-Oxo-4,6,7,8-Tetrahydropyrrolo-[1,2-a]Pyrimidine-6-Carboxylic Acid.
To (S)-3-(CBZ-amino)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxylic acid t-butyl ester (0.20 g, 0.52 mmol) was added 8.0 mL of a 1:1 solution of TFA:CHC13 with 3 drops of H20. The reaction mixture was stirred at rt overnight, at which time it was concentrated under vacuum. CC 14 was added, and the mixture was reconcentrated, and then triturated in Et~O. Filtration provided (S)-3-(CBZ-amino)-4-oxo~,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxylic acid (0.14 g, 82%) as a tan solid 'H NMR (CDC13) 8 2.50-2.63 (m, 2H), 3.16-3.29 (m, 2H), 5.13 (m, 1H), 5.20 (s, 2H), 5.45 (bs, 1H), 7.37 (s, SH), 7.40 (s, 1H), 8.70 (bs, 1H). MS calcd for C16H,SN305+H 330, found 330.
Preparation of Intermediate Ethyl-3-[(S)-3-(CBZ-Amino)-4-Oxo-4,6,7,8-Tetrahydropyrrolo[1,2-a]Pyrimidine-6-1r(Tr-Gln)]-E-Propenoate.
Ethyl-3-[BOC-L-(Tr-Gln)]-E-propenoate (0.28 g, 0.52 mmol) was deprotected and coupled to (S)-3-(CBZ-amino)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-carboxylic acid (0.14 g, 0.41 mmol) using the procedure described in Example 1 for the preparation of ethyl-3-[BOC-L-N-Me-Phe-L-(Tr-Gln)]-E-propenoate, to provide ethyl-3-[(S)-3-(CBZ-amino)-4-oxo-4,6, 7, 8-tetrahydropyrrolo[ 1,2-a]pyrimidine-6-L-(Tr-Gln)]-E-propenoate (0.26 g, 83 % ) as a solid white foam after column chromatography (2% methanol/CHC13)~ 'H NMR (CDC13) 8 1.28 (t, 3H, J = 7.2 Hz), 1.83 (m, 1H), 2.01 (m, 1H), 2.29-2.36 (m, 2H), 2.49-2.51 (m, 2H), 2.97 (m, 1H), 3.19 (m, 1H), w-4.18 (q, 2H, J = 7.2 Hz), 4.53-4.57 (s, 2H), 5.86 (dd, 1H, J = 15.6, 1.6 Hz), 6.79 (dd, 1H, J = 15.6, 5.3 Hz), 6.89 (s, 1H), 7.16-7.37 (m, 21H), 7.53 (d, 1H, J =
7.2 Hz), 8.65 (bs, 1H)~MS calcd for C~,H43N50~+Cs, 886, found 886.
Preparation of Product-Ethyl-3-[(S)-3-(CBZ-Amino)-4-Oxo-4,6,7,8-Tetrahydropyrrolo[1,2-a]Pyrimidine-6-L-Gln]-E-Propenoate.
Ethyl-3-[(S)-3-(CBZ-amino)-4-oxo- 4,6,7,8-tetrahydropyrrolo-[1,2-a]pyrimidine-6-L-(Tr-Gln)]-E-propenoate (0.25 g, 0.33 mmol) was deprotected using the procedure described in Example 22 for the preparation of ethyl-3-(ethylthiocarbonyl-L-I,eu-L-Pro-L-Gln)-E-propenoate, to provide ethyl-3-[(S)-3-(CBZ-amino)-4-oxo4,6,7,8-tetrahydropyrrolo [1,2-a]pyrimidine-6-L-Gln]-E-propenoate (0.10 g, 59%) as a white solid after column chromatography on silica (S% methanol/CHCl3): mp =
204°C
(dec.); IR (thin film) 3282 1720 cm t;'H NMR (CDC13) b 1.29 (t, 3H, J = 7.1 Hz), 1.86 (m, 1H), 2.05 (m, 1H), 2.28-2.35 (m, 2H), 2.46-2.51 (m, 2H), 3.02 (m, 1H), 4.20 (q, 2H, J = 7.2 Hz), 4.62 (m, 1H), 5.00 (dd, 1H, J = 8.3, 3.6 Hz), 5.20 (s, 1H), 5.57 (m, 1H), 5.86 (m, 1H), 5.94 (dd, 1H, J = 15.5, 1.4 Hz), 6.84 (dd, 1H, J =
15.6, 5.2 Hz), 7.36-7.40 (m, SH), 7.44 (s, 2H), 8.69 (m, 1H). HRMS calcd for CuH29N50~+Cs 644.112, found 644.1143; Anal (CuH29N50,) C, H, N.
3'he remaining compounds illustrated above can be produced by the skilled artisan, using routine experimentation, in a manner analogous to the various procedures described above in Examples 1 through 35.

BIOCHEMICAL AND BIOLOGICAL EVALUATION
Inhibition of Rhinovirus Protease Stock solutions (SO mM, in DMSO) of various compounds were prepared;
dilutions were in the same solvent. Recombinant Rhinovirus 3C proteases from serotypes 14, 16, 2 or 89 were prepared by the following standard chromatographic procedures: (1) ion exchange using Q Sepharose Fast Flow from Pharmacia; (2) affinity chromatography using Affl-Gel Blue from Biorad; and (3) sizing using Sephadex from Pharmacia. Assays contained 2 % DMSO, SO mM tris pH 7.6, I mM EDTA, a compound at the indicated concentrations, approximately lp,M substrate, and SO-100 nM
protease. For K; determinations, the compound and the enzyme were preincubated for minutes at 30°C prior to addition of the substrate (substrate start).
The k°b~ values were obtained from reactions initiated by addition of enzyme rather than substrate. RVP
activity is measured in the fluorescence resonance energy transfer assay. The substrate was (N-terminal) DABCYL-(Gly-Arg-Ala-Val-Phe-Gln-Gly-Pro-Val-Gly)-EDANS. In the uncleaved peptide, the EDANS fluorescence was quenched by the proximal DABCYL moiety. When the peptide was cleaved, the quenching was relieved, and activity was measured as an increase in fluorescence signal. Data was analyzed using standard non linear fitting programs (Enzfit), and are shown Table I.

COMPOUND RVP INHIB --~bs/I- se 1 > 100~,M(K;) 52 ND 5,300 (2) ND 617 (16) ND 1,035 3 l2uM(K;) 16,565 (2) ND 292 (16) ND 929 4 2.9~cM(K;) 43,800 (2) ND 541 (16) ND 2,009 ND 17,320 6 ND 9,500 7 ND 3,824 8 ND 6, 885 4.4~.M(K~ 57,000 2.O~,M(K;) 41, 800 11 ND 12, 000 12 ND 5,070 13 ND 355,800 (2) ND 3,980 (16) ND 11,680 14 0.8~cM(K;) 56,400 (2) ND 800 ( 16) ND 1800 2. S~cM(K;) 36,400 (2) ND 3 , 500 (16) ND 5,600 16 12~M(K;) 8,300 (2) ND 600 (16) ND 1,000 17 ND 750,000 _ _ 18 7.O~,M(K;) 423 19 ND 1, 927 20 62~cM(K;) 3,332 21 SO~cM(K;) 256 23 60uM(K;) 605 24 8~cM(K;) 21, 960 (2) ND 7,100 (16) ND 9,300 25 ND 1,469 (2) ND 1,277 (16) ND 770 26 34~,M(Ki) 875 2~ ND 102 (2) ND g7 (16) ND 90 2g SO~cM(K;) 116 29 ~ ND 45 30 SS~cM(K;) 163 33 86(10) 361 34 ND 13,400 (2) ND 940 (16) ND 2,065 35 ND 22,500 (2) ND 1,600 (16) ND 3,480 36 ND 2,000 (2) ND 400 _ .

( 16) ND 750 ND 12,400 (2) ND 2, 500 (16) ND 4,000 38 ND 18,200 39 ND 2,330 40 ND 12,100 41 ND 2,350 42 ND 15,000 43 ND 2,200 ND 12, 300 4$ ND 2,300 46 ND 36,800 4~ ND 6, 500 48 ND 14,050 49 ND 1,910 50 ND 14,000 S1 ND 43,900 52 ND 31,100 54 SS(10) ND

55 20(10) ND

56 ND 15,400 ND 13,500 58 ND 24,300 59 2.8 108,000 In the above table, all data is for RVP serotype-14 unless otherwise noted in parentheses. All strains of human rhinovirus (HRV) were purchased from American __ Type Culture Collection (ATCC), except for serotype 14, which was produced from the infectious cDNA clone constructed and supplied to us by Dr. Roland Rueckert at the Institute for Molecular Virology, University of Wisconsin, Madison, Wisconsin.
The column designated INHIB represents the percent inhibition, with the concentration of the compound in ~M indicated in parentheses, unless K; was assigned as designated by (K;), at 10 minute preincubation with 50 nM RVP prior to addition of substrate was used.
The data in the column designated kobsn was measured from progress curves in enzyme start experiments. The designation NI indicates that no inhibition was obtained when 10 ~cM of a compound was used. The designation ND indicates that a value was not determined for that compound.
Antirhinoviral HI-HeLa Cell Culture Assay In the Cell Protection Assay, the ability of compounds to protect cells against HRV infection was measured by the XTT dye reduction method. This method is described in O.S. Weislow, R. Kiser, D.L. Fine, J. Bader, R.H. Shoemaker, and M.R.
Boyd, J. Natl. Cancer Inst. 1989, 81, 577-586, which document is entirely incorporated herein by reference.
HI-HeLa cells were infected with HRV-14 (unless otherwise noted) at a multiplicity of infection (m.o.i.) of 0.13 (virus particles/cell) or mock-infected with medium only. Infected or mock-infected cells were resuspended at 8 x 105 cells per mL
and incubated with appropriate concentrations of compounds of formulas I and II. Two days later, XTT/PMS was added to test plates, and the amount of formazan produced was quantified spectrophotometrically at 450/650 nm. The ECSO was calculated as the --concentration of compound that increased the percentage of formazan production in compound-treated, virus-infected cells to 50% of that produced by compound-free mock-infected cells. The 50% cytotoxic dose (CCso) was calculated as the concentration of compound that decreased the percentage of formazan produced in compound-treated, mock-infected cells to 50% of that produced in compound-free, mock-infected cells.
The therapeutic index (TI) was calculated by dividing the CCSO by the ECso.
All strains of human rhinovims (HRV) for use in this assay were purchased from American Type Culture Collection (ATCC), except for HRV serotype-14, which was produced from the infectious cDNA clone, constructed and supplied to us by Dr.
Roland Rueckert at the Institute for Molecular Virology, University of Wisconsin, Madison, Wisconsin. HRV stocks were propagated, and antiviral assays were performed in HI-HeLa cells (ATCC). Cells were grown in Minimal Essential Medium, available from Life Technologies, with 10% fetal bovine serum.
The compounds were tested against control compounds WIN 51711, WIN 52084, and WIN 54954, all obtained from Sterling-Winthrop Pharmaceuticals, and control compound Pirodavir, obtained from Janssen Pharmaceuticals. Antiviral data obtained for the test compounds are shown in Table 2 where all data are for HRV serotype-14 unless otherwise noted in parentheses.

Compound # ECso(Er,M) CC~o(E.cM) TI

2 1.0 56 56 _ _ 3 0.18 41.7 232 4 0.23 200 870 0.24 51.4 214 6 2.8 151.4 54 7 1.3 47.9 37 8 10 > 320 > 32 9 0.25 56.2 225 1.8 56.2 31 11 0.53 > 320 > 603 12 4.2 > 320 > 76 13 0.12 17.8 148 14 0.32 15.8 49 0.26 S0.1 192 16 1.7 32 19 17 0.5 53 106 18 5.0 126 25 19 50 > 320 > 6 5.4 56 10.3 21 22 > 320 > 15 22 177. 8 > 320 > 2 24 10 > 100 > 10 14 > 320 > 23 26 56 > 320 > 5 27 > 320 > 320 28 6.9 125 18 7.2 177 25 31 56 > 320 > 6 32 158 > 320 > 2 33 > 320 > 320 34 0.32 > 100 > 312 35 0.19 > 100 > 526 36 11.2 > 100 > 9 37 8.9 >100 >11 38 0.36 > 100 > 278 39 1.6 180 113 40 0.32 45 141 41 2.0 18 9 42 0.45 50.1 111 43 3.5 56.2 16 44 0.54 56.2 104 45 1.78 56.2 32 46 0.54 18 33 47 1.3 18 14 48 0.5 > 10 > 20 49 0.1 71 710 50 3 .2 > 100 > 31 51 12.6 > 100 > g 52 32 > 100 > 3 53 4. 5 > 100 > 22 54 17. 8 > 100 > 6 55 SO > 100 > 2 56 1.6 20 13 57 0.56 SO g9 58 0.56 63 113 59 0.14 > 100 > 714 59 (HRV 1 A) 0.40 > 100 > 250 59 (HRV 10) 0.40 > 100 > 250 WIN 51711 0.78 > 60 > 77 WIN 52084 0.07 > 10 > 143 WIN 54954 2.13 > 63 > 30 Pirodavir 0.03 > 10 > 300 Anticoxsaclcieviral Hi HeLa Cell Culture Assay The ability of compounds to protect cells against CVA-21 or CVB-3 infection was measured by the XTT dye reduction method. Briefly, HI-HeLa cells were infected with CVA-21 or CVB-3 at a multiplicity of infection (m.o.i.) of 0.05 (CVA-21) and 0.08 (CVB-3) or mock-infected with medium only. Infected or uninfected cells were resuspended at 4 x 104 cells per mL and incubated with appropriate concentrations of drug. One day later, XTT/PMS was added to test plates, and the amount of formazan produced was quantified spectrophotometrically at 450/650 nm. The ECso was calculated as the concentration of drug that increased the percentage of formazan production in drug-treated, virus-infected cells to 50% of that produced by drug-free, uninfected cells. The 50% cytotoxic dose (CCso) was calculated as the concentration of drug that decreased the percentage of formazan produced in drug-treated, uninfected cells to 50%
of that produced in drug-free, uninfected cells. The therapeutic index (TI) was calculated by dividing the CCSOby the ECso. --The Coxsackie strains A-21 (CVA-21) and B-3 (CVB-3) were purchased from American Type Culture Collection (ATCC). Virus stocks were propagated and antiviral assays were performed in HI-HeLa cells (ATCC). Cells were grown in Minimal Essential Medium with 10 % fetal bovine serum.
Table 3. Antiviral efficacy of compounds against CVB-3 infection of Hi-HeLa cells.
Compound # ECso(~cM) CCsa(N,M) TI
2 2.0 56 28 WIN 54954 > 100 > 100 Pirodavir > 100 > 100 Table 4. Antiviral efficacy of compounds against CVA-21 infection of Hi-HeLa cells.
Compound # ECso(E.cM) CCso(~,M) TI
2 3.3 56 17 4 1.8 200 111 WIN 54954 > 100 > 100 Pirodavir > 100 > 100 Echovirus-11 and Enterovirus-70 MRCS Cell Culture Assay The Echovirus strain 11 (ECHO-11) and Enterovirus strain 70 (ENT-70) were purchased from American Type Culture Collection (ATCC). Virus stocks were propagated and antiviral assays were performed in MRCS cells (ATCC). Cells were grown in Minimal Essential Medium with 10% fetal bovine serum.
The ability of compounds to protect cells against ECHO-11 or ENT-70 infection was measured by the XTT dye reduction method. Briefly, MRCS cells were infected with ECHO-11 or ENT-70 at a multiplicity of infection (m.o.i.) of 0.0013 (ECHO-11) and 0.0017 (ENT-70) or mock-infected with medium only. Infected or uninfected cells were resuspended at 2 x 104 cells per mL and incubated with appropriate concentrations of drug. One day later, XTT /PMS was added to test plates, and the amount of formazan produced was quantified spectrophotometrically at 450/650 nm. The ECso was calculated as the concentration of drug that increased the percentage of formazan production in drug-treated, virus-infected cells to 50% of that produced by drug-free, uninfected cells. The 50% cytotoxic dose (CCso) was calculated as the concentration of drug that decreased the percentage of formazan produced in drug-treated, uninfected cells to 50%
of that produced in drug-free, uninfected cells. The therapeutic index (TI) was calculated by dividing the CCso by the ECso.
Table 5. Antiviral efficacy of compounds against ECHO-11 infection of MRCS
cells.
Compound ECso(~.cM) CC~o(N,M) TI
# ~

2 3.1 56 18 4 3.2 200 62.5 WIN 54954 > 100 > 100 Pirodavir > 100 > 100 Table 6. Antiviral efficacy of compounds against ENT-70 infection of MRCS
cells.
Compound ECso(N,M) CC~o(p,M) TI _ #

2 0.6 56 93 __ 4 0.3 200 667 WIN 54954 > 100 > 100 Pirodavir > 100 > 100 In describing the invention, the inventors have set forth certain theories and mechanisms in an effort to disclose how or why the invention works in the manner in which it works. These theories and mechanisms are set forth for informational purposes only. Applicants are not to be bound by any specific chemical or physical mechanisms or theories of operation.
While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
Thus, it is intended that the present invention cover the modifications and variations, provided they come within the scope of the appended claims and their equivalents.

Claims (34)

WE CLAIM:

1. A compound of formula (I):
wherein:
M is O or S;
R1 is H, F, an alkyl group, OH, SH, or an O-alkyl group;
R2 and R5 are independently selected from H, or an alkyl group, wherein said alkyl group is different from with the proviso that at least one of R2 or R5 must be and wherein, when R2 or R5 is X is =CH or =CF and Y, is =CH or =CF, or X and Y1 together with Q' form a three-membered ring in which Q' is -C(R10)(R11)- or -O-, X is -CH- or -CF-, and Y is -CH-, -CF-, or -C(alkyl)-, where R10 and R11 independently are H, a halogen, or an alkyl group, or, together with the carbon atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group, or X is -CH2-, -CF2-, -CHF-, or -S-, and Y1 is -O-, -S-, -NR12-, -C(R13)(R14)-, -C(O)-, - C(S)-, or -C(CR13R14)-, wherein R12 is H or alkyl, and R13 and R14 independently are H, F, or an alkyl group, or, together with the atoms to which they are bonded, form a cycloalkyl group or a heterocycloalkyl group;
A1 is C, CH, CF, S, P, Se, N, NR15, S(O), Se(O), P-OR15, or P-NR15R16, wherein R15 and R16 independently are an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, or, together with the atom to which they are bonded, form a heterocycloalkyl group;
D1 is a moiety with a lone pair of electrons capable of forming a hydrogen bond; and B1 is H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -OR17, -SR17, -NR17R18, -NR19NR17R18, or -NR17OR18, wherein R17, R18, and R19 independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;

and with the provisos that when D1 is the moiety ~N with a lone pair of electrons capable of forming a hydrogen bond, B1 does not exist; and when A1 is an sp3 carbon, B1 is not -NR17R18 when D1 is the moiety -NR25R26 with a lone pair of electrons capable of forming a hydrogen bond, wherein R25 and R26 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;
and wherein D1-A1-B1 optionally forms a vitro group where A1 is N;
and further wherein, when R2 or R5 is X is = CH or = CF and Y2 is =C, =CH or = CF, or X and Y2 together with Q' form a three-membered ring in which Q' is -C(R10)(R11)- or -O-, X is -CH- or -CF-, and Y2 is -CH-, -CF-, or -C(alkyl)-, where R10 and R11 independently are H, a halogen, or an alkyl group, or, together with the carbon atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group, or X is -CH2-, -CF2-, -CHF-, or -S-, and Y2 is -O-, -S-, -N(R'12)-, -C(R'13)(R'14)-, -C(O)-, -C(S)-, or -C(CR'13R'14)-, wherein R'12 is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -OR'13, -NR'13R'14, -C(O)-R'13, -SO2R'13, or -C(S)R'13, and R'13 and R'14, independently are H, F, or an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group or, together with the atom to which they are attached, form, a cycloalkyl group or a heterocycloalkyl group;
A2 is C, CH, CF, S, P, Se, N, NR15, S(O), Se(O), P-OR15, or P-NR15R16, wherein R15 and R16 independently are an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group or, together with the atom to which they are bonded, form a heterocycloalkyl group;
D2 is a moiety with a lone pair of electrons capable of forming a hydrogen bond;
and B2 is H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -OR17, -SR17, -NR17R18, -NR19NR17R18, or -NR17OR18, wherein R17, R18, and R19 independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;
and further wherein any combination of Y2, A2, B2, and D2 forms a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;
R3 and R6 are independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -C(O)R17, -OR17, -SR17, -NR17R18, -NR19NR17R18, or -NR17OR18, wherein R17, R18, and R19 independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;

or, R3 and R6, together with the carbon atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group; R4 is any suitable organic moiety, or R4 and R3 or R6, together with the atoms to which they are attached, form a heterocycloalkyl group;
R7 is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -OR17, -SR17, -NR17R18, -NR19NR17R18, or -NR17OR18, wherein R17, R18, and R19 independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;
or R7, together with R3 or R6 and the atoms to which they are attached, forms a heterocycloalkyl group;
R8 is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -NR29R30, -OR29, or -C(O)R29, wherein R29 and R30 each independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;
or R8, together with R4 and the nitrogen atom to which they are attached, forms a heterocycloalkyl group or a heteroaryl group, or R8 and R3 or R6, together with the atoms to which they are attached, forms a heterocycloalkyl group;
Z and Z1 are independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -C(O)R21, -CO2R21, -CN, -C(O)NR21,R22, -C(O)NR21OR22, -C(S)R21, -C(S)NR21R22, -NO2, -SOR21, -SO2R21, -SO2NR21R22, -SO(R21)(OR22), -SONR21, -SO3R21, -PO(OR21)2, -PO(R21)(R22), -PO(NR21R22)(OR23), -PO(NR21R22)(NR23R24), -C(O)NR21NR22R23, or -C(S)NR21NR22R23, wherein R21, R22, R23, and R24 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or wherein any two of R21, R22, R23, and R24, together with the atom(s) to which they are bonded, form a heterocycloalkyl group;
or Z1, as defined above, together with R1, as defined above, and the atoms to which Z1 and R1 are bonded, form a cycloalkyl or heterocycloalkyl group, or Z and Z1, both as defined above, together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group;
with the proviso that when R7 is H, R8 is a moiety other than H;
or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof;
and wherein said compound, pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof has antipicornaviral activity with an EC50 less than or equal to 100 µM in the HI-HeLa cell culture assay.

2. A compound of claim 1, wherein R1 is H or F, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

3. A compound of claim 1, wherein at least one of R4 and R8 is an acyl group or a sulfonyl group, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

4. A compound of claim 1, wherein at least one of R2 or R5 is or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

5. A compound according to claim 4, wherein D1 is -OR25, =O, =S, ~N, =NR25, or -NR25R26, wherein R25 and R26 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, or, together with the nitrogen atom to which they are bonded, form a heterocycloalkyl group; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

6. A compound according to claim 5, wherein D1 is =O; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

7. A compound according to claim 4, wherein A1 is C, CH, S, or S(O); or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

8. A compound according to claim 7, wherein A1 is C; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

9. A compound according to claim 4, wherein B1 is NR17R18, wherein R17 and R18 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

10. A compound according to claim 1, wherein at least one of R2 or R5 is or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

11. A compound according to claim 10, wherein D2 is -OR25, =O, =S, ~N, =NR25, or -NR25R26, wherein R25 and R26 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, or, together with the atom(s) to which they are bonded, form a heterocycloalkyl group; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

12. A compound according to claim 11, wherein D2 is =O; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

13. A compound according to claim 10, wherein A2 is C, CH, S, or S(O); or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

14. A compound according to claim 13, wherein A2 is C; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

15. A compound according to claim 10, wherein B2 is NR17R18, wherein R17 and R18 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

16. A compound according to claim 1, wherein A1 is C, CH, S, or S(O) or wherein A2 is C, CH, S, or S(O); or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

17. A compound according to claim 1, wherein Z and Z1 are independently H, an aryl group, or a heteroaryl group, -C(O)R21, -CO2R21, -CN, -C(O)NR21,R22, -C(O)NR21OR22, -C(S)R21, -C(S)NR21R22, -NO2, -SOR21, -SO2R21, -SO2NR21R22 -SO(NR21)(OR22), SONR21, - SO3R21, -C(O)NR21NR22R23, or -C(S)NR21NR22R23;
wherein R21, R22, and R23 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or wherein any two of R21, R22, and R23, together with the atom(s) to which they are bonded, form a heterocycloalkyl group, or Z and Z1, together with the atoms to which they are bonded, form a heterocycloalkyl group, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

18. A compound according to claim 1, wherein M is O, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

19. A compound having the formula II:
wherein:
R51 is H, F, or an alkyl group;
R52 is selected from one of the following moieties:
wherein:
R35 is H, an alkyl group, an aryl group, -OR38, or -NR38R39, wherein R38 and R39 independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group; and R36 is H or an alkyl group, or R35 and R36, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group or a heteroaryl group;
R3, is an alkyl group, an aryl group, or -NR38R39, wherein R38 and R39 are as defined above;
R41 is H, an alkyl group, an aryl group, -OR38, -SR39, -NR38R39, -NR40NR38R39, or -NR38OR39, or R41 and R36, together with the atoms to which they are attached, form a heterocycloalkyl group, and wherein R38 and R39 are as defined above and R40 is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group; and n is 0, 1 or 2;
R53 is H or an alkyl group;
R54 is an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an O-alkyl group, an O-cycloalkyl group, an O-heterocycloalkyl group, an O-aryl group, an O-heteroaryl group, an S-alkyl group, an NH-alkyl group, an NH-aryl group, an N,N-dialkyl group, or an N,N-diaryl group;
or R54, together with R58 and the nitrogen atom to which they are attached, forms a heterocycloalkyl group or a heteroaryl group;
R57 is H or an alkyl group;

R58 is H, an alkyl group, a cycloalkyl group, -OR70, or -NR70R71, wherein R70 and R71 are independently H or an alkyl group; and Z and Z1 are independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -C(O)R21, -CO2R21, -CN, -C(O)NR21R22, -C(O)NR21OR22, -C(S)R21, -C(S)NR21R22, -NO2, -SOR21, -SO2R21, -SO2NR21R22, -SO(NR21)(OR22), -SONR21, -SO3R21, -PO(OR21)2,-PO(R21)(R22), -PO(NR21R22)(OR23), -PO(NR21R22)(NR23R24), -C(O)NR21NR22R23, or _ C(S)NR21NR22R23, wherein R21, R22, R23, and R24 are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or wherein any two of R21, R22, R23, and R24, together with the atom(s) to which they are bonded, form a heterocycloalkyl group, or wherein Z and Z1, together with the atoms to which they are bonded, form a heterocycloalkyl group;
with the proviso that when R57 is H, R58 is a moiety other than H;
or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

20. A compound according to claim 1, having the formula Ia:
wherein R1, R5, R6, and R7 are H, R2 is CH2CH2C(O)NH2, R4 is CH3, and R3, Z, Z1, and R8 are selected from one of the following groups:
R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is Z is H; Z1 is CO2CH2CH3, R3 is and R8 is R3 is Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z and Z1 together form (wherein the C=O is cis to the R1 group), and R8 is R3 is CH2Ph, Z is H, Z1 is and R8 is R3 is CH2Ph, Z and Z1 together form (wherein the C=O group is cis to the group), and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z and Z1 together form (wherein the C=O group is cis to the group), and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z and Z, together form (wherein the C=O group is cis to the group), and R8 is R3 is Z is H, Z1 is CO2CH2CH3, and R8 is R3 is , Z is CH3, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is CH3, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is and R8 is or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

21. A compound according to claim 1, having the formula Ib:
wherein R1, R3, R5, R7, and Z are H, R2 is CH2CH2C(O)NH2, and Z1, W, W1, and R8 are selected from one of the following groups:
Z1 is CO2CH2CH3, W is H, W1 is Ph, and R8 is Z1 is CO2CH2CH3, W is H, W1 is H, and R8 is Z1 is CO2CH2CH3, W is OCH2Ph, W1 is H, and R8 is Z1 is CO2CH2CH3, W is H, W1 is CH3, and R8 is Z1 is CO2CH2CH3, W is OC(CH3)3, W1 is H, and R8 is Z1 is CO2CH2CH3, W is H, W1 is H, and R8 is or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

22. A compound according to claim 1, having the formula Ic:
wherein R1, R3, R5, R7, and Z are H, R2 is CH2CH2C(O)NH2, R8 is and W2 and Z1 are selected from one of the following groups:
W2 is CH2 and Z1 is CO2CH2CH3;
W2 is CH2 and Z1 is W2 is NCH2Ph and Z1 is CO2CH2CH3; and W2 is NSO2Ph and Z1 is CO2CH2CH3, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

23. A compound according to claim 1, having the formula Id:
wherein R1, R3, R5, R6, R7, and Z are H, R2 is CH2CH2C(O)NH2, Z1 is CO2CH2CH3, and W3 is H or or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

24. A compound according to claim 1, having the formula Ia:
wherein R1, R5, R6, and R7 are each H, R2 is CH2CH2C(O)NH2, R4 is CH3, and R3, Z, Z1, and R8 are selected from one of the following groups:
R3 is CH2Ph, Z is H, Z2 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is C(O)N(CH3)OCH3, and R8 is R3 is CH2Ph, Z is H, Z, is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is CH3, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is CH3, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is CH3, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is CH3, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is CH3, Z1 is CO2CH2CH3, and R8 is R3 is Z is H, Z1 is CO2CH2CH3, and R8 is R3 is Z is CH3, Z1 is CO2CH2CH3, and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2Ph, and R8 is R3 is CH2Ph, Z is H, Z1 is CO2CH2CH2CH3, and R8 is , and R3 is CH2Ph, Z is H, Z1 is CO2CH2CH2OCH3, and R8 is or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

25. A compound according to claim 1, having the formula Ig:
wherein R1, R3, R5, R7, W5, W6, and Z are H, R2 is CH2CH2C(O)NH2, Z1 is CO2CH2CH3, and W7 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

26. A compound according to claim 1, having the formula Ih:
wherein R1, R5, R6, and R7 are H, R2 is CH2CH2C(O)NH2, R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and Wg is or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

27. A compound according to claim 1, having the formula Ij:
wherein R1, R5, R6, and R7 are H, R2 is CH2CH2C(O)NH2, R3 is CH2Ph, Z is H, Z1 is CO2CH2CH3, and W8 is or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

28. A compound according to claim 1, having the following formula X:

wherein R1, R6, and Z are H, R2 is CH2CH2C(O)NH2, R3 is CH2Ph, Z1 is CO2CH2CH3, and R4 is selected from one of the following:
wherein VAR is selected from the group consisting of -CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH2Ph, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

29. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof; and (b) a pharmaceutically acceptable carrier, diluent, vehicle, or excipient.

30. A method of treating a mammalian disease condition mediated by picornaviral protease activity, comprising: administering to a mammal for the purpose of said treating a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

31. A method of inhibiting the activity of a picornaviral 3C protease, comprising:
contacting the picornaviral 3C protease for the purpose of said inhibiting with an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

32. A method of inhibiting the activity of a rhinoviral protease, comprising:
contacting the rhinoviral protease for the purpose of said inhibiting with an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.

33. A compound according to claim 1, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof, wherein said antipicornaviral activity is antirhinoviral activity.

34. A compound according to claim 1, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof, wherein said antipicornaviral activity is anticoxsackieviral activity.